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Abstract 
Introduction: Gaucher disease is a recessive disorder, mutation of the GBA1 gene 
leads to a reduction in β-glucocerebrosidase (GBA) activity, accumulation of 
glucosylceramide and abnormal levels of other sphingolipids. Features include 
hepatosplenomegaly, cytopenia and bone disease including osteopenia and 
osteonecrosis. Enzyme replacement is the most common therapy however bone 
manifestations can be slow to respond, some patients show no improvement or 
continue to suffer bone events. Gaucher patients are reported to have a higher 
incidence of multiple myeloma with an estimated risk ratio up to 51.1.                   
Aim: To investigate the bone marrow microenvironment in GD by partial recreation 
of this environment using co-culture systems.                                                          
Methods: Co-culture of up to 3 cell types, histochemical staining, 
immunofluorescence imaging, functional assay, enzyme activity, therapy and lipid 
assays, cytotoxicity assay, flow cytometry.                                                                
Results: Gaucher patient (GD) peripheral blood mononuclear cell derived osteoclast 
cultures (OC) generated more osteoclasts and at earlier time points than control 
cultures. GD osteoclasts were larger, had more nuclei and resorbed more bone. 
Addition of GBA inhibitor CBE to control OC increased osteoclast generation, size 
and nuclei number. Addition of glucosylceramide to OC increased osteoclast 
numbers in both control and GD cultures. In vitro GD osteoclast numbers correlated 
with active bone disease, bone pain and anaemia. Addition of GD-specific therapies 
to GD OC decreased osteoclast generation, also observed in a selection of patients 
receiving GD-specific therapies. Uncoupling between GD osteoblast precursors and 
osteoclasts was observed. Culture of control OC with plasma cell line NCI-H929 
increased osteoclast generation. CBE inhibition of human osteoblast cell line SaOS-2 
reduced calcium deposition. Glucosylceramide increased NCI-H929 cell number 
after 7 days. NCI-H929 viability increased when in contact with osteoclasts in SaOS-
2 co-cultures.                                                                                                                
Conclusion: Osteoblast and osteoclast dysregulation may contribute to bone 
disease in GD. The GD bone microenvironment may provide a pro-survival 
environment for plasma cells. 
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RANK                             Receptor activator of nuclear factor κB 
RANKL                           Receptor activator of nuclear factor κB ligand 
RPMI                              Roswell Park Memorial Institute medium 
RunX2                            Runt-related transcription factor 2 
S1P                                 Sphingosine-1-phosphate 
S1PR                               Sphingosine-1-phosphate receptor 
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S-ACE                             Serum-angiotensin converting enzyme 
SCARB2                         Scavenger receptor class B member 2 
SDF-1α                          Stromal cell-derived factor 1α 
SEM                               Standard error of the mean 
sFRP                               Secreted frizzled-related protein 
Shc                                 Src Homology 2 Domain Containing   
SMURF-1                       SMAD Ubiquitination Regulatory Factor 1 
Src                                  Sarcoma- Proto-oncogene tyrosine-protein kinase 
SRT                                 Substrate reduction therapy 
STAT                               Signal Transducers and Activators of Transcription protein 
TCR                                 T-cell receptor 
TGF-β                             Transforming growth factor beta 
TGN                                Trans-golgi network  
Th                                   T-helper cell 
THF                                 Follicular helper phenotype 
TIM barrel                    Triose phosphate isomerase barrel or (βα)8-barrel 
TLR9                               Toll-like receptor 9 
TNF-α                             Tumour Necrosis Factor alpha 
TRACP-5b                      Tartrate-resistant acid phosphatase isoform 5b 
TRAP                              Tartrate resistant acid phosphatase 
US/USA                         United states of America 
VCAM-1                         Vascular cell adhesion molecule-1 
VDR                                Vitamin D receptor 
VEGF                              Vascular endothelial growth factor 
VLA-4                             Very late antigen-4 
VNR                                Vitronectin receptor 
Wnt                                Wingless-related integration site 
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1 Introduction 
1.1 Lysosomes 
Lysosomes were first described by Christian de Duve in 1955 when he discovered 
membrane bound organelles containing enzymes with lytic actions and named 
these organelles lysosomes, for which he won the Nobel Prize in Medicine or 
Physiology in 1974 (1). Subsequent electron microscopic studies showed lysosomes 
constitute up to 5% of the intracellular volume of mammalian cells, vary in size 
from 100-500nm in diameter (2) and are distinguished from their precursor, the 
late endosome, by their lack of mannose-6-phosphate receptors (MPR’s) (3).  
Lysosomes contain more than 60 different types of proteases, lipases and 
hydrolases (4) and are primarily responsible for the degradation of proteins, lipids 
and polysaccharides into their respective basic units i.e. amino acids, free fatty 
acids and monosaccharides (5,6). Lysosomal hydrolases are produced in the 
endoplasmic reticulum and transported through the trans-golgi network (TGN), 
many of which acquire mannose-6-phosphate residues to enable sorting through 
pre-lysosomal compartments via MPR’s (3,7). 
While MPR mediated transport is the most common (3), other mechanisms have 
recently been discovered. Patients with mucolipidosis type II (I-cell disease) are 
deficient in N-acetylglucosaminyl phosphotransferase which means proteins cannot 
be labelled with mannose-6-phosphate resulting in many of the hydrolases being 
secreted instead of transported to the lysosome (8). However, some proteins, 
including β-glucocerebrosidase (GC), are still transported to the lysosome. In the 
case of GC this transport is mediated through direct binding with LIMP2 in the 
endoplasmic reticulum, remaining bound until dissociation in the lysosome due to 
the low luminal pH of ~4.6 (2,9). 
Extracellular components for degradation are transported by endocytosis and 
intracellular components by autophagy. Endocytosis begins with fission of the 
plasma membrane to form endocytic vesicles which subsequently undergo a 
maturation process to become early then late endosomes. Mature late endosomes 
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fuse with lysosomes to become endolysosomes. This fusion not only provides the 
material to be degraded but also TGN hydrolases essential for lysosomal function 
(6,8). Intracellular organelles no longer fit for purpose and protein aggregates are 
transported to the lysosome by autophagosomes which can fuse indirectly via late 
endosomes or directly to lysosomes to form autolysosomes (11). Once degraded, 
the products are exported for energy homeostasis or for reutilisation in 
biosynthetic pathways (10). Lysosomal trafficking can be mediated through several 
pathways, these include lysosomal exocytosis, present in all cell types (12) in which 
lysosomes fuse with the plasma membrane, retrograde trafficking in which MPR’s 
are required for hydrolase transport to the lysosome and insoluble lipids are 
recycled back to the TGN (10) and lipid exporters including NPC-1 which is theorised 
to be the exporter for cholesterol, mutations in which lead to cholesterol and 
sphingolipid accumulation in lysosomes resulting in the lysosomal storage disorder 
Niemann-Pick type C (13).  
 
1.2 Lysosomal storage disorders 
Lysosomal storage disorders (LSD’s) are rare metabolic diseases caused by the 
abnormal accumulation of material in lysosomes (14). Although individually rare 
their collective incidence is estimated at 1 in 5000 live births due to there being 
over 50 such diseases currently described (15). The majority of the first clinical 
reports, later identified as LSD’s, were published over a century ago - Tay, 1881; 
Gaucher, 1882; Fabry, 1898; Niemann, 1914; Hunter, 1917. However, as previously 
mentioned the lysosome was not discovered until 1955 by Christian de Duve and 
LSD’s were not defined until 1965 when H.G. Hers discovered that Pompe disease, a 
glycogen storage disorder, exhibited a deficiency in acid alpha glucosidase and 
defined the term “lysosomal enzyme deficiency states” (16). The majority of LSD’s 
are autosomal recessive however several, including Fabry’s disease (alpha 
galactosidase A deficiency) are X-linked (17). LSD’s are generally classified by the 
accumulation of the substrate. These classifications include: Glycogen storage 
disease type II (Pompe disease), Mucopolysaccharidoses (I-VII), Oligosaccharidoses, 
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Lipidoses and Sphingolipidoses (18). There are other classifications which include 
LSD’s caused by non-enzymatic defects but the majority of disorders are caused by 
mutations in lysosomal hydrolases (19) and so included in the classifications stated 
above. However, these classifications are limited by the fact that many lysosomal 
hydrolases are not specific for one substrate. For example, β-galactosidase is 
involved in the degradation of several substrates including keratan sulphate, 
sphingolipids and oligosaccharides, a deficiency in which results in the accumulation 
of all of these substrates but is classified as GM1 gangliosidosis (20).  
Multiple organs and tissues are typically affected. Clinical manifestations may 
include enlarged liver and spleen (hepatosplenomegaly), cardiac disease, facial 
dysmorphia, immune defects and skeletal abnormalities including bone loss and 
remodelling (21). Severity of each LSD is difficult to define as each disease has a 
spectrum of severity ranging from patients with such a mild phenotype that they 
can go undiagnosed to a severity which is incompatible with life (22,23). However, 
many of the most severe forms involve the central nervous system and account for 
up to 75% of LSD’s (24). 
Many variants of mutations in LSD’s result in misfolding or aberrant proteins which, 
although their catalytic activity is usually unaffected, are typically targeted to the 
endoplasmic reticulum associated degradation pathway instead of to the lysosome 
effectively resulting in decreased overall enzyme activity and are theorised to cause 
ER stress and contribute to disease severity (25,26). 
Functional loss of certain lysosomal membrane proteins has been found to result in 
a number of LSD’s. Mutations in lysosomal ion channels and transporters alter ion 
homeostasis within the lysosome impairing the trafficking and degradation of 
substrates leading to LSD’s. Similarly, accumulation of lipids within the lysosome 
may alter the functionality of lysosomal membrane proteins such as ion channels or 
catabolite exporters further exacerbating the effect of the defect (27,28).   
Recently, it has been shown that autophagic capacity is reduced in LSD’s resulting in 
an increased number of autophagosomes that are never cleared by fusion with 
lysosomes leading to a blockage of autophagic movement to and from the lysosome 
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and plasma membrane, termed autophagic flux with the overall effect of an 
accumulation of substrate in the autophagosomes, however the potential impact of 
this remains unclear (20,29).  
A number of therapeutic approaches have been developed to treat LSD’s including 
enzyme replacement therapy (ERT), substrate reduction therapy (SRT), bone 
marrow transplantation and gene therapy (30). The most common therapies being 
ERT and SRT in which the defective enzyme is replaced or the creation of substrate 
is blocked, respectively. Pharmacological chaperones have also been recently 
developed which bind to misfolded proteins and enable these proteins to be 
transported to the lysosome at which point they dissociate due to the low luminal 
pH of the lysosome (31,32).  
 
1.3 Sphingolipidoses 
Sphingolipids are a major category of lipids and are present in all mammalian cells 
and lipoproteins (33). The simplest sphingolipid is ceramide which consists of a fatty 
acid residue attached by an amide link to a sphingosine backbone and is thus 
regarded as a central metabolite in sphingolipid processing (34). Further additions 
to the head group result in more complex sphingolipids. Addition of 
phosphocholine or phosphoethanolamine leads to a group termed sphingomyelins 
while addition of sugar residues produces the glycosphingolipids group which is 
subdivided into cerebrosides (a single glucose or galactose residue), sulphatides 
(sulphated cerebrosides), globosides (more than one sugar residue) and 
gangliosides (three or more sugar residues, one of which must be a sialic acid (35), 
shown in figure 1.1. Cerebrosides are present in all cell types, globosides in visceral 
organs, galactosylceramides and their sulphatides are generally restricted to myelin 
and kidney while gangliosides are typically found in neuronal membranes (35). 
Sphingolipidoses are a group of diseases in which the main storage substrate is a 
sphingolipid caused in the majority by a mutation in a lysosomal hydrolase resulting 
in a reduction in catabolic activity (19), these diseases include Gaucher, Fabry, Tay-
Sachs, Niemann-Pick and metachromatic leukodystrophy among others (36), see 
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figure 1.2. Mutations in transporters can also lead to sphingolipidoses. For example 
mutations in NPC-1 or NPC-2 genes cause the cholesterol trafficking disease 
Niemann–Pick type C disease which due to blocked endosome-lysosome fusion 
results in storage of glycosphingolipids in the late endosome/lysosomes (37). 
Recent research in unrelated diseases have also shown that sphingolipids are highly 
bioactive and have been theorised to play a role in a number of conditions including 
cancer (38), diabetes (39), dermatological diseases (40), lung inflammation (41), 
intestinal immunity and allergy (42) which may help to shed some light on the 
range of pathologies present in sphingolipidoses and LSD’s in general. 
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Figure 1.2 Diagram of sphingolipid metabolism. Source: Metabolic and cellular 
bases of sphingolipidoses. Konrad Sandhoff. Biochemical Society Transactions.           
Dec 01, 2013.  
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1.4 Gaucher disease  
1.4.1 Introduction 
Gaucher disease was first described in 1882 by Phillipe Gaucher. As a medical 
student he examined a 32 year old female and provided descriptions of an enlarged 
spleen and subsequent microscopic study revealed engorged cells, initially thought 
to be malignant (43). Subsequent to this report more cases of patients with 
enlarged cells, identified as macrophages, were reported and given the name 
‘Gaucher cells’ (44), the term still used today. The cause of the disease, deficient 
activity of β-glucocerebrosidase, was discovered in 1965 by Brady et al. Further 
investigation identified β-glucocerebrosidase as a lysosomal enzyme in 1972 and 
patients with Gaucher disease were described as having a lysosomal storage 
disorder thereafter (45). Storage of the enzymes substrate, glucosylceramide, in the 
macrophage results in cells with a small eccentrically placed nuclei surrounded by a 
bright, crinkled cytoplasm (46). The macrophage being the primary storage cell due 
to their function of degrading senescent blood cells, cell debris and microbes 
providing an additional peripheral source of substrate (47).   
The gene encoding β-glucocerebrosidase (GBA) was found to localise to 
chromosome 1q21  in the mid 1980’s (48) and was sequenced in 1989 (49). It is now 
known that GD is an autosomal recessive disorder for which more than 300 
mutations and polymorphisms have been reported (50). However, the exact 
incidence of GD is not clear. Estimated incidence based on screening data from an 
Australian population, published in 1999, was 1:57,000  (51), prevalence in 
Caucasians was estimated at 1:40,000 to 1:60,000 in a report in 2011 (52) while a 
new born screening study in Hungary gave a higher prevalence of 1:13,341 in 2012 
(53). Incidence is significantly higher in the Ashkenazi Jewish population with 
incidence estimated at 1:850 (54) and carrier frequency reported between 1:10 to 
1:17.5 (55,56).   
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1.4.2 GBA1 gene, protein and pseudogene 
Lysosomal β-glucocerebrosidase (GC) is encoded by the GBA1 gene located on 
chromosome 1q21 and consists of 11 exons, 10 introns and is 7.8 kilo bases in size. 
(49). In addition, a pseudogene, GBAP (glucocerebrosidase A pseudogene) 5.7kb in 
size, is located downstream of GBA1 which appears to have arisen due to a tandem 
duplication despite having 96% sequence homology it is missing large portions of 
exons two, four, six, seven and nine (49).  
GBA1 cDNA is about 2kb in length and is translated into a protein of 497 amino acid 
residues (49). Synthesis is initiated from one of two ATG codons within the 
sequence. Transcription occurs predominantly from the upstream initiator, but 
deletion of either ATG codon does not affect overall expression levels in vitro (57). 
GBA1 also has two promoters, one of which has an associated CpG island, a 
common feature of housekeeping genes and possibly explains the expression of GC 
in the majority of cell types (58). 
GC is a 60kDa protein comprising of three domains identified by X-ray 
crystallography in 2003. The third domain contains the catalytic site and consists of 
a TIM barrel (8 α-helices, 8 β-strands) formed from amino acid residues 76-381 and 
416-430 (59).  
 
1.4.3 GBA1 mutations 
Over 250 pathogenic mutations have been reported for the GBA1 gene including 
203 missense, 18 nonsense, 36 insertion/deletions, 14 splice junction variants and 
13 complex alleles (50) carrying two or more mutations resulting from gene 
recombination or conversion with the pseudogene (60). Pathogenic mutations have 
not been described in exon 1, with the majority of mutations occurring in two exon 
blocks (exons 5-7 and 8-11) (50).  
The first mutations to be described were the missense mutations L444P (exon 10) in 
1987 (61) and N370S in 1988 (exon 9) (62) and are the most common (50,63). 
However, allele frequency varies with ethnicity and geographical location. In the 
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Ashkenazi Jewish population, N370S, L444P, R496H, V394L (all missense), 84GG 
(insertion), and ISV2+ 1G>A (splice junction) account for roughly 96% of mutant 
alleles (50,64). The frequency of N370S is higher among Iberians (Portuguese: 
53.7%, Spanish: 46.2%) than other non-Jewish European groups (65,66). In contrast, 
the N370S and 84GG mutations have not been identified among Chinese and 
Japanese GD patients with the most prevalent alleles being L444P (54%) and 
RecNciI (25%) among the Chinese and L444P (41%) and F213I (14%) in the Japanese 
populations (67).  
A number of the mutations described, including N370S which is located at the 
interface between the second and third domains but not in the active site, cause 
destabilising changes in the protein structure which although only partially reduce 
catalytic activity result in retention in the endoplasmic reticulum and subsequent 
degradation (59,68,69). The L444P mutation causes a structural change in the 
hydrophobic core of the Ig-like second domain which is theorised to affect its 
interaction with Saposin C (59), an essential co-factor for lysosomal GC catalysis of 
glucosylceramide (70). The insertion mutation 84GG, which denotes a second 
guanine base insertion at residue 84, results in premature termination of 
transcription which is predicted to severely compromise GC as homozygosity for 
this mutation has not been reported to date (63).  
In addition to pathogenic mutations in the GBA1 gene mutations in the PSAP gene, 
which encodes for prosaposin, a polyprotein which is cleaved into four different 
saposins referred to as Sap A-D (71), also result in a variant form of Gaucher 
disease. As mentioned, saposin C is an essential cofactor for GC, functioning as an 
activator for GC’s activity. While extremely rare, with only 6 cases reported to date  
(72), mutations including p.C315S, p.342_348FDKMCSKdel, p.L349P, p.C382G and 
p.C382F have been identified to cause saposin C deficiency (70).  
Despite elucidation of the mutations, protein structure, processing and activation of 
GC there is still poor correlation of genotype with phenotype. Age of onset and 
disease progression can vary between patients homozygous for the same mutation 
(73), even between twins (74) and mutations can be present across a spectrum of 
severity (75). While the N370S mutation has been found to correlate with mild, 
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non-neuronopathic disease homozygotes can display a wide range of symptoms 
from being asymptomatic to having severe organomegaly and bone involvement 
(73). Similarly, the L444P allele, commonly associated with a severe neuronopathic 
form, has been shown to be present in patients ranging from moderate systemic 
and neurological symptoms to seizures and severe developmental delay (76).  
Therefore, to address this variability, potential candidates for disease modifiers 
have been identified. These candidates include the GBA2, SCARB2 gene (encoding 
the LIMP2 protein), CLN8 and microRNA MiR-127-5p. GBA2 is a non-lysosomal GC 
which has been suggested to have a direct involvement in neurological disorders 
(77). LIMP2 is involved in the mannose-6-phosphate independent trafficking of GC 
(78) while increased CLN8 expression has been suggested to reduce disease severity 
(79). MicroRNA’s, small non-coding RNA’s, have been found to be involved in a 
number of biological processes and diseases. Recently, MiR-127-5p was found to 
reduce GC activity and protein level by down regulation of LIMP-2. In addition, 
other MiRNA’s including miR-16-5p and miR-195-5p were found to upregulate GC 
activity (80).  
 
1.4.4 Clinical presentation 
Gaucher disease is currently considered a continuum of phenotypes from 
asymptomatic to severe (81,82). However, to aid diagnosis GD is generally classified 
into three major clinical types namely types 1, 2 and 3 of which type 1 is the most 
common. Analysis of 1,698 individuals in the International Gaucher registry 
reported 94% as type 1, <1% as type 2 and 5% as type 3 (63). 
Type 1 is characterised by the presence of hepatosplenomegaly (enlargement of 
liver and spleen, with a spleen up to 20 times normal size (4)), clinical or radiological 
evidence of bone disease (including osteopenia, osteonecrosis, osteosclerosis, 
osteolytic lesions, pathological fracture and bone remodelling (84,85)), anaemia, 
thrombocytopenia, lung disease (86), gammopathy, bleeding diathesis, liver 
fibrosis, growth retardation, fatigue, weight loss, pulmonary hypertension 
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(17,60,87–90) and the absence of neurological involvement of the central nervous 
system (91), the presence of which characterises types 2 and 3. 
Although historically classified as a non-neuronopathic phenotype investigation into 
neuronopathic features of type 1 GD patients have revealed occurrence of 
peripheral neuropathy and neurological changes secondary to bone complications 
in a multi-centre, multinational cohort in 2008 (92). In addition a link has been 
established between type 1 GD and the development of early onset Parkinsonism 
(93). These observations led to the finding that there is a high prevalence of GBA1 
mutations in non-GD Parkinson’s disease patients with pathogenic variants 
identified in 5-10% of individuals with Parkinson’s disease (94), making 
heterozygosity for GBA1 mutations a risk factor for developing early onset 
Parkinsonism (95). The mechanism behind this association is under investigation 
but several have been suggested including accumulation of mutant GC within Lewy 
bodies (96) and impaired mitochondrial function (97). In addition, a 2016 study has 
shown increased dimerization of α-synuclein (the protein associated with classical 
Parkinson’s disease) in the red blood cells of GD patients correlating both with 
glucosylceramide levels and the increased oxidative stress observed in GD (98).  
GD patients with central nervous system involvement are classified into type 2 
(acute/infantile) and type 3 (subacute/chronic/juvenile) according to age of onset 
of neurological symptoms and rate of disease progression (99). Type 2 is the most 
severe form with symptoms observed as early as 6 months of age followed by rapid 
progression and limited psychomotor development leading to death by 2 to 4 years 
of age. Neurological involvement can include bulbar signs (stridor, squint, 
swallowing difficulty), pyramidal signs (opisthotonus, head retroflection, spasticity 
and trismus) and cognitive impairment (100). Type 3 is generally less severe; onset 
can occur before 2 years of age but often with slower progression leading to death 
by the third to fourth decade. Symptoms can include ocular apraxia, seizures and 
myoclonic epilepsy (101,102). It has been suggested that type 3 should be divided 
into three subclasses (72,103), types 3a to c, in which type 3a would have early 
onset neurological disease with seizures and horizontal supranuclear gaze palsy but 
mild visceral symptoms. Type 3b would have later onset of seizures but significant 
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hepatosplenomegaly as well as kyphoscoliosis and a barrelled chest. Although type 
3b is regarded as the ‘Norrbottnian type’ (found in high frequency in the Norbotten 
region of Sweden) the clinical distinction between types 3a and 3b is difficult 
therefore these sub-classifications are rarely used (104). Type 3c, more commonly 
referred to as the cardiovascular form, is a distinct subtype predominated by 
cardiovascular disease with calcification of the mitral and aortic valves with mild 
splenomegaly, supranuclear ophthalmoplegia and corneal opacities. This form is 
specifically associated with patients homozygous for the D409H mutation 
(105,106). In contrast, a subtype of type 2 often viewed as a distinct class, the 
perinatal-lethal form is a rare subset with considerable genotypic variability (107). 
Symptoms can include hepatosplenomegaly, pancytopenia, microscopic skin 
changes (108). Distinctive facial features and arthrogryposis have been reported in 
35-43% of patients (109).  
In addition, pathogenic mutations in GBA2, a related gene to GBA1 encoding for a 
non-lysosomal glucosylceramidase, have been shown to cause an autosomal 
recessive form of cerebellar ataxia with spasticity (110) and autosomal recessive 
hereditary spastic paraplegia (111). 
 
1.4.5 Pathophysiology of type 1 GD 
Deficiency in GC activity leads to accumulation of its substrate glucosylceramide in 
macrophages, the primary storage cell in GD, resulting in the formation of foamy 
macrophages classically referred to as ‘Gaucher cells’ (44,46). This storage affects 
all of the cells of the mononuclear phagocyte system including tissue macrophages 
of the spleen, liver (Kupffer cells), lung (alveolar macrophages), central nervous 
system (microglial cells), bone (osteoclasts), bone marrow, lymph nodes, skin, 
urinary tract and gastro-intestinal tract (112). Interestingly, a post mortem 
investigation of the lipid composition of a type 2 GD patient found the fatty acid 
composition of glucosylceramide in cells of the central nervous system (CNS) was 
different to those in the liver and spleen. Glucosylceramide in the CNS was 
predominantly composed of steric acid whereas visceral organs were 
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predominantly composed of palmitic acid suggesting a different origin of 
glucosylceramide in these cells (113).    
Gaucher cells have been shown to accumulate lipid in membrane-bound tubular 
structures by X-ray crystallography (114), express monocytic markers, are tartrate 
resistant acid phosphatase (TRAP) positive and have the phenotype of alternatively 
activated macrophages (115). They are 20-100µM in diameter, accumulate in 
sheets within tissue and are associated with deposition of extracellular sphingolipid, 
inflammatory infiltrate and fibrotic reaction (116,117).    
Hepatosplenomegaly is a clinical hallmark of GD. In the liver, sheets of lipid laden 
Kupffer cells are present but hepatocytes do not appear to store glucosylceramide 
possibly due to excretion into the bile (118). Hepatic pathology includes fibrosis, 
extramedullary haematopoiesis with a suggested increase in gallstones. Other rare 
pathology includes cirrhosis, liver failure, portal hypertension, oesophageal varices 
and hepato-pulmonary syndrome (89,119). Four cases of GD patients which had 
undergone liver transplant, reported by Ayto et al in 2010, were found to have 
favourable outcomes after up to 10 years post-transplant and was therefore 
regarded as a valid option for GD patients with liver failure (119). Splenic pathology 
includes Gaucher cell infiltration, fibrosis, extra-medullary haematopoiesis, 
infarction and nodules which can be mistaken for cancerous infiltration (120). 
However, despite the elevated levels of glucosylceramide in these tissues they 
cannot account for the increase in volume observed. The spleen for example can 
have up to a 25 fold increase in size but the glucosylceramide accounts for <2% of 
that mass (116). 
Bone disease is a common feature of GD with radiological evidence described in up 
to 93% of patients (121). However, the severity of bone involvement can range 
from complete absence of symptoms to severe osteonecrosis and pathological 
fractures (122). The bone disease can be partially explained by bone marrow 
infiltration of Gaucher cells suggested to cause displacement of marrow cells to the 
periphery (123) which may lead to marrow infarcts including osteonecrosis of joints 
(122) and is likely associated with bone marrow fibrosis and impaired 
haematopoiesis (120). In addition, Gaucher cells are hypothesised to elicit an 
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inflammatory response which may affect bone metabolism (122). However, the 
range of severity and the variety of types of bone disease indicate the involvement 
of several mechanisms which cannot be explained by Gaucher cell infiltration alone. 
Pulmonary disease in the form of interstitial lung disease is common for types 2 and 
3 but rare in type 1 GD (120). However, alveolar macrophages have been shown to 
be affected when macrophages were examined by light and electron microscopy 
from a broncho-pulmonary lavage of a young GD patient with respiratory 
symptoms (124). In addition, infiltrates of Gaucher cells have been reported in the 
lung interstitium and alveolar air spaces (125). Evidence for the prevalence of 
pulmonary disease is unclear with one study of 95 type 1 GD patients showing 68% 
having pulmonary function abnormalities (126) while a later study of 150 patients 
found only 5 with clinical evidence of pulmonary involvement (127). Pulmonary 
hypertension is suggested to occur more often in asplenic patients (90) but 
splenectomy is now rarely performed (120,128).  
Renal pathology is rare in GD but it has been described in a small number of 
patients and is associated with storage of glucosylceramide in glomerular mesangial 
and endothelial cells and interstitial cells of the kidney (129). 
 
1.4.6 Molecular and cellular pathology of type 1 GD 
Several cell types have been reported to be affected in GD. Some of these have 
been linked to the presence of Gaucher cells. An immunohistochemical study of 
splenic Gaucher cells by Boven et al in 2004 identified the presence of large M2-like 
anti-inflammatory cells surrounded by smaller M1 cells positive for IL-6, weakly 
expressing IL-1β and secreting MIP-1β. These cells have been theorised to trigger 
the induction of CD4+ T-cells with Th1 or Th2 phenotype (115,122). GD patient 
macrophages have been found to have impaired chemotaxis in response to CCL3, 
CCL5, and CXCL12 and reduced reactive oxygen species production when cultured 
in vitro (130). Macrophages derived from the peripheral blood monocytes of an 
N370S homozygous GD patient by Aflaki et al in 2015 showed an increased 
secretion of IL-1β and IL-6 in comparison to control cells. Interestingly they also 
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found elevated levels of autophagic adaptor p62 which was preventing the delivery 
of inflammasomes to autophagosomes suggesting that dysfunction of the 
inflammasome activation may contribute to visceral pathology and the increased 
prevalence of Parkinson’s disease in GD (131). In addition, a cellular model in which 
macrophages were differentiated from induced pluripotent stem cells (iPSC) of a 
GD patients also expressed higher levels of IL-6, IL-1β and TNF-α than control cells 
(132). Alterations in monocytes, precursors to macrophages, have also been found. 
Monocytes isolated from the peripheral blood of untreated GD patients have a 
decreased capability of SDF-1α dependent migration (133) and have also been 
found to have an altered ratio of anti-inflammatory CD14+ CD16- to pro-
inflammatory CD14+ CD16+ in favour of the pro-inflammatory monocytes when 
compared to control cells (134).  
Immune cell dysregulation has also been reported with a marked decrease in NK 
cells, CD4+ and CD8+ T cells and altered responsiveness of plasmacytoid dendritic 
cells to TLR9 which is theorised to contribute to a decreased response to pathogens 
and favour the development of malignancies (135,136). In addition, a new 
population of type 2 natural killer T cells (NKT) with follicular helper phenotype 
(THF), identified by Nair et al in 2015, have been found in higher percentages in GD 
patients peripheral blood mononuclear cells (PBMC’s) and are thought to be 
capable of regulating B cell activity (137). 
Mesenchymal stem cells (MSC), which can differentiate into several cell types 
including osteoblasts, adipocytes and chondrocytes, have also been found to be 
affected. A study of 10 GD patient bone marrow samples found morphological and 
cell cycle abnormalities and impaired growth potential with a decreased capacity to 
differentiate into osteoblasts (138). However, assessment of bone marrow MSC 
from a GD patient with N370S/L444P mutations were found to have normal growth 
and differentiation capacities but a marked increase in prostaglandin E2, COX-2, 
CCL2 and IL-8 compared to normal controls (139). Models of progenitor cells have 
also found altered phenotypes. GD patient iPSC differentiated to hematopoietic 
progenitor cells demonstrate an increased commitment to myeloid lineage 
differentiation and decreased erythroid differentiation and maturation (140). While 
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a model using the irreversible inhibitor of GC, conduritol β-epoxide (CBE), to mimic 
GD in mesenchymal progenitors found inhibition led to progressive impairment of 
proliferation (141). Assessment of erythrocyte morphology by electron microscopy 
of 9 untreated GD patients by Bratosin et al in 2011 found they have abnormal 
morphology with reduced viability and CD47 expression which are theorised to 
facilitate erythrophagocytosis in untreated patients (142).  
Analysis of GD patient serum and plasma has found an elevation in a number of 
cytokines and chemokines including IL-1β, IL-1 receptor agonist, TNF-α, IL-6, soluble 
IL-2 receptor (143), osteopontin (144), CD163 (145) amongst others which are 
probably due to secretion by activated macrophages. A summary is provided in 
table 1.2. Increased levels of IL-1β, TNFα and IL-6 may contribute to activation of 
coagulation and hypermetabolism (87,112). Other cytokines which promote 
monocyte differentiation into osteoclasts found to be elevated in GD patient 
plasma and serum, in addition to IL-1β, TNFα, IL-6 include IL-10 (146,147), 
macrophage inflammatory protein (MIP) 1α, MIP1β, macrophage colony stimulating 
factor (MCSF) and pulmonary activation regulatory cytokine (PARC) (147–149).  
In addition, recent analysis of the lipid composition of GD patient plasma and urine 
found elevated levels of 20 plasma and 10 urinary lipids including species of 
phosphatidylcholine, sphingomyelin and ceramides (150). With several publications 
showing substantially higher levels of glucosylsphingosine (151,152), the de-
acylated form of glucosylceramide, in GD plasma and serum demonstrates that the 
deficiency of GC affects the synthesis and degradation pathways of many 
sphingolipids several of which are known to be bioactive and involved in other 
diseases, mentioned in section 1.3. Some of the altered sphingolipid concentrations 
measured in GD patient plasma are shown in table 1.1 below.  
Sphingolipid Change 
(ref) 
Sphingolipid Change 
(ref) 
Sphingolipid Change 
(ref) 
Ceramide ↑(150) Sphingosine ↑(153) Sphingomyelin ↑(150) 
Lactosylceramide ↓(154) Sphingosine-1-
phosphate 
↑(153) Phosphatidyl- 
choline 
↑(150) 
Glucosylceramide ↑(155) Glucosylsphingosine ↑(152) 
Table 1.1 Sphingolipid concentrations altered in GD plasma. Up and down arrows 
indicate higher or lower concentrations relative to control cohorts.  
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Cytokine Origin Action References 
IL-1α 
IL-1β 
IL-1RA 
Monocytes 
Macrophages 
Dendritic cells 
Lymphocytes 
Granulocytes 
Fibroblasts 
Pro-inflammatory 
Leukocyte migration 
 
(143,146,156,1
57) 
sIL-2R T-
lymphocytes 
Lymphocyte stimulation 
Pyrogen 
Pro-inflammatory 
(143) 
IL-6 
IL-6 mRNA 
Macrophages 
T-cells 
Plasma cells 
osteoclasts 
B-cell stimulation 
Pro-osteoclastogenic 
Pro or anti-inflammatory 
response 
(143,146,156) 
 
IL-8 Macrophages 
Epithelial 
cells 
Lymphocytes 
Neutrophil chemotaxis 
Granulocyte chemotaxis 
B-cell stimulation 
Pro-inflammatory 
(143,147,156) 
IL-10 Monocytes 
Macrophages 
Lymphocytes 
B-cell survival and 
proliferation 
Anti-inflammatory 
(146,157) 
sCD163 Monocytes 
Macrophages 
Anti-inflammatory (145) 
MCSF Osteoblasts 
Bone marrow 
stromal cells 
HSC differentiation to 
macrophage 
(147,156) 
MIP1-α 
 
Macrophages Pro-inflammatory 
Leukocyte stimulator 
(148) 
MIP1-β Macrophages Monocyte chemotaxis 
NKT chemotaxis 
(148) 
Osteopontin Macrophages 
Osteoblasts 
Osteocytes 
Dendritic cells 
Osteoclast maturation 
Bone remodelling 
(144) 
PARC Monocytes 
Macrophages 
Eosinophils 
T-cell chemotaxis 
Lymphocyte chemotaxis 
(149,157) 
TNF-α Monocytes 
Macrophages 
Fibroblasts 
Inflammation 
Neutrophil chemotaxis 
Macrophage phagocytosis 
(143,146,156,1
58) 
Table 1.2 Plasma and serum cytokines, chemokines and growth factors elevated in 
GD.  
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1.4.7 Clinical biomarkers  
The plasma of GD patients is commonly used to monitor disease by analysis of 
biomarkers. Common biomarkers include chitotriosidase activity (159,160), PARC 
(CCL18) (149), TRAP (160), serum antigen converting enzyme (S-ACE) (160)  and 
ferritin (159). Chitotriosidase is primarily secreted by macrophages, increased 
expression of chitotriosidase by Gaucher cells leads to increased plasma 
chitotriosidase levels (161). Chitotriosidase activity has been found to correlate 
with disease burden and decreases when GD patients are treated with GD specific 
therapies (162). However, approximately 6% of the population are homozygous for 
a null mutation in the gene encoding chitotriosidase, CHIT1, resulting in 
undetectable enzyme activity and up to 34% of individuals heterozygous for the null 
mutation which is expected to have half the measurable activity of wild type 
protein (163,164). PARC/CCL18 is a chemokine which is also overexpressed by 
Gaucher cells (115) and has been shown to parallel chitotriosidase activity, 
correlate with visceral bulk, decrease when GD patients are treated with GD specific 
therapies (149) and can be used to monitor disease severity in GD patients with the 
null mutation for chitotriosdase (165). TRAP, an acid phosphatase expressed in 
osteoclasts and dendritic cells has been shown to be elevated in GD however serum 
levels have not been found to reflect bone disease severity in GD patients 
(116,166). S-ACE is elevated in the serum of GD patients and can be used to 
monitor disease severity and response to GD specific therapies (167). However, ACE 
is expressed in several tissues types (168) and has a common polymorphism 
resulting in variable expression (169). Serum ferritin levels are raised in GD patients 
(170) and are thought to be caused by macrophage activation due to substrate 
accumulation (159) however this can also be the case for several diseases and 
conditions and therefore may not reflect the severity of GD (171,172). Recently, a 
number of potential biomarkers have been suggested for assessing severity and 
response to therapy. Glucosylsphingosine is highly elevated in GD plasma and has 
been found by Fuller et al in 2015 to correlate with changes in chitotriosidase 
activity for patients receiving GD specific therapies (173). Similarly osteopontin, 
produced by immune cells and macrophages, has also been found to be elevated in 
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GD patient plasma, to decrease when patients receive GD specific therapies and to 
correlate with chitotriosidase activity (144). Soluble CD163, again elevated in GD 
patient plasma, is actively shed from the plasma membrane of 
monocytes/macrophages and has been found to correlate with disease severity and 
chitotriosidase activity. In addition it was found to be significantly elevated in 
patients with abnormal BMD and patients with pulmonary hypertension (145). 
Neopterin is a catabolic product of guanosine triphosphate, synthesised by 
macrophages and indicative of a pro-inflammatory immune response. This has also 
been found to be elevated in GD patient plasma and to decrease when GD patients 
receive GD specific therapies (174). However, the most applicable biomarker is 
probably glucosylsphingosine as its elevation in plasma is a direct consequence of a 
reduction in GC activity. Although the other markers also correlate with disease 
severity and the majority decrease when the patient receives GD specific therapy 
they are primarily increased due to sphingolipid storage in the macrophage 
inducing cellular dysfunction and are therefore surrogate biomarkers  
 
1.4.8 Disease severity scoring systems 
The Zimran scoring system has historically been used to document disease burden. 
However, this scoring system was developed before therapies were available for GD 
and before the discovery of biomarkers. This system incorporates weighted scoring 
domains for age of presentation, spleen status, bony disease, liver function, 
hepatomegaly, splenomegaly, cytopenias and clinical signs of liver disease (175). 
However, substantial weighting is given to irreversible factors such as splenectomy, 
osteonecrosis and imaging abnormalities making the scoring system insensitive to 
changes in response to GD specific therapies and therefore not ideal for following 
disease progression (176). The Gaucher disease severity scoring index for type 1 
(GAUSSI-I) is a more recent scoring index, published in 2008, which consists of six 
domains: skeletal, haematological, lung, neurological, visceral and biomarker, 
evaluated in 51 type 1 GD patients and suggested to be more sensitive for 
monitoring response to treatment than the Zimran scoring system (177). However, 
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it has been suggested that the use of the GAUSSI-I scoring system may be limited 
due to its complexity and technological requirements (178). Subsequently, other 
scoring systems have been developed for adult and paediatric GD type 1 patients 
namely the DS3 and PGS3 systems published in 2015 by Weinreb et al and 2013 by 
Kallish et al respectively. The DS3 scoring system was validated in 133 type 1 GD 
patients and consists of 3 domains: bone, haematologic and visceral and was found 
to be effective for assessing disease burden and response to GD specific therapies 
(179). The PGS3 system, designed specifically for paediatric GD type 1 patients, was 
evaluated in 26 patients and found to correlate with disease severity at diagnosis 
and over time. Unlike the other scoring systems, the PGS3 is designed to be 
informative for clinical management rather than to follow response to therapy as 
many of the patients will not have started therapy (178). Comparison of the two 
most recently developed adult scoring systems, GAUSSI-I and DS3, show a marked 
difference in the contribution of the bone domain to the total score with a 
maximum of 26% in GAUSSI-I but a maximum of 42% in DS3 suggesting the need to 
follow bone disease in response to treatment in GD may be of increasing relevance 
clinically for GD patients.  
 
1.4.9 Diagnosis 
Gaucher disease may be suspected in individuals with characteristic bone disease, 
hepatosplenomegaly, haematological changes and CNS involvement however 
clinical findings alone are not regarded as sufficient for diagnosis (54,60). The gold 
standard is the demonstration of deficient GC activity, estimated between 5-25% of 
normal activity, in leukocytes or other nucleated cells (60,121). However, carrier 
testing by enzyme assay is unreliable due to overlap between carrier and non-
carrier enzyme activities. The finding of reduced enzyme activity can be further 
supported by genetic sequencing of the GBA1 gene to confirm the presence of two 
pathogenic alleles. Discovery of a previously undescribed mutation would require 
confirmation of pathogenicity by confirming the deficiency in activity of GC (60). 
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1.4.10 Prognosis for type 1 GD patients 
Analysis of data recorded in the International Collaborative Gaucher Group (ICGG) 
Gaucher Registry of type 1 GD patients found an average life expectancy of 68 years 
compared to 77 years for the reference population from the USA. Splenectomised 
patients were found to have a shorter life expectancy (64 years for splenectomised 
versus 72 years with intact spleen). However, as the earliest current therapy was 
only introduced in 1995, life expectancy is anticipated to increase (180,181).   
 
1.4.11 Treatment for type 1 GD patients 
Prior to the development of GD specific therapies the most common treatments 
included bone marrow transplantation (BMT)/haematopoietic stem cell 
transplantation (HSCT) (182–184) for severe type 1 and 3 GD patients and 
splenectomy for treatment of painful splenic infarcts, cytopenias and diagnostic 
purposes (185,186). However, while HSCT has been found to improve cytopenias 
and hepatomegaly in addition to correcting the metabolic defect (187) it is also 
associated with significant morbidity and mortality (10-25%) (187,188). 
Splenectomy increases the risk of bacterial infection, worsening bone disease and 
development of pulmonary hypertension (112,176,189). Worsening bone disease is 
likely to be due to one of the spleens functions of phagocytosing effete 
erythrocytes which is achieved through having a high number of resident 
macrophages. In GD this may mean the spleen stores a large proportion of the lipid 
laden macrophages therefore splenectomy may force circulating macrophages to 
reside in other tissues such as the bone marrow, increasing Gaucher cell burden 
and thus worsening bone disease. Due to these risks both options are rarely used 
since the development of effective therapies for type 1 GD. Recently, some groups 
have suggested a re-evaluation of HSCT as advances in technologies such as high-
resolution human leukocyte antigen typing enables more accurate donor recipient 
matching (190) and improved techniques for mobilisation and collection of stem 
cells (191) may make this treatment safer and more effective (192).  
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1.4.11.1 Enzyme replacement therapy (ERT) 
The rationale for ERT is based on the observation that most cells secrete small 
quantities of lysosomal enzymes which could be internalised by other cells. It was 
therefore suggested that infusion of recombinant GC would result in its 
internalisation and trafficking to the lysosomes where it metabolises the 
accumulated substrate glucosylceramide (193). In 1976-77 methods for large scale 
purification of GC from human placenta were developed leading to the first infusion 
of GC into patients (194,195). However, initial studies were not as effective as 
expected. This was explained in subsequent research by Furbish et al in 1978 in 
which infusions given to rats demonstrated that unaltered placental GC was 
localising to hepatocytes, cells which store very little glucosylceramide (196). 
Further investigations of the placental GC found it contained a high percentage of 
galactose-terminated oligosaccharide side chains which targeted the enzyme to the 
hepatocytes (197). To re-target the GC the monosaccharide residues were 
sequentially removed from the side chains using the enzymes neuraminidase, β-
galactosidase and β-N-acetylglucosaminidase to expose mannose residues which 
could bind to the macrophage mannose receptor (MMR), be internalised by the 
macrophages and trafficked to the lysosomes (193,198).  
The first trial of the mannose-terminated GC, published in 1991 by Barton et al, 
resulted in a reduction in hepatosplenomegaly and improvement of haematological 
parameters with no serious adverse events (193). Subsequently, this therapy was 
approved by the Food and Drug Administration (FDA) (199) and was marketed by 
Genzyme as alglucerase (Ceredase). However, the preparation of this therapy 
required a large supply of placentas and was therefore both very limited in terms of 
supply and very expensive. In 1994 Genzyme obtained FDA approval for a 
recombinant form of GC produced in Chinese hamster ovary cells named 
imiglucerase (Cerezyme) (200,201). An outcome survey of data recorded in the 
ICGG registry of type 1 GD patients receiving imiglucerase for 10 years showed 
significant improvements in haemoglobin levels, platelet count, bone crises, liver 
and spleen volumes (202).  
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Two other ERT’s have since been developed and given FDA approval: velaglucerase 
alfa (VPRIV, Shire Pharmaceuticals) a gene activated form produced in human 
fibroblast-like cell line (203) and taliglucerase alfa (Elelyso, Protalix/Pfizer) produced 
in carrot cells, the first drug made in plant cells to be given FDA approval (204). 
A 9 month, randomised control study comparing the efficacy of imiglucerase and 
velaglucerase alfa found no difference in their effectiveness although a slightly 
higher risk of drug related adverse events (AE) was found with velaglucerase alfa 
treatment with 8/17 patients with an AE when receiving velaglucerase versus 6/17 
AE for patients receiving imiglucerase (205). In addition, these therapies are well 
tolerated with approximately 10-15% of individuals developing antibodies to 
imiglucerase and 1% of individuals developing antibodies to velaglucerase alfa 
(206,207). Taliglucerase alfa is a much more recent therapy, obtaining approval for 
use in paediatric patients in 2014 (208) therefore there is less clinical data available 
but initial reports show reduction of hepatosplenomegaly, improvement in 
haematological parameters (209), increased bone marrow fat fraction (210) and 
stability in disease parameters when switching from imiglucerase (211). 
Taliglucerase alfa is also the only ERT which is deemed kosher by the US Orthodox 
Union. A basic comparison of the ERT’s are shown in table 1.3 below. 
Enzyme Product name Produced in Biochemical differences 
Imiglucerase Cerezyme Chinese hamster 
ovary cell line (CHO) 
Amino acid substitution 
at residue 495 (R495H) 
Velaglucerase 
alfa 
VPRIV Human fibroblast 
cell line 
Native human enzyme 
Taliglucerase 
alfa 
Elelyso Carrot root cell  
 
Native human enzyme 
with plant glycosylation 
Table 1.3 Comparison of commercially available ERT’s.  
 
1.4.11.2 Substrate reduction therapy (SRT) 
SRT is an alternative treatment strategy to ERT by inhibiting glucosylceramide 
synthase and thus reducing the amount of substrate, glucosylceramide, for the 
defective GC to process (212). This approach was developed to meet the need of 
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patients for whom ERT is not a therapeutic option due to allergy, hypersensitivity or 
poor venous access (213). 
The first compound approved for SRT in mild to moderate GD patients was N-
butyldeoxynojirimycin (miglustat, marketed as Zavesca by Actelion) (214). The main 
advantage of which is its oral administration (215). It has been approved in a 
number of countries including the USA, Canada, EU, Switzerland and Israel (60). 
Miglustat treatment has been shown to result in significant decrease in 
hepatosplenomegaly after 6 to 18 months with bone and haematological 
parameters remaining stable (214,216). Increase in bone density at the lumbar 
spine and femoral neck was reported as early as 6 months (218). However, side 
effects including gastrointestinal dysfunction, peripheral neuropathy and tremors 
most likely caused by its non-specific inhibition of other enzymes including 
intestinal disaccharides with the most common adverse outcomes in clinical trials 
being weight loss, bloating, flatulence and diarrhoea (60,218). Due to these side 
effects miglustat is only recommended for patients with a mild to moderate 
phenotype who are not suitable for ERT (213).  
Recently, a second SRT has been approved by the FDA called eliglustat tartrate 
(Genzyme) a synthetic analogue of 1-phenyl-2-decanoylamino-3- morpholino-1-
propanol formulated as a tartrate salt (219). Eliglustat is designed to be a more 
specific inhibitor of glucosylceramide synthase, experiments with which have 
shown that even at relatively high micromolar concentrations it did not inhibit 
intestinal disaccharides or lysosomal GC (220). In a placebo-controlled phase 3 
study of therapy naïve patients those given eliglustat for 9 months had a 28% 
decrease in spleen volume and a 7% decrease in liver volume with improvement in 
haematological parameters (221). A positive effect on bone was also suggested by a 
significant increase in lumbar spine T-scores in 19 patients enrolled in a phase 2 
study for up to 4 years (222). Reported side effects include diarrhoea, arthralgia, 
fatigue and headache (223). 
 
 
47 
 
1.4.11.3 Pharmacological chaperone therapy (PCT) 
PCT is a rapidly developing field with numerous new compounds under 
development for several diseases in which abnormal protein folding or defective 
trafficking can lead to enzyme deficiency (224). PCT’s are low molecular weight 
compounds designed to stabilise or aid correct folding of the native conformation 
of the mutant enzyme in the endoplasmic reticulum (ER) enabling the enzyme to 
avoid aggregation and degradation by the ER associated degradation pathway 
(ERAD) (225). The stabilised protein can then be transported through the trans-golgi 
network for maturation to the lysosome (226). The PCT is designed to bind to the 
active site at neutral pH and dissociate at the acidic pH present in the lysosome 
(227). Several pathogenic mutations in GD are thought to result in premature ERAD 
mediated degradation including the most common N370S (228). One of the first 
candidates for PCT for GD was the unmodified iminosugar isofagomine which binds 
to the active site of GC and can therefore behave as a competitive inhibitor (229). 
Initial experiments demonstrated isofagomine to be an enhancer of GC activity 
increasing the enzyme activity and protein levels of several mutant GC’s (230), 
including N370S (230), however phase II and III trials found suboptimal 
improvement in key GD clinical parameters (231). It was theorised by Sánchez-
Fernández et al in 2016 that the reason for this may be that the transport of 
isofagomine to the ER and lysosome is inefficient. In addition, it is thought that the 
balance between its action as a competitive inhibitor and chaperone may require 
very accurate dosage both in terms of amount given to the patient and the period 
between doses (225). 
A second PCT, ambroxol hydrochloride found by screening 1040 FDA approved 
drugs (227), has also been shown to increase GC activity and protein levels (232). 
Ambroxol is a mucolytic approved for treatment of respiratory diseases (233) but is 
not currently approved as a therapy for GD. A pilot study in which 12 type 1 GD 
patients received a relatively low dose of ambroxol for 6 months showed no 
adverse effects. The study produced limited clinical effects most likely due to the 
low dosages used but trials with higher doses are planned (234).  
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Due to the fact that PCT’s are chemical compounds optimization strategies can be 
employed to improve pharmacokinetics, toxicity and bio-distribution (235). One 
such example is a modification to the structure of ambroxol resulting in doubling 
the maximum GC activity enhancement in N370S homozygous GD fibroblasts (225). 
 
1.4.11.4 Gene therapy 
GD is considered a potential candidate for gene therapy for several reasons. 1. It is 
a monogenic disorder with studies showing demonstrable cross correction (193) 2. 
only 11-15% of expression was sufficient for correction in vitro (236). In addition, 
the GBA1 gene and the main affected cells have been well characterised. Recent 
studies involving adenovirus (237) and lentivirus (238) vectors demonstrated 
increased expression of GC in mouse models with the study using lentivirus stating 
this expression cured the type 1 GD model used (238). However, several hurdles 
still need to be overcome before this can be considered a viable therapy (239).     
 
1.4.12  Gaucher disease and cancer risk 
Patients with GD have been reported to have an elevated risk of developing both 
haematological and non-haematological cancers when compared to the general 
population (240,241). Reported haematological cancers include: multiple myeloma 
(157,241–243), acute lymphoblastic leukaemia (244), acute myeloid leukaemia 
(245), chronic lymphocytic leukaemia (246), chronic myeloid leukaemia (247,248), 
large B-cell lymphoma (249), T-cell lymphoma (250) and Hodgkin lymphoma (251). 
Non-haematological malignancies include: liver (157,252), lung (253), bone 
(254,255), colon (243), kidney (157,256), testis (256), thyroid (243), prostate 
cancers (243), glioblastoma multiforme (257), dysgerminoma (258) and melanoma 
(242).  
Several studies have been carried out to investigate the incidence of cancer in GD 
patients. In 1982, Lee et al compiled a registry of 239 type 1 GD patients. Of the 35 
patients who died in this cohort 54% (19/35) were attributed to cancer (256). A 
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study in 1993 by Shiran et al reported an increased cancer risk of 14.7 fold for 
haematological and 3.4 fold for non-haematological cancers among 48 type 1 GD 
patients. However, it has been suggested that this study may have overestimated 
the risk as these patients were selected due to referral to a cancer centre and thus 
introduced referral bias (245,259). Zimran et al in 2005 carried out a study of 505 
type 1 GD patients of Ashkenazi Jewish ancestry but found no overall increased risk 
of haematological malignancy with the exception of multiple myeloma (260). 
However, this was a relatively young cohort with a mean age of 37 years which 
probably resulted in underestimation of cancer incidence. A similar issue was 
present in a study by Rosenbloom et al in 2005 which included 2742 type 1 GD 
patients from the ICGG registry. Again this study found no increase in overall cancer 
risk but did record a 5.9-fold increased risk for multiple myeloma. However, the 
population studied was also a relatively young age group and so may have led to an 
underestimation of cancer incidence. 
In 2006 de Fost et al assessed a population of 131 type 1 GD patients from Western 
Europe. This study found an increased risk of 2.5 fold for cancer and 12.7 for 
haematological malignancies. Interestingly, this study also found a higher incidence 
of hepatocellular carcinoma with a standardised rate ratio of 141.3 (157). Taddei et 
al in 2009 assessed a cohort of 403 type 1 GD patients which were either 
homogenous or heterogeneous for the N370S mutation. As the majority of the 
patients were of Ashkenazi Jewish ancestry the relative risk was calculated in 
relation to the Israeli population. In this study 55 cancers were reported in 46 
patients with an overall risk of cancer of 1.8 and 3.45 for haematological cancers 
excluding myeloma (242). A study in 2010 by Lo et al assessed a cohort of 403 type 
1 GD patients 9 of which developed up to 3 sequential cancers. The authors of this 
study suggesting that type 1 GD patients may be at risk of developing multiple 
malignancies and that splenectomised patients appeared to have an elevated risk of 
developing cancer (243). Based on the number of case reports AL amyloidosis is 
suggested to occur more frequently in GD compared to the general population 
(261). Similarly, non-Hodgkin lymphoma has also been found to be more common 
in a cohort of GD patients when compared to the general population (240).  
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1.4.13  Gaucher disease and multiple myeloma 
The incidence of polyclonal gammopathy and paraproteinaemia has been reported 
to be increased in several type 1 GD patient cohorts (262). The incidence of 
polyclonal gammopathy in adult cohorts has been reported in up to 60% of 
patients, with IgG the most common immunoglobulin to be elevated (87,146,262). 
In addition, the incidence of polyclonal gammopathy has been suggested to be 
higher in paediatric GD populations (263). Analysis of the incidence of polyclonal 
and monoclonal gammopathy of unknown significance (MGUS) in type 1 GD 
patients has been shown in large cohorts to follow a temporal sequence with 32% 
having polyclonal gammopathy at a mean age of 62 years, 3.2% MGUS at a mean 
age of 78 years, and 2.2% multiple myeloma at a mean age of 84 years (242,262). 
Population studies have demonstrated that approximately 1% per year of patients 
with MGUS progress to develop multiple myeloma (264). However, it is unknown if 
this rate of progression applies to GD patients (265).  
A number of studies, including those mentioned in section 1.4.12. have shown an 
increased risk of multiple myeloma for type 1 GD patients (146,157,241,242,266). In 
addition, based on the number of case reports multiple myeloma is the most 
common cancer reported in GD (157,241,259) with myeloma and B cell lymphomas 
regarded as the leading cause of death in GD (157,241,242). In the 2006 de Fost 
study, multiple myeloma risk is estimated to be 51.1 fold which was accompanied 
by an increased prevalence of MGUS: 16% in the Netherlands and 7% in Germany 
compared to an estimated 1-2% in a population of a similar age (157). Similarly, 
Taddei in 2009 found the highest risk in their cohort was for multiple myeloma with 
a relative risk of 25 fold. However, this rate was determined only for the first 
incidence of cancer in an individual. When all incidences of multiple myeloma were 
included the relative risk rose to 37.5 fold (242). Landgren et al in 2007 carried out a 
study of 1,525 adult male U.S. veterans with type 1 GD and found no increased risk 
of multiple myeloma. This study has been criticised for its young population and the 
use of ICD codes 272.2 and 272.7 to identify patients with GD are not specific for 
GD and include other lipid storage diseases as well as dyslipidemias (245,267). In 
regards to age, the 2005 study by Rosenbloom showed that 9/10 patients with 
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multiple myeloma were older than 60 years of age (241) suggesting focusing on a 
relatively young cohort will cause a significant underestimation of prevalence in the 
GD population.  
 
1.4.14  Gaucher Disease and myeloma – potential mechanisms 
Several mechanisms have been proposed to contribute to an increased incidence of 
cancer in general and multiple myeloma in particular in GD. As previously 
mentioned several reports have shown that type 1 GD patients may have a 
dysfunctional immune system (268) with marked decreases in NK cells, CD4+ and 
CD8+ T cells and peripheral blood dendritic cells (135,136,269). A study of 5 type 1 
GD patients found defective T-cell function through a reduction of E-rosetting 
capacity proposed to result from hyperferritinaemia which is commonly found in 
GD (269). In addition, ferritin release from Gaucher cells has been suggested to 
reduce T-cell function and IgM release from B cells (270,271).  
One suggested mechanism causing the immune dysregulation are the Gaucher cells 
and alternatively activated macrophages surrounded by highly inflammatory 
macrophages in tissues (115). Several anti and pro-inflammatory cytokines have 
been reported to be elevated in the serum of GD patients including IL-1, MCSF, IL-6 
and TNF-α which may result in chronic stimulation of the immune system (132,147). 
These cytokines have also been proposed to directly underlie the occurrence of 
gammopathies in GD with IL-6 known to stimulate B-cells consistently elevated in 
GD serum (272,273).  
Recently, the role of sphingolipids as bioactive molecules in cancer has been 
suggested to contribute to the increased incidence of cancer in GD. Invariant 
natural killer cells (iNKT) are known to participate in anticancer 
immunosurveillance. They are a subset of αβ T-cells with an invariant TCR alpha 
chain that recognize lipids, one of which has been shown to be endogenous 
glucosylceramide, also shown to be a major signal for both murine and human iNKT 
cells (274,275). Glucosylceramide has also been linked with cell proliferation (276). 
MDCK (Madin-Darby Canine Kidney Epithelial) cells treated with an inhibitor of GC, 
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conduritol β-epoxide, showed a time dependent accumulation of glucosylceramide 
which correlated with increased cellular proliferation (277). In addition, 
glucosylsphingosine has also been suggested to mediate cellular dysfunction (272) 
and to lead to increased levels of sphingosine-1-phosphate which has been shown 
to have proliferative pro-mitogenic, anti-apoptotic and pro-angiogenic effects (278).  
Studies have also demonstrated that several multidrug resistant cell lines have 
increased cellular levels of glucosylceramide including the breast cancer cell line 
MCF-AdrR and epidermoid carcinoma cell line KB-V-1 (279). A comparable increase 
has also been documented in human tumor specimens (280) with drugs such as 
tamoxifen and verapamil shown to markedly decrease glucosylceramide levels 
(274). In this regard, glucosylceramide has been suggested to be involved in drug 
resistance rather than proliferation (281,282) as it has been shown to upregulate 
the expression of the multidrug efflux pump P-glycoprotein (PGP) and to block 
chemotherapeutic-induced oxidative cell death (281–283).  
The role of ceramides, also found to be elevated in GD plasma, in relation to 
inflammation and cancer have also expanded (284). Not only has ceramide been 
shown to be pro-apoptotic and a mediator of pro-apoptotic pathways but also an 
anti-inflammatory and that a metabolite of ceramide, ceramide-1-phosphate, is a 
potent pro-inflammatory mediator (278,285,286). Recent research has also 
suggested unique anti and pro-cancer effects depending on the length of the acyl 
chain of the ceramide species (285,287). In addition, several anti and pro-cancer 
effects are linked to the sphingosine-1-phosphate/ceramide biostat theory which 
purports that sphingosine-1-phosphate is pro-oncogenic and pro-metastatic while 
ceramide regulates anti-cancer fate with ceramide-based therapeutics emerging as 
anti-cancer agents (38,278,285). 
In regards to potential genetic modifiers, several genes in inflammatory pathways 
have been studied but no consistent correlations have been observed (245).     
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1.5 Bone remodelling 
The skeleton is a very specialised and dynamic organ that undergoes continuous 
regeneration (288). Bone modelling occurs during bone formation and takes place 
from the skeletal development in the foetus to the second decade of life (289). 
Modelling is distinct from remodelling as it involves bone formation at sites that 
have not undergone prior resorption and therefore leads to modification of bone 
mass and form. Remodelling occurs throughout life. Very small regions of bone are 
resorbed by osteoclasts followed by recruitment of osteoblast precursors that 
differentiate and deposit bone matrix to replace the amount of bone removed 
(289). Remodelling is crucial for adaption to physical stress, removal of old bone 
and repair of bone damaged by daily physical load to maintain mechanical integrity 
(290,291). Remodelling processes occur asynchronously at different stages of 
progress at anatomically distinct sites throughout the skeleton (292). 5-10% of the 
skeleton is replaced every year and the entire skeleton is completely replaced every 
10 years (293). Osteoclasts and osteoblasts are not present on the bone surface 
simultaneously as the remodelling process can take up to 6 months (294). Early 
studies by Eriksen et al published in 1984 showed bone resorption in the trabeculae 
of the iliac crest takes approximately 3 weeks (295) while bone formation takes a 
further 3-4 months (296). Between these two activities there is a currently poorly 
understood reversal phase (297) which lasts for approximately 5 weeks (295).  
Precise co-ordination of bone removal and replacement is essential to ensure an 
equivalent amount of bone replaces the bone removed (289). To achieve this a 
basic multicellular unit (BMU) is formed. The concept for the BMU originally 
included only osteoclasts and osteoblasts but over recent years the number of cell 
types involved has expanded as other contributors to bone remodelling have been 
discovered. These cells include T-cells, osteocytes, macrophages and precursors of 
osteoclasts and osteoblasts (291,298,299). The BMU differs according to whether 
remodelling is occurring on the bone surface i.e. trabecular bone or within the bone 
i.e. cortical bone. In trabecular remodelling the BMU forms on the surface with a 
canopy of cells predominantly of mesenchymal stem cell origin over either 
osteoclasts or osteoblasts. In this form of BMU the osteoclasts remove an amount 
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of bone and the surface is cleaned up by lining cells and probably macrophages 
(289,300). Osteoblast precursors then fill the resorbed space, differentiate and 
deposit new bone (289). Within the bone the BMU consists of a cutting zone led by 
osteoclasts which are followed by differentiating osteoblasts with remaining space 
filled by blood vessels, nerves and connective tissue, both BMU’s shown in figure 
1.3 obtained from Sims and Martin et al 2014 (289). However, it should be noted 
that 90% of bone remodelling is found on previously resorbed bone on the 
trabecular surface and so the trabecular BMU is the most commonly referred to 
(301,302).     
The tight regulation between osteoclast and osteoblast activity is referred to as 
coupling (289). To ensure this a second structure forms around the BMU, this is 
referred to as the bone remodelling compartment (BRC). This consists of a canopy 
of bone lining/osteoblast cells and a nearby capillary covering the BMU (303). 
Hauge et al have provided direct evidence that when the need for a remodelling 
event has been detected bone lining cells separate from the underlying bone and 
form the raised canopy before bone resorption begins (304). This initiation event is 
thought to be orchestrated by osteocytes as evidence indicates that they can act as 
mechanosensors (305,306). The main purpose of the BRC is hypothesised to 
provide a compartment for intercellular communication between bone cells, 
epithelial, vascular and immune cells which may be accessible via the blood supply 
ensuring maintenance of local concentrations of coupling signals and the correct 
positioning of cells for contact based communication (289).  
The potential influence of immune cells has been of growing interest as it has been 
shown that T-cells can mediate the anabolic effect of parathyroid hormone (PTH) 
known to induce bone formation at low concentrations but bone resorption at high 
concentrations (307,308). In addition, several cytokines produced by T-cells are 
known to either be promoters or inhibitors of osteoclast formation including IL-17, 
IL-4, RANKL and Wnt10b (309–311). A recent finding that B-cells produce Wnt-1, 
known to promote bone formation, further implicates the immune system in 
modulation of bone remodelling (312). It has also been suggested that the canopy 
of bone lining cells may play an important role in the reversal phase as biopsies 
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from postmenopausal and glucocorticoid induced osteoporotic patients exhibited 
incomplete canopies at sites where there was reversal phase arrest i.e. bone was 
resorbed but osteoblast precursors were not recruited and so the bone was not 
replaced (313,314).  
Locally generated cytokines are regarded as the key influences on bone remodelling 
which in turn are often regulated by hormones and the nervous system (289). 
Recent research has shown that signals go in both directions between osteoclasts 
and osteoblasts. One proposed mechanism in addition to cellular and hormonal 
signalling is the release of cytokines from the bone matrix following resorption by 
the osteoclasts (294). Bone is composed of inorganic salts and organic matrix. The 
inorganic material consists of phosphate and calcium ions which form 
hydroxyapatite crystals and make up approximately 65% of the bone composition 
(315,316). 90% of the organic bone matrix consists of collagenous proteins which 
are predominantly type 1 collagen (315). The non-collagenous proteins include a 
range of cytokines and growth factors including transforming growth factor beta 
(TGF-β), bone morphogenic protein-2 (BMP-2), platelet derived growth factor 
(PDGF), insulin-like growth factors (IGF’s), osteopontin, osteonectin, fibronectin and 
bone sialoprotein II (317–321). All are deposited by the osteoblasts during matrix 
production and released by resorption (319). Some of which are then activated by 
plasminogen activators and matrix metalloproteinases (322,323). Their main 
actions are to stimulate osteoblast progenitors including their recruitment 
(324,325), migration (324,326,327) and differentiation (326,328). 
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Figure 1.3 Bone remodelling. Basic multicellular units (BMU) in trabecular bone and 
cortical bone. Sims and Martin. BoneKey reports, 2014 (289).  
 
1.6 Osteoclasts 
Osteoclasts are terminally differentiated giant multinuclear cells (329) formed by 
the fusion of cells of the monocyte/macrophage lineage and are the only known cell 
type to form ruffled membranes and degrade bone (330). Cell-cell fusion occurs 
primarily via the dendritic cell-specific transmembrane protein (DC-STAMP), 
regarded as the master regulator of osteoclastogenesis (331). However, recent 
research by Witwicka et al published in 2015 has shown that a second fusion 
protein, osteoclast-stimulatory transmembrane protein (OC-STAMP), is also 
essential for osteoclastogenesis and is not interchangeable with DC-STAMP (332). In 
addition, DC-STAMP is thought to play a role in bone homeostasis as evidence 
suggests it regulates the differentiation of both osteoblasts and osteoclasts (331). 
Osteoclastogenesis is primarily driven by macrophage colony stimulating factor 
(MCSF), secreted by a number of cells including mesenchymal stem cells (MSC’s) 
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and osteoblasts (333,334), and receptor activator of nuclear factor κB ligand 
(RANKL) secreted in the main by osteoblasts and osteocytes (335,336). Binding of 
MCSF to its receptor (M-CSFR; c-fms) on osteoclast precursors stimulates their 
proliferation, inhibits apoptosis and promotes expression of the RANKL receptor 
(RANK) increasing their sensitivity to RANKL (337,338). The binding of RANKL to its 
receptor induces osteoclast formation (339). In the presence of MCSF, RANKL 
stimulates DNA synthesis and cell proliferation during the early phase of 
osteoclastogenesis but in the later phase exerts an anti-proliferative action (340). It 
is therefore theorised that RANKL optimises osteoclast formation by ensuring a 
sufficient number of pre-osteoclasts for cell-cell contact and fusion (341). To 
mediate osteoclastogenesis RANKL is bound by osteoprotogerin (OPG), a soluble 
decoy receptor secreted by a number of cell types including MSC’s and osteoblasts, 
preventing RANKL from binding to RANK thus inhibiting osteoclastogenesis (342). 
OPG has also been shown to induce apoptosis of both osteoclast precursors and 
mature osteoclasts via the classic Fas/FasL pathway (343). Recent research by Luo 
et al published in 2016 has identified a second decoy receptor, leucine-rich repeat-
containing G-protein-coupled receptor 4 (LGR4) whose expression is induced by 
RANKL signalling and therefore acts as a negative regulator of osteoclastogenesis in 
addition to OPG (344). 
Once formed, osteoclasts are short lived and undergo apoptosis within a few days 
(341). They are defined by their ability to resorb bone, dissolving both inorganic and 
organic components of the bone matrix, by secreting protons and collagenolytic 
enzymes (345). During bone resorption polarization of the osteoclast occurs. This 
results in the formation of four osteoclast membrane domains: the sealing zone 
and ruffled border, which are in contact with the bone surface and the basolateral 
and functional secretory domains which are not in contact with the bone surface 
(346,347). The formation of the ruffled border involves the reorganisation of the 
actin cytoskeleton to form an F-actin ring which creates a podosome, isolating an 
area of the membrane which forms the ruffled border. Maintenance of the ruffled 
border is essential for osteoclast activity and is formed by intense trafficking of 
lysosomal and endosomal components (315). The sealing zone is formed by the 
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binding of αVβ3-integrin (vitronectin receptor) to bone matrix proteins such as 
bone sialoprotein (BSP), osteopontin and vitronectin creating a sealed central 
region in which the ruffled border is located (348). In the ruffled border protons 
and enzymes such as tartrate resistant acid phosphatase (TRAP), matrix 
metalloproteinase-9 (MMP-9) and cathespin K are transported into a compartment 
called the Howship Lacuna to dissolve the bone matrix (346,349–351). The 
degradation products are endocytosed across the ruffled border and transcytosed 
to the plasma membrane (347).   
Osteoclast formation and activity is controlled by both systemic and local factors. 
Systemic factors include parathyroid hormone (PTH), calcitonin (CT), estrogen and 
vitamin D3 (1,25(OH)2 vitamin D3) (288). PTH is secreted by the parathyroid glands 
in response to changes in serum calcium levels (352). Chronic elevation of PTH 
levels leads to trabecular bone loss however its primary action is on MSC’s and 
osteoblasts, increasing RANKL and decreasing OPG production (353) leading to 
increased osteoclast formation. CT is secreted by the thyroid C cells and tissue 
specific alternative splicing of the calcitonin gene results in the production of 
calcitonin gene-related peptide-1 (CGRP-1). Their effects are primarily mediated 
through the calcitonin receptor and calcitonin receptor like receptor respectively 
(354,355), both expressed on osteoclasts (356) resulting in morphological changes 
in osteoclasts inhibiting their motility and activity (357). Estrogen is a major 
hormonal regulator of bone metabolism in both men and women (288). Estrogen 
blocks RANKL/MCSF mediated osteoclast differentiation by reducing c-Jun activity 
(358), suppressing osteoclast differentiation. In addition, estrogen has also been 
shown to modulate a number of cytokines including TNF-α, MCSF, IL-1, IL-6 and 
prostaglandins (359,360). Vitamin D3 is recognised as being essential for the normal 
development and maintenance of bone (288) primarily through endocrine actions 
to stimulate intestinal calcium and phosphate absorption (361). However, research 
by Takeda et al published in 1999 has shown that vitamin D3 has localised effects in 
the bone microenvironment, stimulating osteoclastogenesis by binding to vitamin 
D3 receptor (VDR) expressed by osteoblasts and osteocytes inducing the secretion 
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of RANKL (362). In addition, evidence suggests vitamin D3 can also directly regulate 
osteoclast precursor proliferation and fusion (363,364).  
As research into the regulation of bone remodelling progresses an ever increasing 
number of local factors influencing osteoclast formation and function are being 
discovered, shown in table 1.4. Many of these factors ultimately affect the main 
system of osteoclast regulation, namely the RANKL/RANK/OPG axis (342). Factors 
such as bone morphogenic proteins (including BMP 2 and 7) (365), interleukins 
(including IL-6 and IL-10) (366,367), oncostatin M (368), Wnt proteins (including 
Wnt3a, 5a, 16) (369,370) indirectly affect osteoclast formation and maturation by 
altering the expression and secretion of RANKL and OPG by osteoblasts. While 
other factors such as caveolin 1 (371) and forkhead box protein O1 (FOXO1) (372) 
affect the expression of RANK by osteoclast precursors, altering their sensitivity to 
RANKL.  
RANK/RANKL expression in osteoclasts is also regulated by microRNA’s which are 
non-coding RNA sequences of ~22 nucleotides which can prevent the transcription 
of mRNA. In osteoclasts, these miRNA sequences can be either pro-
osteoclastogenic e.g. miR-148a or anti-osteoclastogenic e.g. miR-503 (373). With 
the continual discovery of different miRNA sequences, many more are likely to be 
found to regulate osteoclastogenesis.  
Several lipids have also been found to modulate osteoclast formation and function. 
These include cholesterol which has been suggested to affect osteoclast viability 
(374), ceramide which has been shown to reduce osteoclast activity by inhibiting 
actin ring formation (375) and lactosylceramide which has been shown to increase 
RANK expression in osteoclasts (376). Furthermore sphingosine-1-phosphate (S1P) 
has been found to be a chemotactic factor, regulating precursor osteoclast 
migration between the bone marrow and the blood (377). S1P is produced by cells 
in the vasculature (378) and at high levels by osteoclasts (379). Regulation of 
osteoclast recruitment is mediated through two receptors, S1PR1 
(chemoattractant) and S1PR2 (chemorepulsant). High concentrations of S1P in the 
blood cause internalisation of S1PR1 and surface expression of S1PR2 on precursor 
osteoclasts resulting in chemorepulsion of the precursors from the blood stream to 
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the bone marrow. Equally, a higher concentration in the bone marrow can cause 
migration to the blood thus regulation of the S1P gradient can affect recruitment 
and formation of osteoclasts in the bone marrow niche (377,380). In addition, S1P 
has also been found to increase expression of RANKL by osteoblasts, further 
enhancing osteoclast generation (380). 
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Factor Origin Generation Activity Ref 
Arginase 1 Osteoclasts ↓ Unknown (381) 
BMP 2 and BMP-7 Osteoblasts, osteoclasts  
↑ 
 
↑ 
(365) 
Caveolin 1 Monocytes, macrophages  
↑ 
 
Unknown 
(371) 
FOXO1 Monocytes, macrophages  
↓ 
 
↓ 
(372) 
IL-1β Osteoblasts, macrophages 
Osteoclasts 
 
↑ 
 
↑ 
(382) 
IL-6 Osteoblasts, macrophages 
Plasma cells 
 
↑ 
 
Unknown 
(366) 
IL-8 Macrophages ↑ ↑ (383) 
IL-10 Monocytes, macrophages 
T-cells 
 
↓ 
 
↓ 
(367) 
IL-11 Osteoblasts ↑ Unknown (384) 
IL-17 T-helper cells ↑ ↑ (385) 
IL-23 NK cells, dendritic cells  
↑ 
 
↑ 
(386) 
LGR4 Osteoblasts, monocytes, 
macrophages 
 
↓ 
 
↓ 
(344) 
MCSF Osteoblasts, osteocytes, 
fibroblasts 
 
↑ 
 
↑ 
(387) 
Micro RNA-148a Monocytes, pre-osteoclasts  
↑ 
 
Unknown 
(373) 
Micro RNA-503 Monocytes, pre-osteoclasts  
↓ 
 
Unknown 
(373) 
MIP-1α, MIP-1β Macrophages, lymphocytes ↑ ↑ (388) 
Notch Macrophages, osteoblasts  
↓ 
 
Unknown 
(389) 
Oncostatin M Macrophages, osteoblasts  
↑ 
 
Unknown 
(368) 
OPG Osteoblasts, MSC’s  
↓ 
 
↓ 
(342) 
RANKL Osteoblasts, osteocytes, MSC’s  
↑ 
 
↑ 
(342) 
Semaphorin 3b Osteoblasts ↑ ↑ (390) 
TGF-β Osteoblasts ↑ ↑ (391) 
TNF-α Monocytes, macrophages ↑ ↑ (392) 
Wnt3a MSC’s, osteoblasts ↓ ↓ (369) 
Wnt5a MSC’s, osteoblasts ↑ ↑ (370) 
Wnt 16 MSC’s, osteoblasts ↓ ↓ (370) 
Table 1.4 Local extracellular and intracellular factors affecting osteoclast generation 
and activity. Ref = reference.  
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1.7  Osteoblasts 
Osteoblasts are derived from MSC’s with initial commitment requiring the 
expression of specific genes including the synthesis of BMP’s and Wnt proteins 
(393) to become precursor osteoblasts which have been found to circulate in the 
blood as well as being resident in the bone marrow (394). Interestingly, it has been 
shown by Gray et al in 1996 that osteoblast precursors can sense the size and shape 
of pits formed by osteoclast resorption and preferentially attach, mature and form 
bone matrix in those locations (395). Osteoblast differentiation is largely mediated 
through the expression of Runt related transcription factor 2 (RunX2), regarded as 
the master gene as RunX-2-null mice lack osteoblasts, in conjunction with Distall-
less homeobox 5 (Dlx-5) and osterix (Osx) (396,397). A recent study by Chen et al 
published in 2015 has also shown mTORC1 to have a distinct role in osteoblast 
maturation (398). Maturation is characterised by a morphological change becoming 
large cuboidal cells with a high expression of Osx and the secretion of bone matrix 
proteins (396). 
Once mature, osteoblasts synthesise bone matrix which occurs in two phases, 
deposition of organic matrix followed by mineralisation. In the first phase, 
osteoblasts secrete collagen proteins, predominantly collagen type 1, non-
collagenous proteins including osteonectin, bone sialoprotein II, osteopontin and 
proteoglycans such as decorin and biglycan (315,399,400). This is followed by the 
mineralisation phase which itself has two stages, the vesicular and fibrillar phases 
(401,402). Matrix vesicles, loaded with calcium ions bound to proteoglycans, bud 
from the apical membrane and are deposited onto the organic matrix. The 
proteoglycans are degraded by osteoblast secreted enzymes and the calcium ions 
are released into the vesicle via annexin calcium channels (401–403). Secretion of 
alkaline phosphatase (ALP) by osteoblasts degrades phosphate-containing 
compounds, releasing phosphate ions which react with the calcium ions to form 
hydroxyapatite crystals. The fibrillary phase occurs when the hydroxyapatite 
crystals rupture the vesicle due to supersaturation leading to the release of these 
crystals onto the organic matrix and its mineralisation (404,405). Additionally, 
osteoblasts produce cytoplasmic processes towards the bone matrix which can 
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come in contact with osteocyte processes leading to further communication and 
modulation of function (406). Finally, osteoblasts can undergo apoptosis or change 
function to become osteocytes or bone lining cells (407,408).  
As with osteoclasts, osteoblast formation and function is regulated by both 
systemic and local factors, many of which affect both cell types. Systemic osteoblast 
factors include PTH, parathyroid related protein (PTHrP), CT, estrogen, vitamin D3, 
insulin-like growth factor 1 (IGF-1) and androgens (321,409–413). PTH, while being 
able to stimulate osteoclastogenesis has also been found to increase proliferation 
and differentiation of precursor osteoblasts (414) and decrease apoptosis of mature 
osteoblasts (415). Daily, low dose injections of PTH have been shown to increase 
osteoblast numbers and bone formation while continuous exposure leads to 
osteoclastogenesis and bone loss (416). PTHrP has very similar effects to PTH as 
both signal through the same receptor, namely PTH1-R (410). However, PTHrP is 
encoded by a different gene to PTH and while PTH is secreted by the parathyroid 
gland PTHrP is secreted by numerous tissues such as skin, blood vessels, smooth 
muscles, bone, kidney and neuronal glial tissues (410).  
Calcitonin has been reported to enhance osteoblast differentiation by inducing 
BMP-2 expression (417) and to inhibit apoptosis of osteoblasts and osteocytes 
(418). Similarly, estrogens have been shown by Kousteni et al in 2001 to inhibit 
osteoblast apoptosis and increase their lifespan by downregulating JNK and 
activating the Src/Shc/ERK signalling pathway (419). Vitamin D3 (1,25(OH)2 vitamin 
D3) has been shown to stimulate differentiation of MSC to osteoblast (420), and to 
affect osteoblasts directly via the vitamin D receptor, VDR, stimulating bone 
formation and mineralization (412). IGF-1 circulates systemically, is secreted locally 
in the bone marrow and is one of the most abundant proteins in the bone matrix 
(321).  
IGF-1 has been suggested to induce MSC migration to the bone marrow as in cell 
culture IGF has been shown to enhance the expression of genes that promote cell 
migration (421). In addition, bone matrix IGF-1 has been shown to induce MSC 
differentiation to osteoblasts by activating mTOR (325) and to stimulate osteoblast 
function and survival (288).  
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Androgens have been shown to increase collagen type 1, osteocalcin and alkaline 
phosphatase secretion leading to increased osteoblast differentiation and 
mineralisation (422,423). Deletion of androgen receptor in the osteoblasts and 
osteocytes of mice led to decreases in trabecular bone mass in male mice 
(424,425). Additionally, in an orchidectomised mouse model, activation of 
androgen receptor by dihydro testosterone prevented osteoblast apoptosis (426) 
suggesting androgens directly regulate both osteoblast development and apoptosis.  
As for osteoclasts, research into local factors influencing osteoblast formation and 
function has also led to the discovery of numerous factors both in the extracellular 
matrix and within MSC’s and osteoblasts, some of the most recent are shown in 
table 1.5. Many of these factors including BMP's 2 and 7, Wnt’s 2, 3a, 5a, 6a,10b 
and numerous micro RNA’s directly influence MSC differentiation into precursor 
osteoblasts and their subsequent maturation (369,373,427–430). In addition, a 
number of these factors, again including BMP’s 2 and 7, Wnt 3a, 5a influence both 
osteoblasts and osteoclasts (365,369,370,427,428) suggesting dual roles depending 
on which cells are present in the BRC and may act as coupling factors connecting 
the activity of osteoclasts with the recruitment of osteoblasts.  
Research is also revealing potential roles of sphingolipids in osteoblast recruitment 
and activity. S1P produced by osteoclasts has been shown to be a chemoattractant 
for MSC’s expressing its receptors, S1PR1 and S1PR2, resulting in their migration to 
the bone marrow and thus also acting as a coupling factor between osteoclasts and 
osteoblasts (431). In addition, catabolism of sphingomyelin by neutral 
sphingomyelinase 2 (nSMase2) has been shown by Khavandgar published in 2011 to 
be essential for mineralisation in a fro/fro mouse model (432).  
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Factor Origin Generation Activity References 
BMP – 2 
4 
7 
9 
T-cells 
Osteoblasts 
Osteocytes 
 
↓ 
 
↑ 
↑ 
 
↑ 
 
(427) 
(433) 
(428) 
(434) 
Claudin-1 Osteoblast ↑  (435) 
Cthrc1 Osteoclast ↑ ↑ (436) 
Irisin Skeletal muscle ↑ ↑ (437) 
   miR-15b 
20a 
29a 
125b 
129-5p 
138 
138-5p 
204 
338-3p 
675-5p 
705 
3077-5p 
MSC’s 
Precursor- osteoblasts 
Osteoblasts 
↑ 
↑ 
↑ 
↓ 
↑ 
↓ 
↓ 
↓ 
↓ 
↓ 
↓ 
↓ 
↑ 
 
 
 
 
 
 
↓ 
 
 
 
 
(373) 
(438) 
(439) 
(373) 
(440) 
(373) 
(441) 
(442) 
(443) 
(441) 
(444) 
(444) 
MMP’s Osteoblasts ↑ ↑ (445) 
Sclerostin Osteocytes ↓ ↓ (446) 
Semaphorin 4D Osteoclasts 
T-cells 
↓ ↓ (447) 
Smurf1 Osteoblast ↓ ↓ (448) 
    Wnt 1 
2 
3a 
5a 
6a 
10a 
10b 
B-lymphocytes 
Osteoblasts 
T-cells 
 
↑ 
↑ 
↑ 
↑ 
 
↑ 
↑ 
 
 
 
 
↑ 
 
(312) 
(449) 
(449) 
(429) 
(430) 
(430) 
(450) 
Table 1.5 Local extracellular and intracellular factors affecting osteoblast 
generation and activity. 
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1.8  Macrophages 
In GD the macrophage is the primary storage cell due to their function of degrading 
senescent blood cells, cell debris and microbes providing an additional peripheral 
source of substrate. Gaucher macrophages have been found to be altered as a 
consequence of this storage with impaired chemotaxis, reduced oxygen species 
production and increased secretion of several cytokines including IL-1β, IL-6 and 
MIP-1β all shown to stimulate osteoclastogenesis. 
In the 1980’s macrophages were found to be distributed near the bone surface in 
Balb/c mice (451) and early studies found enhanced differentiation of mouse 
marrow stromal cells or calvarial osteoblasts when co-cultured with cells of the 
monocyte/macrophage lineage leading to increased alkaline phosphatase activity 
and collagen type 1 synthesis from stromal cell cultures indicating their 
differentiation into functional osteoblasts (452,453). These reports also found 
macrophages in close proximity to bone cells in vivo and secretion of BMP-2 leading 
to increased osteoblast survival and differentiation (454). In 2008, Chiang et al 
identified a discrete population of macrophages dubbed osteal macrophages 
(OsteoMacs) intercalated throughout murine and human osteal tissues (455). These 
OsteoMacs were located adjacent to mature osteoblasts at sights of active bone 
remodelling in a murine model with over 75% of osteoblasts on the surface of the 
cortical bone covered with a canopy of OsteoMacs (456). The removal of 
OsteoMacs from mouse calvaria osteoblast preparations led to a decrease in bone 
nodule formation in vitro (455). The co-culture of primary mouse macrophages with 
bone marrow stromal cells led to an activation in IL-6 secretion by both bone 
marrow macrophages and stromal cells, enhancing MSC migration and 
differentiation when  in vitro (457).                                                                                                                                
In vitro human systems have shown that monocytes and macrophages could 
promote osteoblast differentiation from MSC’s and that this required direct cell-cell 
contact. This contact resulted in the production of oncostatin M by macrophages 
with the osteoblast differentiation dependent on oncostatin M, prostaglandin E2 
and cyclooxygenase 2 (458,459). In addition, oncostatin M has been shown to 
increase mineralisation both in vitro and in vivo (460,461). Interestingly, 
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macrophages co-cultured with MSC’s led to a polarisation of macrophages to an 
alternatively activated (M2) phenotype with increased expression of CD206 and 
production of IL-10, IL-12 with a decrease in production of TNF-α, IL-6 (462,463). A 
separate study by Schlundt et al published in 2015 also found that induction of M2 
macrophages through IL-4 and IL-13 in a murine model significantly enhanced bone 
formation during their 3 week investigation (464). Other research by Asada et al 
published in 2013 has also suggested that macrophages communicate with 
osteocytes in a murine model to influence MSC migration (465). Conversely, 
classically activated macrophages (M1) are known to secrete several pro-
osteoclastic cytokines including TNF-α, IL-1β and IL-6 (466). As inflammatory 
macrophages in addition to OsteoMacs are present in the bone marrow it suggests 
a fine balance needs to be maintained between M1/M2 macrophages to regulate 
bone remodelling (464).  
 
1.9  Multiple myeloma and bone  
Initially, multiple myeloma (MM) begins as monoclonal gammopathy of 
undetermined significance (MGUS), progressing to smouldering myeloma 
(asymptomatic) and finally becoming overt myeloma resulting in bone marrow 
infiltration (467). However, recent findings suggest that the onset of MGUS can 
coincide with skeletal fragility, suggesting the bone destruction may occur at a very 
early stage (468). While MGUS can develop into a number of malignancies including 
lymphoma, amyloidosis, chronic lymphocytic leukaemia and solitary plasmacytoma, 
the most common is MM with an estimated 1% of patients progressing from MGUS 
to MM per year (264). MM is a plasma cell disorder characterised by end organ 
damage including renal impairment, anemia and hypercalcemia (469). In addition, 
more than 80% off MM patients develop bony lesions leading to pain and fractures 
with lytic lesions most common in the spine, skull and long bones with widespread 
osteopenia also a common feature (470). MM bone disease is regarded as distinct 
from other metastatic diseases as in MM there is no bone formation unlike for 
example prostate and breast cancers in which there is increased activity of both 
osteoclasts and osteoblasts (471).   
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Patients with MM are associated with increased numbers of osteoclast progenitor 
cells in the peripheral blood (472), with osteoclast numbers increased in the bone 
marrow of patients with monoclonal gammopathy, increasing further in patients 
with malignant disease (473). Serum TRAP, C-terminal telopeptide (CTX) and 
hydroxyproline (markers of bone turnover) have been shown to be elevated in MM 
patients and to be higher in patients in stage B (472), confirming elevated 
osteoclast activity.  
The serum and bone marrow of MM patients have been found to have high levels 
of several cytokines promoting osteoclast formation and activity including RANKL, 
IL-3, IL-6, IL-7, MIP-1α, stromal derived factor 1α (SDF1α), TNFα, VEGF, osteopontin 
and MMP-13 (474–479). Many of which are secreted by the myeloma cells, 
including RANKL, TNF-α, MIP-1α, VEGF, osteopontin and MMP-13 directly 
increasing osteoclastogenesis (474,477–480). Myeloma cells further enhance 
osteoclastogenesis by downregulating the expression of OPG produced by 
osteoblasts (481).  
Physical interaction has also been found to play a role as histological studies have 
shown that osteolytic lesions occur adjacent to plasma cells in the bone marrow 
specimens of MM patients (482). Myeloma cells adhere to stromal cells and 
osteoclasts via the very late antigen 4 (VLA-4) – vascular cell adhesion molecule 1 
(VCAM-1) interaction which has been shown by Abe et al in 2009 to induce the 
production and secretion of MIP-1α and MIP-1β, stimulating osteoclastogenesis 
(483). Levels of MIP-1α in the bone marrow of MM patients correlate with severity 
of bone disease and high levels have been associated with poor prognosis 
(483,484). It is also hypothesised that myeloma cells fuse with precursor osteoclasts 
to form osteoclast-like cells capable of resorbing bone with one study by Andersen 
et al 2007 finding 30% of osteoclast nuclei in MM patients having a myeloma cell 
origin (485).  
In turn, osteoclasts have been shown to support myeloma cell survival and enhance 
proliferation by firstly upregulating signalling pathways including via signal 
transducer and activator of transcription 3 (STAT3) and mitogen-activated protein 
kinases (MAPK’s) and secondly by secreting soluble factors such as IL-3, IL-6, 
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osteopontin, B-cell activating factor (BAFF) and a proliferation inducing ligand 
(APRIL) (475,486,487). In addition, resorption of the bone matrix results in the 
release of growth factors such as TGF-β and IGF-1 which also promote myeloma cell 
survival and proliferation (488). 
Reduced bone formation due to decreased osteoblast differentiation and activity 
also contributes to the bone disease in MM (489). Several factors secreted by 
myeloma cells including Dickkopf-1 (DKK1), secreted frizzled related protein-2 
(sFRP-2) and sclerostin have been shown to inhibit osteoblast maturation (490–
492). DKK-1, sFRP-2 and sclerostin block Wnt signalling, preventing osteoblast 
maturation and activity (490–492). Other factors elevated in the serum and bone 
marrow of MM patients such as IL-3 and IL-7 have dual affects, promoting 
osteoclastogenesis and inhibiting osteoblast differentiation and maturation 
(493,494).  
A study by Giuliani  et al published in 2005 showed co-culture of myeloma cells with 
osteoblast precursors led to the downregulation of Runx2/CBFA-1, a transcription 
factor essential for osteoblast differentiation (494). The same study showed a 
marked reduction in the number of Runx2/CBFA-1 positive cells in the bone marrow 
biopsies of MM patients (494). In addition, MSC’s have been shown to support 
progression by expressing RANKL and IL-6 (495) while osteoblasts have been 
suggested to suppress myeloma by secreting decorin, a small leucine-rich 
proteoglycan (496). A flow cytometry based study by Noll et al published in 2014 of 
MM patient bone marrow noted an increased number of colony forming MSC 
which correlated with disease burden at time of diagnosis, suggesting the balance 
between MSC’s and osteoblasts may play an important role in the proliferation and 
survival of myeloma cells (495). 
Studies have shown that osteocytes, the most abundant bone cells, are also 
reduced in number in MM bone marrow (497). A second study by Delgado-Calle 
published in 2016, utilising a murine model of human MM, found myeloma cells 
physically interact with osteocytes resulting in caspase-3 dependent apoptosis of 
osteocytes. Induction of apoptosis led to an increase in RANKL expression. In 
addition, osteocyte – myeloma cell contact reciprocally activated Notch signalling 
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increasing Notch 3 and Notch 4 receptor expression stimulating MM cell growth 
(498).  
Studies have also shown that macrophages infiltrate MM bone marrow and that 
myeloma cells specifically attract peripheral blood monocytes by interacting with 
bone marrow stromal cells (499,500). This interaction results in an increase in 
expression of a number of chemokines including CCL2, CCL3, CCL14 and CXCL12 
leading to chemoattraction of the monocytes to tumor sites (499,500). Myeloma 
cells affect macrophage polarization (500), increasing the expression of factors that 
stimulate the survival of plasma cell proliferation and survival including IL-6, IL-10, 
LIGHT and VEGF while lowering the expression of IL-12 and TNF-α (501–504).  
 
1.10  Bone disease in GD 
As previously mentioned, bone disease is a very common and debilitating feature of 
GD with patients suffering from a wide variety of manifestations including 
osteopenia, osteonecrosis, osteosclerosis, osteolytic lesions, pathological fracture 
and bone remodelling such as Erlenmeyer flask formation (84,85). A 2015 analysis 
by Grabowski et al of data on 681 type 1 GD patients entered into the International 
Collaborative Gaucher Group (ICGG) Gaucher Registry found an average of 84% of 
patients had bone lesions increasing to 96.3% for the N370S/84GG genotype (27 
patients). The most common bone feature being osteoporosis present in an 
average of 75% of patients (101). A second study of 100 type 1 GD patients by 
Deegan et al in 2011 combining clinical and questionnaire data found evidence of 
Erlenmeyer flask formation in 59%, osteonecrosis in 43%, fragility fracture in 28%, 
osteomyelitis in 6% and lytic lesions in 4% of patients with mobility impaired in 32% 
and 15% experienced significant pain (84). In addition, Baris et al in 2016 
highlighted that bone crises are not restricted to long bones. In a cohort of 100 
patients small bone crises represented 31.5% of all bone crises (505).  
In paediatric cohorts, a study by Ciana et al in 2012 of 18 patients found 44.4% had 
Erlenmeyer flask deformity and 16.6% had pathological Z scores (≤ -2.0) (506). A 
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study by Mistry et al published in 2011 of type 1 GD patients in the ICGG Gaucher 
registry found 44% (n = 43) of children and 76% (n = 41) of adolescents had low 
bone mineral densities with Z scores of ≤ -1. Demonstrating that the regulation of 
bone metabolism and development is disrupted at a young age in some GD patients 
which may suggest additional causes of bone manifestations to Gaucher cell bone 
marrow infiltration (510).  
Since the advent of ERT several long term studies have shown significant increases 
in bone mineral density and reduction of bone crises in type 1 GD patients with 
improvement in bone pain recorded as early as 3 months after receiving ERT (506–
510). However, a number of studies have also shown some patients continue to 
suffer bone events while on ERT. A study by Stirnemann et al published in 2010 
found bone events occurred in 4 of 21 patients on ERT with a bone event prior to 
beginning ERT and 6 of the remaining 41 patients developed bone events only 
during ERT (85). Deegan et al published in 2011 found 8 patients developed new 
osteonecrosis after the start of ERT while Baris et al published in 2016 found small 
bone crises increased after the initiation of ERT (84,505). In 2008 de Fost et al 
reported 12 out of 40 type 1 GD patients continued to experience bone disease 
despite increasing doses of ERT (511). These observations suggest further research 
is required to identify the mechanisms behind the bone manifestations in GD to 
determine the most effective potential therapies for these refractive patients. 
Bone disease in GD patients is generally assessed by dual X-ray absorbiometry 
(DEXA) in conjunction with magnetic resonance imaging (MRI) (123) however these 
techniques only provide a snapshot of disease progression and cannot provide 
information on when bone dysregulation begins or whether a patient is undergoing 
a period of bone loss. Therefore, to address this issue several studies have been 
carried out to assess the efficacy of markers of bone turnover. These studies have 
included the measurement of bone formation markers including osteocalcin, bone 
alkaline phosphatase (B-ALP), Procollagen I carboxyterminal propeptide (PICP), N-
terminal propeptide of type I collagen (PINP) and bone resorption markers including 
collagen type 1 cross-linked C-telopeptide (CTX), tartrate-resistant acid 
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phosphatase 5b (TRACP 5b), cathepsin K, urinary hydroxyproline, deoxypyridinoline 
(Dpyr) and collagen type 1 cross-linked N-telopeptide (NTX) (508,512–517).  
The most common marker assessed are osteocalcin and CTX however of the five 
studies measuring osteocalcin only two found a significant decrease (512,515) while 
the remaining three found no significant difference (508,513,516). In regards to 
CTX, two studies found a significant increase (513,514), a third found no difference 
(515) while a fourth measured a significantly lower concentration compared to the 
control population (512). However, in the fourth study a greater proportional 
decrease in osteocalcin was also detected and it was concluded that bone 
resorption exceeded bone formation (512). A decrease in PICP was found in two 
studies (513,514), an increase in cathepsin K in two studies (518,519) and TRACP 5b 
in another study (517). No significant changes in BALP, PINP, urinary 
hydroxyproline, Dpyr or NTX were found (508,513,515,516).  
These findings suggest there may be both a reduction in bone formation due to the 
decreases in osteocalcin and PICP and an increase in bone resorption as shown by 
increases in CTX, cathepsin K and TRAP5b. However, due to conflicting data 
between studies and the fact that few studies have measured the same analytes in 
their respective patient cohorts it is not possible to draw a definite conclusion from 
these findings. 
As previously detailed in table 1.2 numerous proteins have been found to be 
elevated in the plasma and serum of type 1 GD patients. Interestingly, the majority 
of these proteins including IL-1β, IL-6, IL-8, MCSF, MIP-1α, MIP-1β and TNF-α are 
known to stimulate osteoclast generation and activity 
(143,147,148,382,387,388,392,520). In addition, osteopontin, a negatively charged 
protein known to bind calcium and thus preventing bone mineralisation, is also 
elevated in GD serum (144). Systemic regulation may also be affected as two 
studies have shown that GD patients have a deficiency in 1,25(OH)2 vitamin D3 
which is known to stimulate osteoblast differentiation (521,522). Taken together, 
these findings suggest GD bone marrow may have a highly pro-osteoclastogenic 
environment which may in part explain the bone loss observed in GD patients.  
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To further investigate the cellular aspects of bone disease in GD several animal and 
cellular models have been created. Currently, the only murine model with notable 
bone involvement is the Mistry model in which exons 8 through 11 of the GBA1 
gene were conditionally deleted in the cells of the hematopoietic and mesenchymal 
lineages. These mice showed histological evidence of medullary infarction and 
associated avascular osteonecrosis in addition to osteopenia. Cellular examination 
showed reduced proliferation of bone marrow stromal cells and reduced osteoblast 
differentiation, confirmed by a reduction in alkaline phosphatase (ALP), bone 
sialoprotein (BSP), Runx2, and osterix mRNA expression. However, no alteration in 
osteoclast number or activity were found (272). Supporting evidence has also been 
provided by research published in 2015 by Zancan et al using Zebra fish models in 
which Gba1 loss of function was attained either by knock down using morpholino 
oligonucleotides or via genetic knockdown by introducing a point mutation in the 
splicing donor site of GBA1 exon 4. In both Zebra fish models loss of Gba1 function 
was associated with impaired canonical Wnt signalling, osteoblast differentiation 
and reduced bone mineralisation (523). 
For cellular studies evidence suggests both osteoblasts and osteoclasts may be 
dysregulated in GD. Several studies investigating MSC’s with Gba1 deficiency either 
by CBE inhibition or isolation of MSC from GD patient bone marrow found 
impairment in MSC proliferation and differentiation into both adipocytes and 
osteoblasts (138,139,141,524).  
Our group began investigating the characteristics of Gaucher patient osteoclasts in 
2005, presenting initial findings as posters in 2005, 2006, 2007 and 2008. Based on 
these findings this project was initiated in April 2012 to investigate both osteoclast 
and osteoblast function and their interaction in relation to GD. Since this projects 
instigation research by Mucci et al published in August 2012 demonstrated that 
treatment of osteoclast precursors with conditioned medium from CBE treated 
peripheral blood mononuclear cells (PBMC’s) resulted in increased osteoclast 
differentiation (525). Mucci et al published in 2015 also found higher osteoclast 
generation of PBMC’s isolated from type 1 GD patients when compared to controls 
confirming our findings (134).  
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Furthermore, T-cells and macrophages, both known to play a role in regulating 
osteoclast formation, have been found to be altered in GD patients. Research by 
Lacerda et al published in 1999 has shown changes in total T-lymphocyte numbers 
and alteration in CD4+/CD8+ T-lymphocyte ratio (527). Mucci et al, published in 
2015, found an increase in the CD14+CD16+ pro-inflammatory monocyte subset 
found to produce several pro-osteoclastic cytokines in addition to increased 
expression of RANKL on the surface of T-cells (134).   
Taken together, evidence suggests there is dysregulation of the bone 
microenvironment in GD leading to uncoupling between osteoclasts and 
osteoblasts involving both systemic and local factors.   
 
1.11   Aims and hypotheses 
Bone disease is a common feature of GD with radiological evidence described in up 
to 93% of patients ranging from osteopenia and bone remodelling to avascular 
necrosis. At the initiation of this project no group had published in vitro data on 
Gaucher patient osteoclasts or their interactions with osteoblasts in the bone 
microenvironment. However, investigations into the bone microenvironment by 
some groups have suggested there may be alterations in MSC function and 
increased resorption of control osteoclasts when cultured in CBE treated MSC 
conditioned medium. In addition, our previous findings suggested GD osteoclasts 
may have altered characteristics when compared to control osteoclasts therefore 
the aims of this project are: 
(1) To understand the roles of osteoclasts in Gaucher patient bone disease. 
(2) To understand the relationship between in vitro findings and clinical 
features of bone disease in GD patients. 
(3) To understand the role of osteoblasts in GD bone disease. 
(4) To understand the relationship between plasma cells and in vitro GD 
osteoclastogenesis. 
(5) To understand the effects of interaction between osteoblasts, osteoclasts 
and plasma cells in Gaucher disease. 
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These aims are explored with the hypotheses detailed below. 
 
Chapter 3 
Hypothesis 1: Circulating GD monocytes have an increased potential to form 
osteoclasts compared to control monocytes.  
Rationale: The majority of GD patients have low BMD with an average of 75% 
presenting with osteopenia. This bone loss could result from increased osteoclast 
number and/or activity, decreased osteoblast number and/or activity or a 
combination thereof. Several groups have found increased pro-osteoclastic 
cytokines in the plasma and serum of GD patients. Sphingolipids including ceramide 
and sphingosine-1-phosphate, both found to be elevated in GD serum, have been 
reported to affect osteoclast migration and maturation.  
Methods: Differentiation of monocytes isolated from the peripheral blood of GD 
patients and control subjects into functional osteoclasts by culture with established 
osteoclastogenic cytokines RANKL and MCSF. Osteoclasts will be identified either by 
being histochemically positive for TRAP or high surface expression of vitronectin 
receptor in conjunction with actin ring formation labelled with fluorochromes. 
 
Hypothesis 2a: Increased osteoclastogenesis is directly related to β-
glucocerebrosidase deficiency rather than protein misfolding. 
Rationale: GD results from pathogenic mutations in the GBA gene causing either a 
decrease in β-glucocerebrosidase activity or misfolding of the protein resulting in 
degradation by the ER associated degradation pathway (ERAD). Data generated by 
our group prior to this project and research published during this project by Mucci 
et al with the irreversible inhibitor of β-glucocerebrosidase CBE in cell lines showed 
inhibition resulted in increased osteoclastogenesis suggesting it is directly related to 
a decrease in to β-glucocerebrosidase activity.  
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Methods: Culture of control subject monocytes with CBE in the presence of 
osteoclastogenic cytokines RANKL and MCSF. Osteoclasts will be identified either by 
being histochemically positive for TRAP or high surface expression of vitronectin 
receptor in conjunction with actin ring formation labelled with fluorochromes. 
 
Hypothesis 2b: Addition of GD-specific therapies to GD osteoclast cultures reduces 
osteoclastogenesis. 
Rationale: If increased osteoclastogenesis is directly related to β-
glucocerebrosidase deficiency, replacement of the deficient enzyme or reduction of 
the substrate should reverse this effect. 
Methods: Culture of GD or control subject monocytes with ERT or SRT in the 
presence of osteoclastogenic cytokines RANKL and MCSF. Osteoclasts will be 
identified either by being histochemically positive for TRAP or high surface 
expression of vitronectin receptor in conjunction with actin ring formation labelled 
with fluorochromes. 
 
Hypothesis 3: The altered sphingolipid profile found in GD patients causes 
increased osteoclastogenesis. 
Rationale: A number of sphingolipids concentrations have been found to be 
elevated in GD serum and plasma including ceramide, sphingosine, S1P, 
glucosylsphingosine and glucosylceramide. Research has shown roles for 
sphingolipids such as ceramide, sphingosine-1-phosphate and lactosylceramide in 
the formation and function of osteoclasts. The elevated concentrations of these 
sphingolipids, possibly including glucosylsphingosine and glucosylceramide - the 
roles of which in relation to osteoclasts have yet to be elucidated, may cause 
increased osteoclastogenesis.  
Methods: Culture of GD or control subject monocytes with a number of different 
sphingolipids added exogenously in the presence of osteoclastogenic cytokines 
RANKL and MCSF. Osteoclasts will be identified either by being histochemically 
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positive for TRAP or high surface expression of vitronectin receptor in conjunction 
with actin ring formation labelled with fluorochromes. 
 
Chapter 4. 
Hypothesis 1: GD patients with active bone disease generate more osteoclasts in 
vitro. 
Rationale: A number of bone diseases such as osteoporosis can be caused by 
increased osteoclast generation leading to increased bone resorption. The number 
of nuclei per osteoclast has also been shown to correlate to osteoclast activity. 
Methods: Correlation of MRI based evidence of active bone disease with 
contemporaneous in vitro osteoclast generation and size.  
 
Hypothesis 2: GD patients with anaemia generate more osteoclasts in vitro.  
Rationale: A recent publication by Khan et al in 2012 has shown anaemia to be a 
risk factor for avascular necrosis in GD patients with anaemic patients 60% more 
likely to develop AVN with an adjusted odds ratio of 1.56. 
Methods: Correlation of patients with levels of haemoglobin indicative of anaemia 
with in vitro osteoclast generation.  
 
Hypothesis 3: Treatment of GD patients with GD-specific therapies will reduce in 
vitro osteoclast generation. 
Rationale: Previous data in this thesis has shown increased osteoclast generation is 
directly related to a decrease in β-glucocerebrosidase activity and that addition of 
GD-specific therapy to GD in vitro cultures reduced osteoclast generation. 
Therefore, GD-specific treatments such as ERT and SRT designed to replace the 
enzyme or reduce the impact of its decreased activity will probably ameliorate the 
effect on osteoclastogenesis in vivo. 
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Methods: Compare osteoclast generation of naïve patients with patients receiving 
therapy. Longitudinal study of individual patients by taking blood samples for 
osteoclast culture at each patient visit. Osteoclasts will be identified either by being 
histochemically positive for TRAP or high surface expression of vitronectin receptor 
in conjunction with actin ring formation labelled with fluorochromes. 
 
Chapter 5. 
Hypothesis 1: There is dysregulation between osteoblasts and osteoclasts, 
commonly referred to as uncoupling, in GD patients. 
Rationale: Osteoblasts and osteoclasts are normally very tightly regulated primarily 
by each other. In GD increased osteoclast generation and activity may result in an 
imbalance between osteoclast and osteoblast number and function leading to bone 
loss.  
Methods: Flow cytometry using markers identifying osteoblast precursor 
percentage in peripheral blood samples is correlated with the number of 
osteoclasts generated by contemporaneous in vitro osteoclast cultures.  
 
Hypothesis 2: Osteoblast mineralisation is reduced when β-glucocerebrosidase 
activity is inhibited.  
Rationale: Studies of a GD murine model by Mistry et al (272) showed reduced 
proliferation of bone marrow stromal cells and reduced osteoblast differentiation 
and two Zebra fish GD models developed by Zancan et al (524) demonstrated loss 
of Gba1 function was associated with impaired canonical Wnt signalling, osteoblast 
differentiation and reduced bone mineralisation.   
Methods: Primary and cell line osteoblasts cultured with CBE under mineralising 
condition. Mineralisation quantified by alizarin red staining and solubilisation.   
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Hypothesis 3: Osteoblast mineralisation is reduced in the presence of exogenous 
glucosylceramide. 
Rationale: Previous data in this thesis has shown exogenous glucosylceramide 
directly affects osteoclast generation by significantly increasing osteoclast numbers 
in both control and Gaucher cultures indicating that this is a bioactive sphingolipid 
and therefore may also affect osteoblast function.   
Methods: Primary and cell line osteoblasts cultured with exogenous 
glucosylceramide under mineralising condition. Mineralisation quantified by alizarin 
red staining and solubilisation.   
 
Hypothesis 4: Osteoblast function is not directly impacted by GD-specific therapies. 
Rationale: Previous data in this thesis has shown GD-specific therapies reduce 
osteoclast generation in vitro both directly and when given to patients. However, a 
subset of patients have been reported to continue to suffer bone events while 
receiving GD-specific therapy suggesting a negative impact on osteoblast function is 
negating the reduction in osteoclast numbers. This may be via the indirect impact 
of reduced osteoclast activity having the overall effect of reducing bone matrix 
resorption which in turn means a reduction in osteoblast signalling factors released 
from the bone matrix.  
Methods: Primary and cell line osteoblasts cultured with GD-specific therapies in 
the absence or presence of CBE under mineralising conditions. Mineralisation 
quantified by alizarin red staining and solubilisation.   
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Chapter 6. 
Hypothesis 1: GD osteoclastogenesis is further enhanced when cultured with 
myeloma plasma cells e.g. the NCI-H929 myelolma plasma cell line. 
Rationale: Myeloma patient plasma cells and myeloma plasma cell lines have been 
reported to express cytokines such as IL-6, RANKL, TNF-α, MIP-1α known to 
stimulate osteoclastogenesis, contributing to the osteopenia and bone lesions 
found in over 80% of myeloma patients. 
Methods: Co-culture of control or GD patient osteoclast cultures with a myeloma 
plasma cell line. Osteoclasts will be identified by being histochemically positive for 
TRAP. 
 
Hypothesis 2: The altered sphingolipid profile in GD patients creates a pro-survival 
environment for plasma cells which in turn stimulate osteoclast generation, 
creating a positive effector loop between plasma cells and osteoclasts in GD.  
Rationale: Several sphingolipids including glucosylsphingosine and 
glucosylceramide have been suggested to have roles as bioactive molecules in 
cancer. Both sphingolipids have been linked with increasing cellular proliferation 
and reducing apoptosis and glucosylceramide has been suggested to be involved in 
drug resistance.  
Methods: Culture of a myeloma plasma cell line with a range of exogenous 
sphingolipids. Cell number determined by haemocytometer.  
 
Chapter 7. 
Hypothesis 1: GD osteoblast-osteoclast interaction with plasma cells enhances 
overall bone loss.  
Rationale: Plasma cells have been shown to increase osteoclastogenesis and to 
secrete cytokines which induce osteoclast generation and function and to decrease 
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differentiation of MSC’s into osteoblasts. In addition, MGUS patients have been 
reported to have lower BMD. 
Methods: Co-culture of primary and cell line osteoblasts with primary osteoclasts 
and myeloma plasma cell line. Mineralisation quantified by alizarin red staining and 
solubilisation.    
 
Hypothesis 2: GD osteoclasts can protect plasma cells from apoptosis. 
Rationale: Osteoclasts have been shown to secrete cytokines including IL-6 which 
stimulate plasma cell proliferation and survival. 
Methods: Co-culture of primary and cell line osteoblasts with primary osteoclasts 
and myeloma plasma cell line. Viability assessed by flow cytometry.  
 
 
Definition:  
Bone event – clinical events such as avascular necrosis, bone infarct or fracture 
which occurred within 3 months of the initiation of an osteoclast assay for that 
patient. Excluding ongoing bone disease such as osteopenia and osteoporosis. 
This definition applies to the term ‘bone event’ when used in results and discussion 
sections of this thesis. 
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2  Materials and methods:  
2.1  Patient and healthy control recruitment. 
This study was approved by the Royal Free Hospital Multi-centre Research Ethics 
Committee (MREC) to recruit healthy controls or individuals with either Gaucher 
disease or myeloma.  
All patients received a patient information sheet 14 days prior to providing 
informed consent. Each recruited individual was assigned a unique identification 
code. Patient data was stored in a secure location on a password protected system 
and access was limited to the study investigators. Tissue specimens including bone 
marrow were acquired and stored in accordance with the Human Tissue Act.  
 
Unless otherwise stated all reagents were supplied by Sigma Aldrich, Poole, UK. 
 
2.2  Cell culture medium 
A10 – alpha minimal essential medium (MEMα) (ThermoFisher Scientific, Paisley, 
UK) supplemented with 10% foetal bovine serum (ThermoFisher Scientific, Paisley, 
UK), 10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer 
(ThermoFisher Scientific, Paisley, UK), 2mM L-Glutamine and 100 units/ml penicillin, 
0.1mg/ml streptomycin (supplied as penicillin/streptomycin solution). 
D10 – Dulbecco’s modified Eagle medium (DMEM) (ThermoFisher Scientific, Paisley, 
UK) supplemented as for A10 
R10 – RPMI 164 medium (ThermoFisher Scientific, Paisley, UK) supplemented as for 
A10. 
MSC proliferation medium– MesenCult® Proliferation Kit (Human) (STEMCELL 
Technologies, Grenoble, FR) comprising 450ml MesenCult basal medium with 50ml 
MesenCult™ Stem Cell Stimulatory Supplements, further supplemented with 10mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (ThermoFisher 
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Scientific, Paisley, UK), 2mM L-Glutamine and 100 units/ml penicillin, 0.1mg/ml 
streptomycin (supplied as penicillin/streptomycin solution). 
A10-OB – A10 supplemented with 5mM β-glycerophosphate disodium salt hydrate, 
200µM L-ascorbic acid 2-phosphate sesquimagnesium salt hydrate, 10nM 
dexamethasone. 
 D10-OB – D10 supplemented with 4mM β-glycerophosphate disodium salt hydrate 
and 100µM L-ascorbic acid 2-phosphate sesquimagnesium salt hydrate.  
R10-OC – R10 supplemented with 25ng/ml recombinant human macrophage colony 
stimulating factor (MCSF) (Cambridge Bioscience, Cambridge, UK) and 30ng/ml 
recombinant human receptor activator of NFκB ligand (RANKL) (Peprotech EC, 
London, UK). 
A10-triple culture medium – A10-OB supplemented with 25ng/ml human MCSF, 
30ng/ml human RANKL. 
D10-triple culture medium – D10-OB supplemented with 25ng/ml human MCSF, 
30ng/ml human RANKL. 
 
2.3  Gaucher disease related reagent preparation. 
(a) Inhibitors. 
100mM stock solutions of conduritol β-epoxide (CBE) (Merck chemicals ltd, 
Nottingham, UK) and isofagomine D-tartrate (Cambridge bioscience, 
Cambridge, UK) were made by addition of pure solid to sterile distilled H2O. 
Stocks were stored in 100µl aliquots at -20°C until required. 
 
(b) Therapies. 
200 units/ml stock solutions of Imiglucerase (Genzyme, Massachusetts, USA) 
and velaglucerase alpha (Shire Pharmaceuticals Group Plc, St Helier, Jersey) 
were prepared by addition of provided solid in sterile PBS. Stocks were 
stored in 100µl aliquots at -20°C until required. 
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10mM stock solutions of Miglustat (a kind gift of Actelion Pharmaceuticals, 
Basel, Switzerland) were prepared by addition of the pure solid to sterile 
PBS. Stocks were store in 100µl aliquots at -20°C until required. 
10mM stock solution of ambroxol hydrochloride was made by addition of 
pure solid to sterile PBS. Stocks were stored in 100µl aliquots at -20°C until 
required. 
 
(c) Sphingolipids. 
Sphingosine (Enzo life sciences, Exeter, UK), sphingosine-1-phosphate, 
glucosylsphingosine (Insight Biolotechnology, Wembley, UK), ceramide 
(Oxford Bioscience, Oxford, UK), lactosylceramide (Universal Biologicals, 
Cambridge, UK), glucosylceramide (Universal Biologicals, Cambridge, UK). 
10mM stock solutions were made for all above sphingolipids by addition of 
100% methanol to lyophilised solid. In the cases of ceramide, 
lactosylceramide and glucosylceramide the mixture required heating to 50°C 
in a water bath to dissolve the sphingolipid. Stocks were stored in 100µl 
aliquots at -20°C until required. When added to medium a minimum of 10ml 
working concentration was made i.e. 1µl of stock was added to 10ml 
medium. 
 
2.4 Bone disc preparation. 
Bone discs were made from confiscated elephant tusk kindly donated for research 
by the customs department at Heathrow Airport.  
Discs were made in three stages – firstly the distal (narrow) end of the elephant 
tusk was sawn off to make a 1-1.5cm thick disc using a hacksaw. The disc was then 
cut in half width ways with a hacksaw to create two semi-circular sections. The 
second stage involved placing one of the sections on an Isomet low speed, figure 2-
1, (Buehler, Dusseldorf, DE) by using a provided chuck and screwing the section in 
to ensure it was firmly secured and that the flat end of the section was parallel to 
the diamond edged circular saw (Buehler, series 15 LC) once the chuck was 
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attached to the support arm. Weights provided were added to the counterbalance 
to a total of 150g and the speed was set to level 3. Wafers of the bone section 
0.55mm thick were made and cleaned with 70% ethanol to remove lubricating fluid. 
Finally, a heavy duty leather punch (Draper tools Ltd, Hampshire, UK) was used to 
punch 6mm discs out of the bone wafer by gradually increasing pressure. As the 
section could be cut in three different planes the direction which produced a bone 
surface optimal for osteoclast activity i.e. the surface which generated the most 
bone pits during osteoclast culture was chosen. This process is shown in 
diagrammatic form on the next page, figure 2.2. 
 
 
 
Figure 2.1 Diagram of Buehler isomet low speed saw (unlabelled diagram 
obtained from operation and maintenance instruction manual). 
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2.5 Cell culture methods 
 
2.5.1 General cell culture. 
All primary cells and cell lines were incubated in a humidified atmosphere with 5% 
CO2 at 37°C (Heraeus Instruments, Michigan, US). To minimise possible incubator 
contamination sterile water, added to maintain a humidified atmosphere, also 
contained 1g/l copper (II) sulphate pentahydrate (Fisher Scientific, Loughborough, 
UK). 
 
2.5.2 Freezing and liquid nitrogen storage of cells. 
 For long term storage cells were pelleted and re-suspended at 1-3x106cells/ml in 
freezing medium comprising 90% fetal bovine serum (FBS) (ThermoFisher Scientific, 
Paisley, UK) and 10% dimethylsulphoxide (DMSO). The resultant cell suspension was 
pipetted into cryovials, 1ml per vial, prior to being transferred to a propan-2-ol 
freezing box and gradually cooled at 1°C/minute in a -80°C freezer. The following 
day the cryovials were transferred to liquid nitrogen dewars. 
 
2.5.3 Thawing cells from liquid nitrogen storage. 
Cryovials containing frozen cell suspension were taken from a liquid nitrogen dewar 
and immediately transferred to a pre-warmed 37°C water bath with gentle shaking 
until thawed. The 1ml cell suspension was then slowly pipetted into 11ml of 
warmed relevant growth medium e.g. 37°C D10 for SaOs-2, and centrifuged at 250g 
for 5 minutes at room temperature. Cells were re-suspended in 6ml of relevant 
medium and pipetted into a 25cm2 tissue culture flask (Fisher Scientific, 
Loughborough, UK) and placed in an incubator.  
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2.5.4 Cell lines. 
(a) NCI-H929 – Generously provided by Dr Ellie Necheva, Cytogenetics 
laboratory, academic haematology, Royal Free hospital, UK. A non-adherent 
human multiple myeloma cell line stated to be positive for plasma cell 
antigen 1 (PCA-1) and CD38. Maintained in R10 with a doubling time of 
approximately 70 hours, cells were sub-cultured twice per week maintaining 
a density between 0.5 and 1x106 cells/ml.  
 
(b) SaOs-2 (Sigma Aldrich, Poole, UK) – An adherent human osteoblast-like cell 
line isolated from a primary osteosarcoma. Maintained in D10 with an 
approximate doubling time of 43 hours, cells were sub-cultured twice per 
week. Briefly, ~80% confluent cells were detached using 0.25% trypsin-
0.2g/l Ethylenediaminetetraacetic acid (EDTA) tetrasodium salt solution, 
counted by haemocytometer and re-seeded at 1x106 cells per 75cm2 in new 
tissue culture flasks.  
 
2.5.5 Primary cells. 
(a) Isolation of peripheral blood mononuclear cells (PBMCs).  
20mls of blood was collected in a sterile 30ml universal container with 1000 
units preservative free heparin (200µl of 5,000U/ml, Wockhardt UK Ltd, 
Wrexham, UK) and inverted several times to ensure adequate mixing to 
prevent sample clotting. Heparinised blood was transferred to 50ml conical 
centrifuge tubes, mixed with 10ml of sterile 3% dextran (dextran-500, Fisher 
Scientific, Loughborough, UK) in phosphate buffered saline (supplied as PBS 
tablets) and incubated in a 37°C water bath for 45 minutes. The two 
resultant fractions (supernatant which was predominantly plasma, 
lymphocytes and monocytes and non-supernatant which was predominantly 
red blood cells and neutrophils) were transferred to two separate 50ml 
centrifuge tubes. The total volume in each tube was made up to 20mls by 
addition of P.E.G., a solution made up of sterile PBS with 1mM EDTA 
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tetrasodium salt and 10mM D-glucose both added by filtering through 
sterile 0.2µM pore syringe filters (Fisher Scientific, Loughborough, UK). Both 
cell suspensions were then carefully layered onto 12mls each of ficoll-paque 
plus (VWR international, Lutterworth, UK) in separate 50ml centrifuge 
tubes. Samples were centrifuged at 650g at 4°C for 25 minutes with 
minimum acceleration and deceleration. The resultant white cell layer, 
immediately above the ficoll layer, was carefully removed by sterile pipette 
from both tubes, combined and brought to a total volume of 50ml with 
P.E.G and centrifuged at 400g at 4°C for 10 minutes with full acceleration 
and braking. The supernatant was discarded and the remaining cell pellet 
was re-suspended in 50ml P.E.G, centrifuged at 400g at 4°C for 10 minutes 
and re-suspended in 5ml of R10.  
 
(b) Isolation of mesenchymal stem cells from bone marrow.  
5ml of bone marrow aspirate was collected in a sterile 30ml universal 
container with 9ml of A10 and 1000 units of preservative free heparin. The 
total volume was made up to 25ml with A10. The resultant cell suspension 
was carefully layered onto 25ml of ficoll-paque plus in a sterile 50ml 
centrifuge tube and centrifuged at 650g at 4°C for 25 minutes with 
minimum acceleration and deceleration. The white cell layer immediately 
above the ficoll-paque layer was carefully pipetted off and transferred to 
another sterile 50ml centrifuge tube. The total volume of white cells was 
made up to 50ml with A10 and centrifuged at 400g at 4°C for 5 minutes with 
full acceleration and braking. The supernatant was discarded and the 
remaining cell pellet was re-suspended in 12ml MSC proliferation medium. 
This cell suspension was pipetted into a 75cm2 tissue culture flask and 
placed in an incubator. After 24 hours all medium, containing non-adherent 
cells, was removed and replaced with 10ml PBS. The flask was gently 
shaken, PBS was removed and replaced with 10ml PBS. Again, the flask was 
gently shaken and PBS was removed to be replaced with 12ml MSC 
proliferation medium. The flask was placed in an incubator for expansion 
until MSC were ~80% confluent at which point MSC’s were sub-cultured by 
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using 0.25% trypsin-EDTA and re-seeded into three 75cm2 tissue culture 
flasks for further expansion.  
 
2.5.6 NCI-H929 total cell counting. 
To assess the effect of sphingolipids on NCI-H929 total cell number over time 1ml of 
1x105cells/ml in R10 were placed in triplicate in wells of 24 well plates for each 
sphingolipid condition and placed in an incubator. At each time point, a plate was 
removed from the incubator, cells were re-suspended by repeated pipetting prior 
to removal of 50µl of cells to be counted on a haemocytometer under a Nikon 
Eclipse E400 bright field microscope and plates were returned to the incubator until 
the next time point.    
 
2.5.7 Cell differentiation cultures. 
(a) Osteoclast culture. 
Peripheral blood mononuclear cells (PBMC’s) were separated from whole 
blood as described above in 2.5.5(a). Total cell number was counted using a 
phase contrast microscope and haemocytometer. Percentage monocytes 
was determined by staining between 0.5-1.0x106 PBMC’s with 
CD14FITC/CD64PE (detailed description in section 2.6 and table 2.1) before 
undergoing flow cytometry analysis using a FACSCalibur flow cytometer 
(Becton Disckinson, Oxford, UK) as shown in figure 2.3. 
PBMC’s were re-suspended in R10 at a cell density of 5x105 monocytes/ml 
and cultured in either a 24 well plate on ethanol sterilised 6mm round glass 
coverslips (VWR international, Lutterworth, UK), 4 coverslips per well or in a 
96 well plate on ethanol sterilised 6mm bone discs, 1 disc per well. 500µl of 
cell suspension was added per well of a 24 well plate and 100µl of cell 
suspension was added per well of a 96 well plate. Once the cell suspension 
was added to the plate it was transferred to an incubator. After 2 hours 
incubation non-adherent cells were washed off by removal of the medium  
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Figure 2.3 Flow cytometry of CD14/64. The percentage of monocytes, 
CD14+/CD64+ in the upper right quadrant, shown in the table as % Gated, 
Quad UR, highlighted with a red box.  
 
containing non-adherent cells and addition of sterile PBS (1ml for 24 well, 
200µl for 96 well). After gentle repeated pipetting PBS was removed and 
replaced with PBS and the wash step was repeated. Finally, the PBS was 
removed and replaced with R10-OC medium (1ml for 24 well, 200µl for 96 
well) and the plate was transferred to an incubator. Medium was replaced 
twice per week for up to 21 days.  
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(b) SaOs-2 osteoblast culture optimisation 
To determine the optimal conditions for calcium deposition by SaOs-2 cells 
48 well plates were seeded with SaOs-2 cells at a density of 1x104 cells/cm2 
with a range of concentrations of β-glycerophosphate disodium salt hydrate 
(β-Gly) and L-ascorbic acid 2-phosphate sesquimagnesium salt hydrate (A-2-
P) in D10, each combination in duplicate as shown below in figure 2.4a. In 
addition to using a range of stimulatory concentrations a time course was 
also carried out whereby cultures were fixed and stained for calcium with 
the alizarin red method after 14, 21 and 28 days. An example of the staining, 
prior to solubilisation is shown in figure 2.4b for day 21.  
 
 
 
 
 
 
(c) SaOs-2 osteoblast culture.  
When SaOs-2 cells had reached ~80% confluence in a 75cm2 tissue culture 
flask cells were washed by replacing growth medium with 10ml PBS 
followed by gentle shaking. The PBS was removed and the wash step 
repeated to remove extraneous protein. The PBS was removed and cells 
were incubated with 6ml 0.25% trypsin-EDTA for 5-10 minutes followed by 
repeated tapping of the side of the flask to which the cells were attached 
until all cells were completely detached, confirmed by viewing with an 
Olympus CK40 phase contrast microscope. 10ml of D10 was added to the 
Figure 2.4 (a) Diagram of the range of conditions used to determine optimal 
conditions for calcium deposition by SaOs-2 cell line. (b) Example image of 
degree of calcium deposition by SaOs-2 cells after 21 days of culture. Calcium 
stained with alizarin red. 
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cell suspension prior to being transferred to a sterile 50ml centrifuge tube 
which was then centrifuged at 400g at 4°C for 10 minutes with full 
acceleration and braking. The supernatant was discarded and the remaining 
cell pellet was re-suspended in 5ml D10. To determine the number of viable 
cells 10µl of cell suspension was mixed with 10µl of trypan blue. 15µl of this 
mixture was pipetted onto a haemocytometer and the number of unstained 
cells was counted using a Nikon Eclipse E400 bright field microscope. Cell 
density was adjusted to 2x104 cells/ml and were plated at 1x104 cells/cm2 of 
culture surface (24 well = 2x104 cells per well, 96 well = 0.64x104 cells per 
well). The tissue culture plate was then transferred to an incubator and the 
cells were allowed to attach to the tissue culture plastic for 24 hours after 
which time D10 was removed and replaced with D10-OB (1ml for 24 well, 
200µl for 96 well) and placed back into the incubator. Medium was changed 
twice per week for 21 days.  
 
(d) MSC osteoblast culture optimisation. 
To determine the optimal conditions for calcium deposition by MSC’s, 24 
well plates were seeded with MSC’s at a density of 2x104 cells/cm2 with a 
range of concentrations of β-glycerophosphate disodium salt hydrate (β-
Gly), dexamethasone and L-ascorbic acid 2-phosphate sesquimagnesium salt 
hydrate (A-2-P) in A10. Each combination was cultured in a well of three 
separate 24 well plates resulting in 3 data points for each condition as 
shown in figure 2.5. These plates were cultured for 35 days prior to calcium 
quantification by alizarin red staining. A separate time course was also 
performed once optimal conditions were determined. 
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(e) MSC osteoblast culture. 
When MSC’s had reached ~80% confluence in a 75cm2 tissue culture flask 
cells were detached by washing with PBS, incubating with 0.25% trypsin-
EDTA and cells were counted using trypan blue as in the SaOs-2 osteoblast 
culture protocol except that the medium used was A10 instead of D10. Once 
counted cell density was adjusted to 4x104 cells/ml and were plated at 2x104 
cells/cm2 of culture surface (24 well = 4x104 cells per well, 96 well = 1.28x104 
cells per well). The tissue culture plate was then transferred to an incubator 
and the cells were allowed to attach to the tissue culture plastic for 24 hours 
after which time A10 was removed and replaced with A10-OB (1ml for 24 
well, 200µl for 96 well) and placed back into the incubator. Medium was 
changed once per week for 35 days. 
 
 
 
 
Figure 2.5 Diagram showing the range of conditions used to determine optimal 
conditions for calcium deposition by osteoblasts differentiated from MSC.  
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(f) Osteoclast-plasma cell co-culture 
Osteoclast cultures were set-up as previously described. After 14 days of 
culture medium in all wells was replaced with 1ml R10-OC prior to addition 
of hanging cell culture inserts (referred to as transwells henceforth) with a 
0.4µm pore size polyethylene terephthalate (PET) membrane (Millipore LTD, 
Watford, UK) into the relevant wells. For wells which included plasma cells, 
500µl of NCI-H929 cell suspension at a density of 4x104 cells/ml was added 
either directly to wells (when no transwell was present) or to the transwell.  
For wells which did not receive plasma cells 500µl of R10-OC was added 
either directly to the well (when no transwell was present) or to the 
transwell resulting in a final volume of 1.5ml of medium in all wells. The 
plates were transferred to an incubator for a further 4 days at which time 
medium was replaced by removal of 1ml of medium from the well of the 24 
well plate, not the transwell, with care taken not to disturb either the 
adhered cells in the well or the transwell. The plates were returned to the 
incubator for a final 3 days. 
 
(g) Osteoblast-osteoclast-plasma cell co-culture 
Prior to the triple culture set-up either SaOs-2 cells or MSC’s were 
differentiated into mature osteoblasts and stimulated to deposit calcium 
matrix by culture in either D10-OB for SaOs-2 for 21 days or A10-OB for MSC 
for 35 days in wells of 24 well plates as previously described. At this point 
PBMC’s were isolated and cell density was adjusted to 5x105 monocytes/ml, 
as previously described for osteoclast culture, in either D10-triple culture 
medium (for SaOs-2) or A10-triple culture medium (for MSC). 500µl of 
PBMC’s suspension was added per well of a 24 well plate, each well 
containing either 4 glass coverslips, osteoblasts or a transwell with 
osteoblasts attached to the surface of the 24 well plate. In wells containing 
osteoblasts all culture medium was removed prior to the addition of the 
PBMC suspension. Once the cell suspension was added to the plate it was 
transferred to an incubator. After 2 hours incubation non-adherent cells 
were washed off by removal of the medium containing non-adherent cells 
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and addition of sterile PBS. After gentle repeated pipetting PBS was 
removed and replaced with PBS and the wash step was repeated. Finally, 
the PBS was removed and replaced with D10-triple culture medium (SaOs-2) 
or A10-triple culture medium (MSC), 1ml per well, and the plate was 
transferred to an incubator. Medium was replaced twice per week for 14 
days. At this point, medium was removed from all wells containing cells 
including from transwell and replaced with 1ml of D10-triple culture 
medium (SaOs-2) or A10-triple culture medium (MSC) directly to the well of 
the 24 well plate. For wells which included plasma cells, 500µl of NCI-H929 
cell suspension at a density of 4x104 cells/ml was added either directly to 
wells (when no transwell was present) or to the transwell.  For wells which 
did not receive plasma cells 500µl of the appropriate medium was added 
either directly to the well (when no transwell was present) or to the 
transwell resulting in a final volume of 1.5ml of medium in all wells. The 
plates were transferred to an incubator for a further 4 days at which time 
medium was replaced by removal of 1ml of medium from the well of the 24 
well plate, not the transwell, with care taken not to disturb either the 
adhered cells in the well or the transwell. The plates were returned to the 
incubator for a final 3 days. All combinations of cells with and without 
transwell are shown in figure 2.6. 
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2.6 Flow cytometry antibodies 
General flow cytometry. 
Throughout this project monoclonal antibodies were used as direct conjugates for 
flow cytometry. Generally, 0.1-1x106cell/100µl were incubated in the dark with an 
antibody cocktail for 15-30 minutes. Cells were washed in PBS twice by addition of 
1ml PBS followed by centrifugation at 400g for 5 minutes at 4°C and removal of 
supernatant. Cells were re-suspended in PBS (except for annexin V/Pi assay – see 
method below) or FACSflow (Becton Disckinson, Oxford, UK) prior to analysis. 
Target Species Ig Class Product 
code 
Company Clone Conjugate Dilution/ 
incubation 
time 
Human 
CD14/64 
Mouse IgG2bκ, 
IgG2κ 
333179 BD MψP9, 
MD22 
FITC/PE 1:20 
15 minutes 
Annexin 
V 
- - V13242 Thermo 
Fisher 
- FITC 1:20 
15 minutes 
Human 
CD105 
Mouse IgGκ 560839 BD 266 PE 1:30 
30 minutes 
Human 
CD90 
Mouse IgG1κ 559869 BD 5E10 APC 1:30 
30 minutes 
Human 
CD73 
Mouse IgG1κ 561254 BD AD2 FITC 1:30 
30 minutes 
Human 
CD44 
Mouse IgG2bκ 560532 BD G44-
26 
APC-H7 1:30 
30 minutes 
Human 
CD19 
Mouse IgG1κ 557835 BD SJ25C1 PE-CY7 1:30 
30 minutes 
Human 
HLA-DR 
Mouse IgG2a, 
κ 
307615 Biolegend L243 PE/Cy7 1:30 
30 minutes 
Human 
CD45 
Mouse IgG1, κ 560274 BD 2D1 APC-H7 1:30 
30 minutes 
Table 2.1 Antibodies used in flow cytometry. Continued on the next page.  
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Target Species Ig Class Product 
Code 
Company Clone Conjugate Dilution/ 
incubation 
time 
Human 
CD14 
Mouse IgG2a, 
κ 
561116 BD M5E2 PerCP-
Cy5.5 
1:30 
Human 
CD34 
Mouse IgG1, κ 347222 BD 8G12 PerCP-
Cy5.5 
1:30 
Isotype 
control 
Mouse IgG1, κ 641401 BD X40 APC-H7 1:30 
Isotype 
control 
Mouse IgG1κ 557646 BD MOPC-
21 
PE-CY7 1:30 
Isotype 
control 
Mouse IgG1κ 554681 BD MOPC-
21 
APC 1:30 
Isotype 
control 
Mouse IgG1κ 552834 BD MOPC-
21 
PERCP 
CY5.5 
1:30 
Table 2.1 continued. Antibodies used in flow cytometry.  
Stained samples were kept on ice if there was a delay for analysis. Samples were 
acquired on a FACSCalibur and analysed with CellQuestTM (Becton Dickinson, 
Oxford, UK) or FlowJo 7.6.1 software (Tree Star Inc, Oregon, US). Typically between 
10,000 and 50,000 events were collected for analysis. 
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2.7 Cell viability assays 
 
2.7.1 Annexin V/Propidium iodide flow cytometry assay. 
Annexin V is a calcium-dependent phospholipid binding protein which preferentially 
binds to phosphatidylserine (PS). In healthy cells, PS is normally found on the 
cytoplasmic side of the plasma membrane bi-layer however during early apoptosis 
PS is translocated to the extracellular surface. By using Annexin V FITC as a probe in 
a calcium rich buffer in conjunction with propidium iodide (PI), which cannot be 
excluded by cells which are either dead or in a late phase of apoptosis and binds to 
DNA, both the degree and stages of apoptosis can be determined in a single assay 
by flow cytometry. Cells in early apoptosis are Annexin V+ve, PI-ve, necrotic cells 
which are dead or in late phase apoptosis are Annexin V+ve, PI+ve. The flow plots 
showing the gated populations are shown below in figure 2.7. 
 
 
 
An annexin V FITC/PI staining kit, including buffer and stains, was obtained from 
ThermoFisher Scientific and staining was performed in accordance with 
manufacturers’ instructions. Briefly, between 0.5-1x105 NCI-H929 cells were gently 
re-suspended through repeated pipetting and transferred to 15ml centrifuge tubes 
Figure 2.7 Example flow plots of annexin V/PI staining of NCI-H929 cells. (a) Plot 
of total cell population. (b) Plot of total cell population with annexin V FITC on 
the horizontal axis versus propidium iodide on the vertical axis.  
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and centrifuged at 400g for 5 minutes at 4°C. After which supernatant was removed 
and the cell pellet was re-suspended in 5ml PBS, centrifuged at 400g for 5 minutes 
at 4°C. This PBS wash step was repeated once more after which the cell pellet was 
re-suspended in 100µl annexin V binding buffer and transferred to a FACS tube 
(Becton Disckinson, Oxford, UK). 5µl FITC labelled annexin V (100µg/ml) was added 
to the cell suspension followed by 10µl of propidium iodide solution (10µg/ml). 
Samples were incubated at room temperature in the dark for 15 minutes after 
which time 400µl annexin V binding buffer was added and the cell suspension was 
gently vortexed prior to analysis with a FACSCalibur flow cytometer (Becton 
Disckinson, Oxford, UK). PI emission maxima is 638nm and can be measured in FL2, 
FITC emission maxima is 520nm and can be measured in FL1 on the flow cytometer. 
 
2.7.2 MTS dye reduction assay. 
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) is a tetrazolium salt which is converted to a water soluble formazan 
which can be detected at absorbance of 490-500nm, this reaction is thought to be 
carried out by NAD(P)H-dependent dehydrogenase enzymes in the mitochondria. 
Cells were seeded in triplicate in 96 well plates at the density used under standard 
differentiation culture conditions i.e. monocytes for osteoclast cultures were 
seeded at 1.25x105, SaOs-2 at 1x104 and MSC’s at 2x104 cells/cm2 for osteoblast 
cultures in their respective optimised medium. Cells were cultured with the reagent 
of interest e.g CBE at relevant concentrations in 200µl of the respective medium 
and assessed for cell viability at either the first medium change i.e. day 4 for 
osteoclast and SaOs-2 and day 7 for MSC or as a time course over the duration of 
the culture. At the chosen time point medium was removed and replaced with 
100µl of the respective medium which was also added to three empty wells to 
serve as blanks. To all wells containing medium 20µl of the supplied MTS solution 
(CellTiter 96 AQueous One Solution Cell Proliferation Assay, Promega UK Ltd, 
Southampton, UK) was added and placed in an incubator for between 1 and 4 hours 
as according to manufacturers’ instructions. Once sufficient colour change was 
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observed, changing from yellow to brown, all wells containing medium and MTS 
were carefully re-suspended by pipetting to ensure the formazan product was fully 
solubilised while avoiding the creation of bubbles. Absorbance was then measured 
at 490nm using a BMG FluoStar Galaxy plate reader (reference wavelength 650nm).  
 
2.8 Staining protocols. 
2.8.1 Tartrate resistant acid phosphatase (TRAP) staining. 
TRAP is an enzyme highly expressed by osteoclasts. Fast garnet GBC salt in the 
presence of a naphthol is converted into a highly insoluble azo dye by TRAP 
allowing the visualisation of TRAP activity and thus identification of osteoclasts. 
TRAP assay kits were obtained from Sigma Aldrich and staining was performed 
according to manufacturers’ instructions. Briefly, each 6mm glass coverslip on 
which PBMC’s were attached and had been cultured in R10-OC for between 7 and 
21 days were carefully lifted out of a well of a 24 well plate using ethanol sterilised 
#7 watchmaker forceps (SLS LTD, Hessle, UK), washed once in PBS prior to fixing by 
being submerged in a mixture of acetone, citrate and distilled water for 30 seconds. 
The glass coverslip was then washed in distilled water, placed in a clean well of a 24 
well plate and allowed to air dry for a minimum of 30 minutes during which time 
the TRAP stain was prepared. This preparation involved pre-heating 8.8ml distilled 
water in a centrifuge tube to 37°C in a water bath prior to the addition of 3mg fast 
garnet powder, followed by vigorous vortexing to ensure fast garnet was in 
solution. Once achieved 400µl tartrate solution, 400µl acetate and 400µl naphthol 
bi-phosphoric acid was added in order. The solution was again vortexed, placed in a 
water bath to return the solution to 37°C, filtered into a new centrifuge tube with a 
0.2µM pore syringe filter. 500µl of TRAP stain was added to each well containing 2 
coverslips and incubated for 1 hour at 37°C in the dark after which time the stain 
was removed and the coverslips were washed in 1ml distilled water 5 times and air 
dried overnight prior to mounting on a glass slide, cell side facing upwards, with 
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DPX mountant. Osteoclasts were defined as cells with 3 or more nuclei with a 
red/pink staining indicative of TRAP activity as shown in figure 2.8. 
 
 
 
2.8.2 Vitronectin receptor (CD51/61) Alexa Fluor 488/ texas red 
phalloidin staining. 
The α5β3 vitronectin receptor (VNR) is a member of the integrin superfamily and is 
highly expressed on the cell surface of osteoclasts. To facilitate the focal release of 
bone matrix degrading proteins osteoclasts form filamentous (F) actin ring 
structures. Phalloidin is a phallotoxin which binds monomerically to F actin 
therefore fluorescent conjugates of phalloidin when used in conjunction with 
antibody mediated fluorescent staining of VNR allows for specific identification of 
osteoclasts i.e. cells which are strongly positive for VNR and have an actin ring/s are 
counted as osteoclasts as shown in figure 2.9. 
A 6mm glass coverslip or bone disc on which PBMC’s were attached and had been 
cultured in R10-OC for between 7 and 21 days were carefully lifted out of a well of a 
24 well plate (96 well plate for bone discs) using ethanol sterilised #7 watchmaker 
forceps and transferred to a well of a 24 well plate containing 1ml PBS and 
incubated for 5 minutes at room temperature. PBS was removed and replaced with 
Figure 2.8 Example image of TRAP staining of osteoclasts generated from a GD 
subject culture showing large multinucleate cells with distinct red/pink intracellular 
staining. 
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1ml PBS repeating the previous wash step. PBS was removed and replaced with 
500µl 4% paraformaldehyde in PBS pH7.0 and incubated at room temperature for 
20 minutes. The paraformaldehyde was removed and the wash step with 1ml PBS 
was repeated twice. PBS was removed and replaced with 500µl 1% BSA in PBS and 
incubated for 20 minutes at room temperature. 1% BSA was removed and replaced 
with 200µl vitronectin receptor (CD51/61) 1°mouse anti-human antibody (BD 
biosciences, Oxford, UK) solution comprising a 1:50 dilution (10µg/ml) of antibody 
in 1% BSA in PBS and incubated for 75 minutes at room temperature in the dark. 
Vitronectin receptor solution was removed and the wash step with 1ml PBS was 
repeated three times, incubated in the dark for this and all subsequent wash steps. 
PBS was removed and replaced with a 200µl Alexa Fluor 488 F(ab’)2 fragment of 
rabbit anti-mouse IgG (ThermoFisher Scientific, Paisley, UK) solution comprising a 
1:200 dilution of F(ab’)2 fragment (10µg/ml) in PBS. Alexa Fluor 488 solution was 
removed and the wash step with 1ml PBS was repeated three times. PBS was 
removed and replaced with 500µl 0.1% Triton X-100 (VWR, Lutterworth, UK) in PBS 
and incubated for 10 minutes at room temperature. The 0.1% triton was removed 
and the wash step with 1ml PBS was repeated twice. PBS was removed and 
replaced with 200µl Texas Red-X phalloidin solution (5µl Texas Red-X phalloidin 
stock solution = 1 unit (ThermoFisher Scientific, Paisley, UK) in 200µl 1% BSA in PBS) 
and incubated for 30 minutes at room temperature in the dark. Texas Red-X 
Figure 2.9 Example images of fluorescent staining of vitronectin receptor (green) 
and F-actin (red). (a) Gaucher subject osteoclast culture on glass. (b) Control 
subject osteoclast culture on bone. 
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phalloidin solution was removed and the wash step with 1ml PBS was repeated 
three times. Coverslips were removed from PBS with #7 watchmaker forceps and 
mounted onto a glass slide with Prolong Gold anti-fade mountant (ThermoFisher 
Scientific, Paisley, UK) and kept in the dark until visualisation with a fluorescence 
microscope (either an Olympus IX70 confocal fluorescence microscope with an 
Olympus LSR Ultraview camera or a Zeiss LSM510meta confocal microscope).  
 
2.8.3 Toluidine blue staining. 
A 6mm bone disc on which PBMC’s were attached and had been cultured in R10-OC 
for 21 days was carefully lifted out of a well of a 96 well plate using ethanol 
sterilised #7 watchmaker forceps and transferred to a well of a 24 well plate 
containing 1ml distilled water. Water was removed and replaced with 1ml distilled 
water. This wash step was repeated once more followed by the removal of water 
and addition of 200µl mammalian cell lysis buffer and incubation at room 
temperature for a minimum of 30 minutes with shaking. The cell lysis buffer was 
then removed and wash steps with 1ml distilled water were repeated 3 times. 
Water was replaced with 500µl 1% toluidine blue in 0.5% sodium tetraborate 
solution made with distilled and incubated at room temperature with gentle 
shaking for between 30 and 60 seconds. The toluidine blue solution was removed 
and wash steps with 1ml distilled water were repeated 5 times. Distilled water was 
removed and the bone disc was air dried overnight. Pit formation was determined 
by counting individual pits using a phase contrast microscope.  
 
2.8.4 Alizarin red staining. 
Alizarin red S is a water soluble anthraquinone derivative which chelates calcium in 
a stoichiometric ratio of 1:1 at pH 4.1-4.3 to form a brick red dye which can 
subsequently be solubilised in acetic acid and quantified by colourimetry. 
Medium was removed from wells of a 24 well plate of SaOs-2 cell line or MSC 
derived osteoblast cultures and replaced with 1ml PBS lacking Ca2+ and Mg2+ 
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(ThermoFisher Scientific, Paisley, UK). PBS was removed and replaced with 1ml PBS 
lacking Ca2+ and Mg2+ as a second wash step. PBS was replaced with 500µl 4% 
paraformaldehyde in PBS lacking Ca2+ and Mg2+, pH7.0 and incubated at room 
temperature for 15 minutes. Paraformaldehyde was removed and replaced with 
1ml distilled water. The water was removed and again replaced with 1ml distilled 
water. The water was removed and replaced with 500µl 40mM alizarin red S 
solution which had been adjusted to pH4.1 with 10% ammonium hydroxide in 
distilled water and filtered with a 0.2µM pore syringe filter. The 24 well plate was 
incubated at room temperature for 20 minutes with gentle shaking. Alizarin red was 
removed and replaced with 1ml distilled water and the plate was gently shaken for 
5 minutes prior to removal of water to be replaced with 1ml distilled water. This 
wash step was repeated a total of 5 times. At the final wash step water was 
removed and replaced with 600µl per well 10% acetic acid in distilled water and 
incubated at room temperature for 30 minutes with gentle shaking. Cells were 
detached with a cell scraper and the resultant slurry was transferred to a 1.5ml 
microcentrifuge tube, vortexed for 30 seconds, overlaid with 500µl mineral oil and 
transferred to a water bath pre-heated to 85°C and incubated for 10 minutes. After 
which the microcentrifuge tube was cooled in ice before centrifugation at 2000g for 
15 minutes in a microcentrifuge. 500µl of supernatant was transferred to a clean 
1.5ml microcentrifuge tube to which was added 200µl 10% ammonium hydroxide 
and briefly vortexed. 150µl of resultant solution was transferred to each of 3 wells 
of a 96 well plate. For quantification a range of alizarin red concentrations were 
added to the 96 well plate to produce a standard curve, each concentration in 
triplicate. These concentrations were 2, 1, 0.5, 0.25, 0.125, 0.0625, 0.03125, 0mM 
alizarin red S prepared in a diluent of 10% acetic acid and 10% ammonium 
hydroxide (ratio of 5:2).  
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 2.9 β-glucocerebrosidase activity fluorimetric assay. 
Cells were seeded in triplicate in 96 well plates at the density used under standard 
differentiation culture conditions in their respective optimised medium as in the 
MTS method (NCI-H929 at a density of 4x104 cells/ml). Cells were cultured with the 
β-glucocerebrosidase inhibitor of interest i.e. conduritol β-epoxide (CBE) or 
isofagomine tartrate, at relevant concentrations in 200µl of the respective medium 
and assessed for cell viability after 4 days of culture. For adherent cells, after 4 days, 
medium was removed and replaced with 200µl PBS which was again removed and 
replaced with PBS as second wash step. PBS was removed and replaced with 50µl 
distilled H20. Cells were detached by scraping with a 200µl pipette tip until no cells 
were observed to be attached when viewed under an Olympus CK40 phase contrast 
microscope. The 50µl cell suspension of each replicate was transferred to a 0.65ml 
microcentrifuge tube so each tube contained a total of 150µl of cell suspension. 
Non-adherent cells (NCI-H929) were re-suspended by repeated pipetting prior to 
transfer of replicates to a 15ml centrifuge tube i.e. 1 tube per condition. Cells were 
centrifuged at 400g at 4°C for 10 minutes with full acceleration and braking. 
Supernatant was removed and replaced with 1ml PBS, again centrifuged at 400g at 
4°C for 10 minutes as a wash step. PBS was removed and the wash step was 
repeated after which PBS was removed and replaced with 150µl distilled H20. The 
cell pellet was re-suspended by repeated pipetting prior to transfer to a 0.65ml 
microcentrifuge tube. The suspension of either adherent or non-adherent cells was 
freeze thawed by placing the tube in a -80°C freezer for a minimum of 30 minutes 
followed by thawing at room temperature. The resultant lysate was vortexed prior 
to being centrifuged at 2000g for 5 minutes. Supernatant was transferred to a 
0.65ml microcentrifuge tube. As enzyme activity was quantified as nmol/hr/mg 
protein, total protein was determined using a bicinchoninic acid protein assay kit 
(Sigma Aldrich, Poole, UK) and was performed according to manufacturers’ 
instructions. Briefly, protein concentration was measured against a standard curve 
of BSA dilution from 0-1000µg/ml. 25µl of the diluted standard or cell lysate was 
transferred to a well of a 96 well plate, in duplicate. 200µl of a 10:1 solution of 
bicinchoninic acid : Copper(II) Sulfate Pentahydrate 4% solution was added to each 
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well and placed in an incubator for 30 minutes. Absorbance was then measured at 
562nm using a BMG FluoStar Galaxy plate reader (reference wavelength 650nm). 
The following solutions were prepared for the β-glucocerebrosidase activity assay. 
Buffer: 0.15M McIlvaine citrate phosphate buffer, pH 5.2. 100ml was prepared by 
combining 46.9ml 0.1M citric acid with 53.1ml 0.2M Na2HPO4.2H2O solution. Stored 
at room temperature. 
Standard: A stock solution of 4-methylumbelliferone was prepared by dissolving 
176.9mg in 1L distilled H20 warmed to 80°C. 100µl of stock solution was added to 
19.9ml distilled H2O to give a working solution of 5nmol/ml. Stock and working 
solutions were stored at -20°C until required.  
Glycine stop solution: 55.7ml of solution A (75g glycine and 58g NaCl in 1L distilled 
H20 was combined with 44.3ml of solution B (1M NaOH). Stored at room 
temperature. 
4-methylumbelliferylglucopyranoside (4-MUG) substrate+inhibitor.                      
For a 1L solution – 9.6g of competitive inhibitor sodium taurocholate was added to 
a 0.2mM solution of 4-MUG in McIlvaine citrate phosphate buffer. Stored at -20°C 
until required.  
The β-glucocerebrosidase activity assay was then performed in a 96 well plate as 
shown below, figure 2.10. 
 
 
20µl of sample supernatant was added to sample wells e.g. Sample 1. Once all 
samples were added 20µl of 4-MUG substrate+inhibitor was added to the substrate 
blank and sample wells. The 96 well plate was then incubated at 37°C for 2 hours in 
the dark. The enzyme reaction was terminated by addition of 200µl glycine stop 
solution to sample wells and substrate blank. 20µl sample supernatant was added 
Figure 2.10 96 well plate layout for β-glucocerebrosidase activity fluorimetric assay. 
109 
 
to standard, substrate blank and sample blank followed by 20µl H2O to sample 
blank. 20µl standard was added to standard wells followed by 200µl glycine stop 
solution to standard and sample blank wells. Fluorescence was measured using a 
BMG FluoStar Galaxy plate reader (excitation 365nm, emission 450nm). Enzyme 
activity was calculated using the formula below. 
((Average of sample-substrate blank)/(Standard-sample blank)*(60/120)*(1000/µg 
protein)*(1000/20)) 
Note: Fluorescence reading for standard must be multiplied by 10 at the start of the 
calculation as 20μl of 5nmol/ml standard is added to wells = 0.1nmoles whereas the 
units of the calculation are nmol/hr/mg. 
 
2.10 Statistics. 
All experimental data was analysed by either Microsoft Excel versions 2012-2016 
(Microsoft Corporation, California, US) or GraphPad Prism 5.0TM (GraphPad 
Software Inc, California, US). Standard deviation (SD), standard error of the mean 
(SEM) and mean were used to summarise the data. The D'Agostino-Pearson 
omnibus normality test was used to determine whether data fitted a Gaussian 
(normal) distribution. Unpaired t-tests were used for unpaired parametric data and 
Mann-Whitney U tests were used for unpaired non-parametric data. Paired t-tests 
were used for paired parametric data sets while Wilcoxon signed rank tests were 
used for non-parametric paired data sets. All tests were two tailed and a p value of 
< 0.05 was regarded as statistically significant.  
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3   In vitro osteoclast cultures 
3.1 Introduction 
In type 1 Gaucher disease (GD) one of the most common and clinically significant 
features is bone disease with 75-90% of patients suffering skeletal symptoms which 
in some patients can be severely debilitating (506,528). The most common bone 
features are osteonecrosis with 43% of patients having a history of osteonecrosis in 
a UK cohort (122) and osteopenia/osteoporosis with one study from the Gaucher 
registry suggesting that 76% of Gaucher patients between the ages of 12 and 20 
had low bone mineral density and an increased risk of fracture (529).  Although 
bone disease can respond to ERT it can take several years to show improvement 
(84,507) with considerable residual skeletal disease after several years of ERT (84). 
Potential challenges for effective treatment of skeletal aspects of type 1 GD are that 
the understanding of the bone microenvironment and the mechanisms underlying 
the bone disease including the effect of therapies on the cells in this environment 
are still poorly understood. 
The main storage cell in type 1 GD is the macrophage primarily due to its role of 
phagocytosis in particular of effete red blood cells (530) resulting in foamy 
macrophages commonly referred to as Gaucher cells. These cells are present in 
Gaucher patient bone marrow and are thought to be an important contributing 
factor to bone disease as they have been shown to secrete several cytokines 
including IL6 which is known to affect several cell types in the bone 
microenvironment. However, while the number of these cells diminish over time 
with therapy the bone disease is much slower to respond suggesting other cells and 
factors in the bone microenvironment are also contributing to the skeletal disease. 
Osteoclasts, cells which degrade bone matrix, are terminally differentiated from the 
same lineage as macrophages, namely monocytes, and are also phagocytic (531). 
Due to this shared lineage and phagocytic activity it may be possible that 
osteoclasts are also affected by the altered sphingolipid profile of Gaucher patients 
resulting in a change in their numbers and/or activity.  
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The relatively recent development over the last 15 or so years of in vitro techniques 
for differentiating osteoclasts from peripheral blood by culturing with RANKL and 
MCSF, negating the need to co-culture with osteoblasts (532,533), has led to a rapid 
increase in our understanding of the origins and functions of osteoclasts. Use of this 
established and relatively non-invasive technique to study osteoclasts from 
Gaucher patients may therefore provide insight into the bone microenvironment of 
these patients. 
However, true osteoclasts are traditionally defined by their ability to degrade and 
resorb bone matrix resulting in the creation of pits, usually circular, in the bone 
surface. Historically, de-vitalized bone, dentine or ivory slices have been used as a 
substrate on which to culture osteoclasts. Recent developments have led to the use 
of calcium phosphate coated glass to act as a substrate due to the limited 
availability of the other substrates however this substrate lacks the proteins 
normally present in the bone matrix. While de-vitalised bone is probably the most 
biologically relevant substrate the presence of pre-existing bone pits makes 
identification of new pits problematic. Therefore, if available, dentine or ivory is 
probably the most applicable substrate for assessment of osteoclast activity as 
neither have pre-existing bone pits due to the mode of their formation. 
Recent publications have shown that several sphingolipids are involved in 
osteoclast migration, differentiation and activity. In particular sphingosine-1-
phosphate has been shown to play a critical role in regulating the migration of 
osteoclast precursors to and from the peripheral blood and the bone marrow 
compartment (380). Lactosylceramide has been linked to RANKL mediated 
osteoclastogenesis (534) while ceramide has been suggested to increase osteoclast 
survival but reduce their resorptive activity (535). 
Taken together these findings suggest the altered sphingolipid profile found in 
Gaucher patients may markedly affect the bone microenvironment and directly 
affect osteoclasts potentially explaining at least in part the bone disease observed 
in GD.   
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3.2 Aims and Hypotheses 
Aim: To understand the roles of osteoclasts in Gaucher patient bone disease. 
Objectives:  
(1) To characterise GD patient osteoclast generation, size and activity in vitro 
compared to control subjects. 
(2) To determine the effect of Gaucher-specific therapies on GD osteoclast 
generation and activity in vitro. 
(3) To determine the effect of sphingolipids on both control and GD osteoclast 
generation and activity in vitro. 
  
Hypothesis 1: Circulating GD monocytes have an increased potential to form 
osteoclasts compared to control monocytes.  
Rationale: The majority of GD patients have low BMD with an average of 75% 
presenting with osteopenia. This bone loss could result from increased osteoclast 
number and/or activity, decreased osteoblast number and/or activity or a 
combination thereof. Several groups have found increased pro-osteoclastic 
cytokines in the plasma and serum of GD patients. Sphingolipids including ceramide 
and sphingosine-1-phosphate, both found to be elevated in GD serum, have been 
reported to affect osteoclast migration and maturation.  
Methods: Differentiation of monocytes isolated from the peripheral blood of GD 
patients and control subjects into functional osteoclasts by culture with established 
osteoclastogenic cytokines RANKL and MCSF. Osteoclasts will be identified either by 
being histochemically positive for TRAP or high surface expression of vitronectin 
receptor in conjunction with actin ring formation labelled with fluorochromes. 
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Hypothesis 2a: Increased osteoclastogenesis is directly related to β-
glucocerebrosidase deficiency rather than protein misfolding. 
Rationale: GD results from pathogenic mutations in the GBA gene causing either a 
decrease in β-glucocerebrosidase activity or misfolding of the protein resulting in 
degradation by the ER associated degradation pathway (ERAD). Data generated by 
our group prior to this project and research published during this project by Mucci 
et al with the irreversible inhibitor of β-glucocerebrosidase CBE in cell lines showed 
inhibition resulted in increased osteoclastogenesis suggesting it is directly related to 
a decrease in to β-glucocerebrosidase activity.  
Methods: Culture of control subject monocytes with CBE in the presence of 
osteoclastogenic cytokines RANKL and MCSF. Osteoclasts will be identified either by 
being histochemically positive for TRAP or high surface expression of vitronectin 
receptor in conjunction with actin ring formation labelled with fluorochromes. 
 
Hypothesis 2b: Addition of GD-specific therapies to GD osteoclast cultures reduces 
osteoclastogenesis. 
Rationale: If increased osteoclastogenesis is directly related to β-
glucocerebrosidase deficiency, replacement of the deficient enzyme or reduction of 
the substrate should reverse this effect. 
Methods: Culture of GD or control subject monocytes with ERT or SRT in the 
presence of osteoclastogenic cytokines RANKL and MCSF. Osteoclasts will be 
identified either by being histochemically positive for TRAP or high surface 
expression of vitronectin receptor in conjunction with actin ring formation labelled 
with fluorochromes. 
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Hypothesis 3: The altered sphingolipid profile found in GD patients causes 
increased osteoclastogenesis. 
Rationale: A number of sphingolipids concentrations have been found to be 
elevated in GD serum and plasma including ceramide, sphingosine, S1P, 
glucosylsphingosine and glucosylceramide. Research has shown roles for 
sphingolipids such as ceramide, sphingosine-1-phosphate and lactosylceramide in 
the formation and function of osteoclasts. The elevated concentrations of these 
sphingolipids, possibly including glucosylsphingosine and glucosylceramide - the 
roles of which in relation to osteoclasts have yet to be elucidated, may cause 
increased osteoclastogenesis.  
Methods: Culture of GD or control subject monocytes with a number of different 
sphingolipids added exogenously in the presence of osteoclastogenic cytokines 
RANKL and MCSF. Osteoclasts will be identified either by being histochemically 
positive for TRAP or high surface expression of vitronectin receptor in conjunction 
with actin ring formation labelled with fluorochromes. 
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3.3 Results 
3.3.1 Increased generation, activity and nucleation of Gaucher derived 
osteoclasts.  
Monocytes isolated from the peripheral blood of control and Gaucher subjects 
(1.25x105/cm2) were cultured in osteoclastogenic medium for up to 21 days on 
glass coverslips. At either day 14 or 21 these cells were fixed and stained for 
tartrate resistant acid phosphatase activity (TRAP), highly expressed in osteoclasts, 
resulting in pink deposits within osteoclasts and thus allowing their identification by 
direct light microscopy, as shown by arrows in figure 3.1a. At both time points 
osteoclast numbers were significantly higher in Gaucher subject cultures compared 
to control (day 14 p = 0.0008, day 21 p = 0.0016, figure 3.1b). When these 
monocytes were cultured in osteoclastogenic medium for 21 days on bone discs, 
active osteoclasts resorbed the bone creating pits and furrows in the bone surface. 
After 21 days the cells were lysed and washed from the bone surface which was 
then stained with toluidine blue to allow visualisation of the pits as indicated by 
arrows in figure 3.1c. Enumeration by direct light microscopy found Gaucher 
subject cultures generated significantly more pits than control cultures (p = 0.02, 
figure 3.1d), suggesting the osteoclasts were either more active or more numerous 
in Gaucher subject cultures than in control. It has been previously shown that 
osteoclasts with more nuclei have higher resorptive activity (536). TRAP staining of 
osteoclasts cultured on glass enabled visualisation by direct light microscopy of 
nuclei within the osteoclasts, as shown by arrows in figure 3.1e. By averaging the 
number of nuclei per osteoclast in different control and Gaucher subject cultures a 
significantly higher number of nuclei were present in Gaucher subject osteoclasts 
compared to control cultures (p = 0.0001, figure 3.1f) suggesting that Gaucher 
subject derived osteoclasts are both more numerous and more active in 
comparison to control subject derived osteoclasts.  
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Figure 3.1 Increased generation, activity and nucleation of Gaucher derived 
osteoclasts. (a) Representative TRAP staining of Gaucher derived osteoclasts, 
indicated by arrows, cultured for 21 days on glass. (b) Number of osteoclasts 
generated from adherent mononuclear cells after 14 and 21 days of culture on 
glass. Control n = 25, Gaucher n = 38, mean ± SEM plotted. (c) Representative image 
of bone pits generated in b, toluidine blue staining, pits indicated by arrows.          
(d) Bone pits resorbed by osteoclasts after 21 days of culture on bone, mean shown 
by horizontal line. (e) Representative image of a TRAP stained Gaucher derived 
osteoclast, nuclei indicated by arrows. (f) Averaged nuclei per osteoclast of TRAP 
stained osteoclast cultures, mean ± SEM shown by horizontal lines. * p ≤ 0.05,       
** p ≤ 0.01, *** p ≤ 0.001, unpaired t-tests. 
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3.3.2 Gaucher derived osteoclast generation occurs earlier than 
control derived osteoclasts.  
To determine whether the significantly higher number of osteoclasts generated in 
Gaucher subject cultures and nuclei present in Gaucher subject osteoclasts was 
gender specific the data was divided into groups of male and female for both 
control and Gaucher subject cultures. Osteoclast number and nuclei per osteoclast 
was significantly higher for Gaucher subject osteoclast cultures compared to control 
for both genders (osteoclast number: female p = 0.028, male = 0.034, nuclei 
number: female p = 0.036, male p = 0.012, figure 3.2a and b) and no significant 
differences were found between either control male and female or Gaucher male 
and female groups.  
The finding of significantly higher osteoclast generation at day 14 in Gaucher 
subject cultures, figure 3.1a, suggested osteoclasts were being generated earlier in 
comparison to control cultures. To confirm this finding mononuclear cells cultured 
in osteoclastogenic medium were fixed at days 7, 10, 14 and 21 to create a time 
course of generation. Significantly higher osteoclast generation in Gaucher subject 
cultures was found from day 10 (day 7 p = 0.09, day 10 p = 0.007, figure 3.2c) 
confirming the hypothesis that Gaucher subject osteoclasts form more quickly in 
comparison to controls. 
To investigate whether the increased rate and total number of osteoclasts 
generated in Gaucher subject cultures was dependent on the presence of the 
osteoclastogenic cytokines RANKL and MCSF, mononuclear cells were cultured with 
either one or both of these cytokines excluded for 21 days on glass. Significantly 
more osteoclasts were formed in Gaucher subject cultures when RANKL was 
excluded compared to control subjects (p = 0.041, figure 3.2d). However 
numerically this difference is very small and does not account for the highly 
significant differences previously observed in figures 3.1a and 3.2c.  
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Figure 3.2 Characterisation of Gaucher derived osteoclasts. (a) Number of 
osteoclasts generated from adherent mononuclear cells on glass, determined by 
TRAP staining, after 21 days of culture. (b) Averaged nuclei per osteoclast of TRAP 
stained osteoclast cultures, mean shown by horizontal line. (c) Number of 
osteoclasts generated from adherent mononuclear cells on glass, determined by 
TRAP staining, at several time point over the 21-day culture. N = 5 for control and 
Gaucher subject at each time point, mean ± SEM plotted. (d) Number of osteoclasts 
generated after 21 days of culture in R10 with the cytokine indicated. A minimum of 
8 subjects were cultured for each condition. Mean ± SEM is plotted. * p ≤ 0.05, ** p 
≤ 0.01, unpaired t-tests. 
 
 
3.3.3 Gaucher subject mononuclear cells lack an inhibitory signal for 
osteoclastogenesis. 
To determine whether the increase in osteoclastogenesis was caused by stimulation 
or a lack of inhibition and also whether this was mediated by physical contact or 
soluble factors, control and Gaucher subject mononuclear cells were cultured in 
osteoclastogenic medium for 21 days in each other’s presence. Control and 
Gaucher subject cells were either adhered onto separate glass coverslips and 
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subsequently transferred to the same well so that they were sharing the same 
medium but physically separated, figures 3.3a and 3.3b, or mixed together prior to 
being adhered onto glass coverslips so that the cells were both in physical contact 
and sharing the same medium, figures 3.3c and 3.3d. To assess whether osteoclast 
generation had been affected in the contact experiments the number of osteoclasts 
generated by control and Gaucher subjects when cultured on their own was added 
together and halved to provide an expected number of osteoclasts in the mixed 
culture assuming osteoclast generation was unaffected, referred to as 
Control+Gaucher expected, with the actual osteoclast number generated from the 
mixed culture labelled as Control+Gaucher actual in figures 3.3c and 3.3d. After 14 
days Gaucher subject derived osteoclast numbers in both separate and contact co-
cultures were not significantly different to those of control subjects and were 
significantly lower than Gaucher subject cultured on their own when separated 
(Gaucher vs Gaucher co-culture, p = 0.0133, figure 3.3a) and the actual value when 
cultured in contact (Gaucher vs control+Gaucher actual, p = 0.0101, figure 3.3c). 
However, by day 21 the number of osteoclasts for Gaucher subjects in the co-
cultures for both separated and contact conditions were significantly higher than 
for control subjects (Control vs Gaucher co-culture p = 0.0402, figure 3.3b. Control 
vs control+Gaucher actual p = 0.0491, figure 3.3d). A significantly lower number of 
Gaucher subject derived osteoclasts in co-culture was still observed when 
compared to Gaucher subjects alone when physically separated (Gaucher vs 
Gaucher co-culture p = 0.0064, figure 3.3b) and when compared to the actual value 
in the contact cultures (Gaucher vs control+Gaucher actual p = 0.0057, figure 3.3d). 
These findings suggest Gaucher subject mononuclear cells lack an inhibitory signal 
for osteoclastogenesis as a stimulatory factor generated by the Gaucher subject 
cells would have significantly increased the number in the control cultures. These 
results also suggest that this signal may be soluble although this experiment does 
not exclude the possibility that inhibition is mediated through both soluble and 
contact dependent factors.  
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Figure 3.3 Co-culture of control and Gaucher subject osteoclasts. (a, b) Number of 
osteoclasts generated after (a) 14 days and (b) 21 days of culture in which control 
and Gaucher subject mononuclear cells were adhered onto separate glass 
coverslips overnight and transferred to wells of 24 well plates, 4 coverslips per well. 
Combinations included 4 control coverslips, 4 Gaucher coverslips or 2 control 
coverslips with 2 Gaucher coverslips. Control or Gaucher co-culture indicates the 
number of osteoclasts generated by control or Gaucher subjects in the final 
combination previously stated. (c, d) Number of osteoclasts generated when 
mononuclear cells isolated from control and Gaucher subjects were mixed in equal 
numbers, adhered onto glass coverslips and cultured for (c) 14 days and (d) 21 days, 
labelled as control + Gaucher actual. Control + Gaucher expected is a calculation of 
control plus Gaucher osteoclasts divided by 2. Mean shown by horizontal line. * p ≤ 
0.05, ** p ≤ 0.01, paired t-tests. 
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3.3.4  Potential cross correction  
An alternative possibility to a lack of an inhibitory signal is cross correction of the 
deficient enzyme, β-glucocerebrosidase, from the control to the Gaucher subject 
cells via secretion of the enzyme into the culture medium. To assess this possibility 
β-glucocerebrosidase activity was measured in the supernatant of control and 
Gaucher subject osteoclast cultures after 21 days of culture. β-glucocerebrosidase 
activity was significantly higher in control than Gaucher subject supernatant (p = 
0.04, figure 3.4) however activity was very low for both cohorts.  
 
Figure 3.4 Glucocerebrosidase activity measured in control and Gaucher subject 
supernatant from 21-day old osteoclast cultures. Control n = 18, Gaucher n = 19. 
Mean ± SEM plotted. * p ≤ 0.05, unpaired t-test. 
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3.3.5  β-glucocerebrosidase inhibition by CBE increased generation, 
size and nucleation of control subject derived osteoclasts. 
To investigate the role of reduced β-glucocerebrosidase activity in osteoclast 
generation, control subject mononuclear cells were cultured on glass in 
osteoclastogenic medium with an irreversible inhibitor of β-glucocerebrosidase, 
conduritol-β-epoxide (CBE), at a concentration which reduced the activity of β-
glucocerebrosidase by up to 99% as shown in figure 3.5c (p = 0.0003). Medium 
(including inhibitor) was replaced twice per week. As the binding of the inhibitor to 
the enzyme is irreversible it was necessary to prove that the inhibitor was added at 
a high enough concentration (100µM) to ensure inhibition was still sufficient after 
the maximum period between medium changes, hence the time point of 4 days 
stated in figure 3.5c. Addition of CBE to the control subject osteoclast cultures for 
21 days resulted in the generation of larger, more nucleated cells as can be seen in 
figure 3.5a (without CBE) compared to figure 3.5b (with CBE). Osteoclast generation 
in control subject cultures was also significantly increased in the presence of CBE (p 
= 0.001, figure 3.5d). However, this increase only partially recapitulates the degree 
of osteoclast generation observed in Gaucher subject cultures suggesting additional 
factors may also affect the rate of osteoclastogenesis of Gaucher mononuclear 
cells. In addition, although CBE inhibition resulted in a significant reduction of β-
glucocerebrosidase activity in Gaucher subject cultures (p = 0.05) no significant 
increase in osteoclast numbers was observed again suggesting other factors are 
responsible for the osteoclast generation by Gaucher subject cultures being higher 
than inhibited control cultures.  
 
123 
 
 
 
Figure 3.5 Effect of CBE on osteoclast generation. (a, b) Representative TRAP 
stained images of osteoclasts generated from control subject adherent 
mononuclear cells after 21 days of culture in the (a) absence or (b) presence of 
100µM CBE. (c) Glucocerebrosidase activity measured in whole cell lysates of 
adherent mononuclear cells cultured for 4 days with CBE, n = 8 for control and 
Gaucher per condition. (d) Number of osteoclasts generated from adherent 
mononuclear cells cultured for 21 days on glass. Control n = 17 per condition, 
Gaucher n = 22 per condition. Mean ± SEM plotted. * p ≤ 0.05, *** p ≤ 0.001. Paired 
t-tests.  
 
 
3.3.6 Gaucher disease specific therapies reduce osteoclast generation 
in Gaucher patient derived cultures in vitro. 
To assess the effect of Gaucher specific therapies on osteoclast generation, control 
(figure 3.6) and Gaucher (figure 3.7) subject mononuclear cells were cultured in 
osteoclastogenic medium with enzyme replacement therapies imiglucerase (1 
unit/ml), velaglucerase (1unit/ml), substrate reduction therapy miglustat (50µM) or 
a combination of imiglucerase (1unit/ml) and miglustat (50µM) for 21 days with 
medium (including therapies) replaced twice per week. In control subject osteoclast 
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cultures only the addition of imiglucerase significantly reduced the number of 
osteoclasts generated (p = 0.0015, figure 3.6). In contrast, a significant reduction in 
osteoclastogenesis was observed in Gaucher subject cultures when in the presence 
of any of the therapies. However, the most statistically significant reduction was 
again attained by addition of imiglucerase (imiglucerase p = 0.001, velaglucerase p = 
0.013, miglustat p = 0.023, imiglucerase+miglustat p = 0.05, figure 3.7). Suggesting 
the increase in osteoclast generation in Gaucher subject cultures is directly related 
to this disease and possibly the reduced activity of β-glucocerebrosidase.  
 
Control subjects 
 
Figure 3.6 Effect of therapy on control osteoclast generation in vitro. Number of 
osteoclasts generated from control subjects adherent mononuclear cells cultured 
for 21 days on glass in the presence of (a) imiglucerase (1 unit/ml), (b) 
velaglucerase (1 unit/ml), (c) miglustat (50µM) or (d) imiglucerase (1 unit/ml) + 
miglustat (50µM).  ** p ≤ 0.01, paired t-tests. 
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Gaucher patients. 
 
Figure 3.7 Effect of therapy on Gaucher osteoclast generation in vitro. Number of 
osteoclasts generated from Gaucher subjects adherent mononuclear cells cultured 
for 21 days on glass in the presence of (a) imiglucerase (1 unit/ml), (b) 
velaglucerase (1 unit/ml), (c) miglustat (50µM) or (d) imiglucerase (1 unit/ml) + 
miglustat (50µM). * p ≤ 0.05, *** p ≤ 0.001, paired t-tests.   
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3.3.7 Ambroxol hydrochloride reduces osteoclast generation and 
activity in both control and Gaucher patient derived cultures. 
Recent publications have shown that ambroxol hydrochloride, currently licensed as 
an expectorant and used as a treatment for several respiratory diseases (233,537), 
has the molecular structure to act as a pharmacological chaperone for β-
glucocerebrosidase, increasing its lysosomal fraction and activity (538,539). It is 
therefore regarded as a potential therapy for Gaucher disease. In order to study the 
effect of this potential chaperone therapy on in vitro Gaucher subject osteoclast 
generation and activity, control and Gaucher subject mononuclear cells were 
cultured on glass or bone for 21 days in osteoclastogenic medium in the presence 
of 20µM ambroxol hydrochloride, medium replaced twice per week. In control 
cultures the addition of ambroxol significantly reduced both osteoclast generation 
(p = 0.008, figure 3.8a) and resorptive activity (pit formation) p = 0.005, figure 3.8b. 
A similar effect was observed for Gaucher subject cultures in which again osteoclast 
number (p = 0.005, figure 3.8c) and activity (p = 0.006, figure 3.8d) were 
significantly reduced. While these effects suggest increased osteoclastogenesis is at 
least in part related to β-glucocerebrosidase activity, ambroxol’s marked effect of 
reducing osteoclast number and activity in control cultures suggests this compound 
may be affecting osteoclast formation, maturation and activity through a 
mechanism independent of β-glucocerebrosidase.  
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Figure 3.8 Ambroxol reduces osteoclastogenesis and osteoclast activity. (a, c) 
Number of osteoclasts generated from adherent mononuclear cells after 21 days of 
culture on glass in the absence or presence of 20uM ambroxol hydrochloride, 
determined by TRAP staining. (a) Control n = 6, (c) Gaucher n = 7, mean ± SEM 
plotted, paired t-tests. (b, d) Bone pits resorbed by osteoclasts after 21 days of 
culture on bone. (b) Control n = 6, (d) Gaucher n = 7, mean ± SEM plotted, unpaired 
t-tests. Control shown as white bars, Gaucher shown as black bars. ** p ≤ 0.01 
 
 
3.3.8 Blocking TNF-α reduces control subject but not Gaucher patient 
derived osteoclast generation.  
TNFα, a cytokine mainly produced by monocytes (392), shown to induce 
osteoclastogenesis (540) has been found to be significantly higher in the serum of 
Gaucher patients (143) and has been suggested to be a factor for the observed 
increase in osteoclastogenesis in other cellular models of GD (525,541). To 
elucidate a potential mechanism for the increased osteoclast generation in the GD 
osteoclast cultures TNF-α signalling was either stimulated by addition of TNF-α or 
inhibited by addition of a TNF-α blocking antibody to the osteoclast cultures from 
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initiation of the culture, replaced twice per week for the duration of the culture. 
Addition of a TNFα neutralising antibody (2ng/ml) to control or Gaucher subject 
mononuclear cells cultured in osteoclastogenic medium for 21 days on glass 
resulted in a significant decrease in osteoclast number in control cultures (p = 0.03, 
figure 3.9a). A decrease in osteoclast numbers was also observed in Gaucher 
subject cultures however this difference was not significant (figure 3.9c). Addition 
of TNFα to similar cultures did not significantly affect osteoclast generation for 
either control or Gaucher subjects (figures 3.9b and 3.9d respectively).  
 
Figure 3.9 Effect of TNF on osteoclast generation. Number of osteoclasts generated 
from adherent mononuclear cells after 21 days of culture on glass in the absence or 
presence of (a, c) 2ng/ml anti-TNFα, (b, d) 10ng/ml TNFα, determined by TRAP 
staining. Control (white bars) n = 6, Gaucher (black bars) n = 7, mean ± SEM plotted, 
paired t-tests. * p ≤ 0.05 
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3.3.9 Specific sphingolipids affect osteoclastogenesis in vitro. 
Gaucher patient serum has been shown to have elevated concentrations of 
glucosylsphingosine, glucosylceramide, sphingosine and sphingosine-1-phosphate. 
To investigate the exogenous effect of these lipids and others present in the lipid 
synthesis pathway on osteoclast generation and activity, control and Gaucher 
subject mononuclear cells were cultured in osteoclastogenic medium for 21 days on 
glass in the presence of a sphingolipid (1µM) or of the solvent used, methanol, at a 
dilution of 1:10,000 methanol (or lipid):medium. Medium and thus sphingolipid was 
replaced twice per week. Addition of sphingosine to control subject cultures led to 
a significant decrease in osteoclast generation (p = 0.029, figure 3.10a) in 
comparison to solvent alone while addition of lactosylceramide or glucosylceramide 
resulted in significant increases in osteoclast generation (lactosylceramide p = 
0.043, glucosylceramide p = 0.006, figure 3.10a). However, while the significant 
increases in osteoclast generation were accompanied by respective increases in 
resorptive activity these increases did not attain statistical significance (figure 
3.10b). Interestingly, the addition of sphingosine-1-phosphate to control subject 
cultures had the opposite outcome with osteoclast numbers being increased but 
not reaching significance (p = 0.08) while activity was significantly increased (p = 
0.011, figure 3.10b). Sphingolipid addition to Gaucher subject cultures did not result 
in significant changes in either osteoclast number (figure 3.11) or activity (figure 
3.12) with the exception of glucosylceramide. As in control cultures addition of 
exogenous glucosylceramide resulted in a significant increase in osteoclast 
generation after 21 days (p = 0.028) (figure 3.11f) however this increase did not 
lead to an increase in resorption pits (figure 3.12).   
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Figure 3.10 Addition of sphingolipids to control osteoclast cultures. (a) Number of 
osteoclasts generated from control subjects adherent mononuclear cells after 21 
days of culture on glass in the absence or presence of 1µM of the lipid indicated.  
(b) Bone pits resorbed by osteoclasts after 21 days of culture on bone in the 
absence or presence of 1µM of the lipid indicated. Lipids added in a methanol 
solution at a dilution factor of 1:10,000. N = 6 per condition, mean ± SEM plotted.   
* p ≤ 0.05, ** p ≤ 0.01, paired t-tests.  
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Figure 3.11 Addition of sphingolipids to Gaucher osteoclast cultures. Number of 
osteoclasts generated from Gaucher subjects adherent mononuclear cells after 21 
days of culture on glass in the absence or presence of 1µM of the lipid indicated. N 
per condition = (a) 16, (b) 10, (c) 8, (d) 13, (e) 11, (f) 11. Lipids added in a methanol 
solution at a dilution factor of 1:10,000. Mean ± SEM plotted. *p ≤ 0.05. Unpaired t-
tests.  
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Figure 3.12 Addition of sphingolipids to Gaucher osteoclast cultures. Bone pits 
resorbed by osteoclasts after 21 days of culture on bone in the absence or presence 
of 1µM of the sphingolipid indicated. N per condition = (a) 16, (b) 11, (c) 13, (d) 10, 
(e) 10, (f) 8. Lipids added in a methanol solution at a dilution factor of 1:10,000. 
Mean ± SEM plotted. 
 
3.3.10 Osteoclasts can be generated from myeloma patient peripheral 
blood and bone marrow. 
To determine whether in vitro osteoclast generation of multiple myeloma subjects 
was similar to control or Gaucher subjects, mononuclear cells were isolated from 
peripheral blood and bone marrow of multiple myeloma subjects. Peripheral blood 
mononuclear cells were cultured on glass in osteoclastogenic medium for 21 days in 
the presence of β-glucocerebrosidase inhibitors CBE or isofagomine or Gaucher 
disease specific therapies imiglucerase or miglustat. While effects on osteoclast 
generation could be discerned statistical significance could not be attained due to 
an insufficient number of subjects. Mononuclear cells were also isolated from bone 
marrow samples subsequent to stromal cell removal by an additional adherence 
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step. The mononuclear cells were adhered onto glass coverslips or bone discs and 
cultured in osteoclastogenic medium for 21 days, representative images of TRAP 
stained osteoclasts are shown for cultures on glass (figures 3.14a and b) and on 
bone (figures 3.14c and d, white arrows indicate TRAP+ve osteoclasts, black arrows 
indicate resorption pits). The representative images on glass show that the 
osteoclasts generated from bone marrow isolates were very large, highly nucleated 
and numerous. Images on bone disc show a very high density of pits indicating that 
mononuclear cells isolated from bone marrow may have a high propensity to form 
osteoclasts with substantial resorptive activity. Osteoclast generation was 
significantly greater in cultures of mononuclear cells isolated from bone marrow 
compared to those isolated from peripheral blood of multiple myeloma subjects (p 
= 0.027), control subjects (p < 0.0001) and Gaucher subjects (p = 0.0002), data not 
shown. However, this observation is based on bone marrow samples from only 3 
multiple myeloma subjects, this cohort should be increased to confirm this 
observation. Mononuclear cells cultured in osteoclastogenic medium in the 
presence of 50µM Miglustat for 21 days on glass generated significantly fewer 
osteoclasts in comparison to standard conditions (p = 0.02, figure 3.14f). However, 
no difference in osteoclast activity (pit number) was observed when mononuclear 
cells were cultured in osteoclastogenic medium in the presence of miglustat on 
bone discs (figure 3.14h). Similarly, no significant differences were observed for 
addition of CBE, imiglucerase or ambroxol hydrochloride for either osteoclast 
generation or activity (figures 3.14g and h). Again the cohort is very small and will 
need to be expanded to determine the veracity of these observations.  
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Figure 3.13 Multiple myeloma peripheral blood osteoclast cultures. Number of 
osteoclasts generated from adherent mononuclear cells after 21 days of culture on 
glass. (a) Addition of 100uM CBE, n= 4. (b) Addition of 100uM isofagomine, n = 2   
(c) Addition of 1 unit/ml imiglucerase or 50uM miglustat, n = 4. Mean ± SEM 
plotted. Paired t-tests, no significances.  
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Figure 3.14 Multiple myeloma bone marrow osteoclast cultures.                               
(a, b) Representative images of TRAP stained osteoclasts cultured for 21 days on 
glass. (c, d) Representative images of TRAP stained osteoclasts and pits cultured on 
bone for 21 days. Osteoclasts indicated with white arrows, pits indicated with black 
arrows. (e, f, g) Number of osteoclasts generated from adherent mononuclear cells 
after 21 days of culture on glass. (e) Addition of 100µM CBE, n = 3, (f) Addition of 
50µM miglustat, n = 3, (g) Addition of 1 unit/ml imiglucerase or 20µM ambroxol 
hydrochloride, n = 2, (h) Bone pits resorbed by osteoclasts after 21 days of culture 
on bone. Conditions at concentrations as stated for culture on glass, isofagomine 
added at 100µM, n = 2 per condition. Mean ± SEM plotted.  *p ≤ 0.05, paired t-test 
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3.4 Discussion 
Bone disease is a very common and debilitating feature of GD. As detailed in table 
1.2 several pro-osteoclastogenic proteins have been found to be elevated in the 
plasma and serum of type 1 GD patients including IL-1β, IL-8, MIP-1α, MIP-1β and 
TNF-α. Systemic regulation may also be affected as two studies have shown that GD 
patients have a deficiency in 1,25(OH)2 vitamin D3 which is known to stimulate 
osteoblast differentiation (521,522). Taken together, these findings suggest GD 
bone marrow may have a highly pro-osteoclastogenic environment which may in 
part explain the bone loss observed in GD patients. In addition, osteoclasts are 
terminally differentiated from monocytes, as are the main storage cells in GD, 
macrophages. Therefore, our initial studies focused on characterising osteoclasts 
differentiated from GD monocytes in vitro. 
The results from this chapter demonstrate for the first time that GD patient derived 
osteoclasts are abnormal and osteoclasts may play a central role in the pathology of 
bone disease in GD, many of these results being published by our group in October 
2013 (526). This data supports our preliminary findings presented as posters from 
2005 to 2008 and the finding by Mucci et al published in 2012 that treatment of 
osteoclast precursors with conditioned medium from CBE treated peripheral blood 
mononuclear cells (PBMC’s) resulted in increased osteoclast differentiation (525). 
 
Increased osteoclast generation in GD cultures 
From our studies we have found significantly more osteoclasts were generated at 
days 14 and 21 of osteoclast culture from GD monocytes than control monocytes 
suggesting either that a larger proportion of GD monocytes are osteoclast 
precursors or that GD monocytes have an increased capacity for differentiating into 
osteoclasts and may be more sensitive to pro-osteoclastogenic cytokines. 
Functional assessment of osteoclast activity involving osteoclast generation on 
bone followed by counting the number of pits resorbed by active osteoclasts 
resulted in GD osteoclast cultures producing significantly more resorption pits than 
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control cultures. This increased resorption could simply be a direct consequence of 
increased osteoclast number but could also indicate these osteoclasts have higher 
individual activity.  
Light microscopy counting of nuclei per osteoclast showed GD osteoclasts had more 
nuclei and were consequently larger when cultured on glass. The combination of 
increased number and size may explain the increased activity as previously 
published research demonstrated a direct correlation between the number of 
nuclei and the resorptive activity of osteoclasts (536). However, it should be noted 
that this study assessed the activity of osteoclasts generated from normal subjects 
and therefore this correlation may not be the case for GD derived osteoclasts. 
No difference was found for gender in relation to number of osteoclasts generated 
and nuclei per osteoclast. Both male and female GD patients had significantly 
higher numbers of osteoclast and nuclei than control male and females respectively 
suggesting gender may not be a factor in GD specific bone disease however, it does 
not preclude the possibility of low oestrogen levels due to menopause further 
increasing osteoclast generation (315,542) in female GD patients exacerbating the 
bone complications commonly seen in GD.  
Osteoclasts were generated much earlier in GD cultures compared to controls 
suggesting monocytes could also be pre-stimulated or pre-committed to form 
osteoclasts in addition to more precursors as control osteoclast generation did not 
‘catch up’ but might if cultured for longer. However, human osteoclasts have a 
relatively short lifespan of about 2 weeks (543) therefore extending the duration of 
the culture beyond 21 days may not lead to an overall increase in osteoclast 
number as osteoclast loss by apoptosis may be equivalent to formation. 
To investigate whether GD osteoclast precursors are more sensitive to pro-
osteoclastogenic cytokines MCSF and RANKL than control cells cultures were set up 
with neither cytokine, MCSF only, RANKL only or both.  From these experiments a 
significant difference in osteoclast generation in the presence of MCSF only was 
found. Numerically this difference is very small and appears to have a minimal 
effect which does not account for the increases observed under standard culture 
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conditions however it may also indicate that GD osteoclast precursors are more 
sensitive to stimulation than control osteoclast precursors. 
To determine whether the increase in osteoclast generation in GD cultures is due to 
a stimulatory signal or a lack of inhibitory signal and whether this/these signals are 
secreted or require cellular contact GD and control monocytes were cultured in the 
same well either physically separated or mixed together to enable direct cellular 
contact. Culture of GD and control monocytes in osteoclastogenic conditions in the 
same well but adhered to separate coverslips resulted in significantly fewer 
osteoclasts generated compared to Gaucher in isolation after both 14 and 21 days 
suggests control monocytes secrete a factor, either not present or expressed at 
much lower levels by GD monocytes, which inhibits osteoclastogenesis, acting as a 
negative regulator. This data indicates a lack of inhibitory signal as if there was a 
stimulatory factor produced by GD monocytes the number of control osteoclasts 
would have increased. Evidence that GD patient monocytes/osteoclast precursors 
can still respond to this factor suggests therapies designed to inhibit osteoclast 
formation may be effective.  
However, while at day 14 there was no statistically significant difference between 
control and Gaucher osteoclast generation (when cultured in the presence of 
controls) a significant difference was noted at day 21 with GD cultures generating 
more osteoclasts. Therefore, this negative regulator may only slow osteoclast 
formation but does not reduce the eventual number of osteoclasts generated 
suggesting there may be a higher percentage of osteoclast precursors in the 
monocyte population of GD patients.    
A very similar effect was observed when GD and control monocytes were mixed 
and cultured in contact as for when cells were separated. However, while evidence 
from cultures in which the cells were physically separated clearly suggests a role of 
a secreted factor/s it does not exclude the role of contact dependent factors 
involved in osteoclast precursor fusion proteins such as DC-STAMP and OC-STAMP 
which if overexpressed may lead to the earlier osteoclast development observed in 
GD osteoclast cultures as both are essential for osteoclast precursor cellular fusion 
with DC-STAMP considered a master regulator of osteoclastogenesis (331). It is also 
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possible that the inhibitory factor may simply be cross correction of the deficient 
enzyme, secreted from control monocytes and taken up by GD monocytes. 
However, uptake of exogenous native β-glucocerebrosidase may be limited as a 
publication by Takasaki et al in 1984 found human placental β-glucocerebrosidase 
contained a high percentage of galactose-terminated oligosaccharide side chains 
which targeted the enzyme to hepatocytes (197) and Brady et al in 1991 
demonstrated that efficient uptake of β-glucocerebrosidase by monocytes and 
macrophages required modification of the oligosaccharide side chains from 
terminating in sialic acid or galactose to terminating in mannose residues to take 
advantage of the expression of mannose receptors on the cell surface of monocytes 
and macrophages, also found to be expressed on the cell surface of osteoclasts 
(544). To address this β-glucocerebrosidase activity was measured in the 
supernatant of cultures. Activity in control and Gaucher supernatants was very low 
when compared to activity measured in cell lysate (normal range of 5-
15nmol/hr/mg in standard leukocyte assay) therefore it is unlikely that the 
reduction in osteoclast generation was due to cross-correction of secreted enzyme 
as with little activity in the supernatant and potentially limited cellular uptake only 
a very small increase in cellular of β-glucocerebrosidase is likely. However, this may 
be an additional factor as small increases in functional enzyme may be sufficient to 
reduce the rate of osteoclast generation observed. 
 
Increased osteoclastogenesis is directly related to β-glucocerebrosidase 
deficiency. 
Conduritol β-epoxide (CBE) is an irreversible inhibitor of β-glucocerebrosidase, 
binding to its active site, preventing it from binding to and catalysing its substrate 
glucosylceramide. This inhibitor has been used by a number of groups such as 
Mucci et al, Lecourt et al and Berger et al (141,524,525) to create cellular models of 
GD.  
 Culture of control monocytes with CBE to create a model of GD resulted in much 
larger osteoclasts with a higher averaged number of nuclei per osteoclast than non-
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inhibited control osteoclast cultures. CBE inhibited controls also generated 
significantly more osteoclasts but not as many as GD osteoclasts. These findings 
demonstrate increased osteoclastogenesis and activity is at least in part related to 
reduced GBA activity but also suggest that either there are other osteoclast specific 
factors involved, that GD monocytes and osteoclast precursors already have 
sphingolipid storage or that there is a larger pool of osteoclast precursors in the 
mononuclear cell population which CBE cannot mimic/create. However, 21 days of 
culture with CBE may not be sufficient time to result in substantial 
glucosylceramide accumulation although previous experiments using CBE have 
demonstrated the accumulation of glucosylceramide at 72 hours in the THP1 cell 
line and by day 15 in fibroblast cultures (545). It may also indicate that long term 
exposure to glucosylceramide is required to create a larger pool of osteoclast 
precursors. 
 
Addition of GD-specific therapies to GD osteoclast cultures reduces 
osteoclastogenesis. 
 Since the advent of enzyme replacement therapy (ERT) several long term studies 
have shown significant increases in bone mineral density and reduction of bone 
crises in type 1 GD (506–510). However, a number of studies have also shown some 
patients continue to suffer bone events while on ERT (84,505,511). To investigate 
the effects of GD-specific therapies including ERT (imiglucerase, velaglucerase) and 
SRT (miglustat) on control and GD osteoclast generation and activity and to further 
test the hypothesis that increased osteoclastogenesis is directly related to a 
deficiency in β-glucocerebrosidase activity these therapies were added to 
osteoclast culture medium for the duration of culture.  
Addition of GD specific therapy to GD osteoclast cultures resulted in significant 
reduction in osteoclast generation for all therapies. Previous results such as CBE 
inhibition indicated that the effect was specifically related to a reduction in β-
glucocerebrosidase activity therefore addition of functional enzyme or reduction in 
substrate burden should reverse this effect. These findings therefore provide 
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further support for the theory that the increased osteoclastogenesis is directly 
related to a reduction in enzyme activity resulting in sphingolipid 
accumulation/dysregulation/altered ratios which in turn may lead to altered 
signalling either directly by lipids or indirectly by cytokines. 
Addition of GD-specific therapy to control osteoclast cultures resulted in a 
reduction in osteoclastogenesis in general but only reached significance for 
imiglucerase. This may be due to the low numbers of osteoclasts generated by 
control cells in this culture system. To determine whether the effect of therapy is 
specific to GD osteoclast cultures it would be necessary to alter the conditions in 
control cultures to enhance osteoclast generation by increasing the pro-osteoclastic 
cytokines MCSF and RANKL to enable the observation of a reduction in osteoclast 
numbers in the presence of GD-specific therapies. If this is not the case it would 
suggest that the factors are specific to GD and therefore we would not expect to 
see a significant reduction in controls. 
Another therapeutic approach is the use of pharmacological chaperone therapies 
(PCT). These are low molecular weight compounds which stabilise or aid correct 
protein folding and are designed to bind to the active site at neutral pH and 
dissociate at the acidic pH present in the lysosome. One such PCT is ambroxol 
hydrochloride which has been shown to increase GC activity and protein levels in 
human primary skin fibroblasts (538). However, although ambroxol may be a 
promising therapy for GD it is not currently approved as a therapy for GD. 
Addition of ambroxol to osteoclast culture medium resulted in a similar effect as 
observed for ERT and SRT in relation to the GD osteoclast numbers however, a 
significant decrease was also observed for control osteoclasts. The clear effect on 
control osteoclast generation would suggest that β-glucocerebrosidase regulates 
osteoclast generation directly through an inverse ratio i.e. the more β-
glucocerebrosidase, the fewer osteoclasts. However, this could be for a number of 
possible reasons (a) β-glucocerebrosidase is directly involved in the signalling 
cascades involved in osteoclast fusion and formation, (b) glucosylceramide induces 
osteoclast generation therefore an increase in β-glucocerebrosidase would lower 
the amount of glucosylceramide reducing the pro-osteoclastogenic signal, (c) 
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ceramide, shown to be a bioactive lipid and a breakdown product of 
glucosylceramide, inhibits osteoclast differentiation, (d) ambroxol hydrochloride 
has off-target effects, it is also used as an expectorant and is known to affect other 
enzymes (232,546) which may also affect osteoclastogenesis. This is possibly the 
case as ambroxol is a pharmacological chaperone it may not affect cells with normal 
lysosomal β-glucocerebrosidase activity as trafficking to the lysosome is already 
optimal and therefore further enhancement by ambroxol may be minimal. 
Reduced osteoclast numbers were reflected in a reduction in osteoclast activity for 
both control and GD cultures. Again, ambroxol appears to affect osteoclast activity, 
however whether this is due to a decrease in osteoclast number or an effect on 
osteoclast function is yet to be determined. The fact that percentage reduction for 
both number and activity is very similar may support the former. 
TNF-α is a pro-osteoclastic cytokine which plays a major role in the regulation of 
bone homeostasis (392). A recent publication by Mucci et al in 2012 suggests that 
TNF-α may be an important cytokine in mediating the increased osteoclastogenesis 
in their CBE model of GD (525). To investigate this effect on control and GD 
osteoclast generation TNF-α signalling was either blocked by addition of a TNF-α 
blocking antibody or stimulated by addition of TNF-α to osteoclast culture medium. 
Addition of TNF-α blocking antibody significantly reduced the number of osteoclasts 
generated in control cultures but not in GD cultures. Although a reduction is 
observed in the GD cohort this did not reach significance (p = 0.16). Based on this 
preliminary data of 8 samples a power calculation based on a paired t-test, with 
significance level of 5% and power of 90% the estimated subject size is 36. 
Therefore, more samples will be required to determine whether GD osteoclast 
generation is affected by blocking TNF-α signalling.  
TNF-α did not increase osteoclast numbers for either control or GD cultures. This 
may be due to the inclusion of RANKL in the cultures superseding the effect of the 
TNF as both cytokines are members of the TNF superfamily and use many of the 
same TNF Receptor-Associated Factor (TRAF) family of adaptor proteins for 
intracellular signalling (392,547). To determine this, it would be necessary to set up 
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cultures lacking RANKL however publications have shown that RANKL is the primary 
pro-osteoclastogenic cytokine (547,548), in addition to data shown in figure 3.2d in 
which very few osteoclasts were generated when GD subject osteoclast cultures did 
not include RANKL such conditions may not be deemed physiologically relevant. 
 
The altered sphingolipid profile found in GD patients causes increased 
osteoclastogenesis. 
Several sphingolipids have been found to modulate osteoclast formation and 
function. These include ceramide which has been shown to reduce osteoclast 
activity by inhibiting actin ring formation (375), lactosylceramide which has been 
shown to increase RANK expression in osteoclasts (376) and sphingosine-1-
phosphate (S1P) which has been found to be a chemotactic factor, regulating 
precursor osteoclast migration between the bone marrow and the blood (378). To 
investigate the potential roles of sphingolipids in osteoclastogenesis several 
sphingolipids in the synthesis and degradation pathway of glucosylceramide, shown 
in figure 1.2, were added to osteoclast medium for the duration of the cultures. 
Glucosylsphingosine, not shown in figure 1.2, was also added to osteoclast medium. 
Glucosylsphingosine is not present in figure 1.2 as the source of this sphingolipid, 
found to be in very high concentrations in GD plasma, remains unclear and is 
theorised to be formed from the glucosylation of sphingosine and from the 
deacylation of glucosylceramide (549).   
Addition of sphingosine to control osteoclast cultures resulted in a significant 
decrease in osteoclast generation. Sphingosine has been reported to be a pro-
apoptotic lipid for other cell types (550) and therefore may be reducing 
osteoclastogenesis non-specifically via this mechanism by inducing apoptosis in the 
osteoclast precursors or mature osteoclasts or in both. In addition, this may be 
exacerbated as it has also been shown that cells which undergo apoptosis can also 
release pro-apoptotic signals inducing apoptosis in other cells in the culture 
(551,552). However, if inhibiting osteoclast generation is a function of sphingosine, 
shown to be elevated in GD serum, previous results in relation to osteoclast 
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generation in this chapter would suggest the effect is either minimal in vivo or is 
negated by the over-abundance of other pro-osteoclastic signalling molecules 
including other sphingolipids.  
In contrast, addition of lactosylceramide to control cultures resulted in a significant 
increase in osteoclast generation suggesting lactosylceramide may be a pro-
osteoclastic factor however reports suggest lactosylceramide concentrations are 
lower in GD serum than control subject serum (154,553) which therefore may 
suggest an overall negative effect on osteoclastogenesis. However, publications 
which measured lactosylceramide in GD serum and GD storage cells are very few. 
Further analysis of GD serum, bone marrow aspirate, monocytes and osteoclasts 
may be necessary to clarify its concentration in comparison to the normal 
population.  
Addition of glucosylceramide to control cultures also resulted in a significant 
increase in osteoclast generation. Again, this result suggests it may be a pro-
osteoclastic factor. As it is one of the main storage lipid in GD with levels up to 3 
fold higher than controls when measured in GD serum and plasma (155) this effect 
may be clinically significant as although in this culture system the increase is 
modest and does not account for the large differences observed in osteoclast 
generation between control and GD these cells are only exposed to the sphingolipid 
for 21 days while in vivo the osteoclast precursors, circulating in the blood prior to 
migrating to the bone marrow, may be exposed to this sphingolipid for much 
longer.  
However, an increase in osteoclast number was not accompanied by an increase in 
resorption, with the exception of S1P. This may be due to the osteoclasts being less 
active or it may be due to the limitations of the resorption assay as there was 
substantial variation both between replicates and patients in this set of 
experiments. Therefore, a larger cohort is required to determine whether this is a 
true result or a statistical anomaly.  
In comparison, addition of sphingosine to GD osteoclast cultures did not affect 
osteoclast generation nor did the addition of lactosylceramide. This may suggest 
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that GD osteoclast precursors respond differently to stimulus. If this is the case the 
elevated levels of sphingosine in GD serum will not inhibit osteoclastogenesis while 
the lower concentration of lactosylceramide will not have an effect on osteoclast 
numbers. It may also be that if GD osteoclast precursors are pre-stimulated the 
negative and positive effects of sphingosine and lactosylceramide respectively 
could be negated depending on what stage these sphingolipids affect osteoclast 
development.  
Addition of glucosylceramide further enhanced osteoclastogenesis in GD cultures, 
increasing osteoclast generation by 37.9 % (figure 3.11f), providing further evidence 
that glucosylceramide has a pro-osteoclastic function and possibly that it has a 
strong effect as it can drive osteoclastogenesis in a culture already producing high 
osteoclast numbers.  
However, as before this difference is not observed in regards to activity suggesting 
glucosylceramide may affect osteoclast numbers but not their activity indicating 
additional factors may be required. 
 
Comparison of MM and GD in vitro osteoclast generation. 
A number of studies have shown an increased risk of multiple myeloma (MM) for 
type 1 GD patients (146,157,241,242,266). Bone disease is common to GD and MM 
with clinical features of bone disease present in more than 80% of both disorders 
(101,470). To investigate the characteristics of MM osteoclasts for comparison to 
GD osteoclasts peripheral blood monocytes and bone marrow osteoclast precursors 
were cultured in osteoclast medium alone, in the presence of CBE or GD-specific 
therapies. 
Interestingly, culture of MM peripheral blood mononuclear cells with CBE did not 
result in the increase in osteoclast numbers observed in control cultures suggesting 
MM monocytes either do not respond to the same factors or are being stimulated 
through a different pathway.  
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Osteoclasts obtained from the peripheral blood of MM patients showed reduced 
generation in the presence of GD-specific therapies however the cohort size was 
too small for any definite conclusions to be reached. Further patient samples are 
required to determine whether the finding with CBE is true and whether GD-
specific therapies reduce osteoclast generation. If the latter is the case it may 
suggest the effect of therapies on lipid composition may be critical for influencing 
osteoclast formation. 
Generation of osteoclasts from MM bone marrow led to a markedly higher number 
of osteoclasts than generated from peripheral blood. This may be as expected as 
peripheral blood only contains osteoclast precursors while bone marrow contains 
migrated osteoclast precursors and mature osteoclasts therefore the density of 
osteoclasts isolated and differentiated is likely to be much higher. It may also be 
due to the MM as MM patients are known to suffer bone events indicative of 
increased osteoclast activity. 
Osteoclasts isolated from MM bone marrow also exhibit high resorptive activity 
creating over 4000 pits per disc in some case, completely covering the surface of 
the bone disc. As noted in previous findings this may simply reflect the increased 
number of osteoclasts however it may also suggest that MM patient BM derived 
osteoclasts are hyperactive. Either result supports the evidence that increased bone 
resorption is responsible for the bone disease in MM patients (474). 
 
Limitations. 
All of the above findings were generated from in vitro culture which has several 
limitations compared to in vivo studies. Firstly, the osteoclasts were generated in 
isolation which does not take into account the potential effects of other cells in the 
bone marrow such as mesenchymal stem cells, osteoblasts, osteocytes, plasma 
cells, and T-cells. Secondly, these cells were cultured as a monolayer which does 
not replicate the three-dimensional environment present in vivo. Thirdly, cell 
cultures were performed in static medium. This method can lead to a depletion of 
147 
 
nutrients and osteogenic factors and a build-up of waste products between 
medium changes. 
 
Summary. 
In summary, GD subject osteoclast cultures generated osteoclasts earlier and in 
greater numbers than control cultures. These osteoclasts were larger with more 
nuclei and had increased resorptive activity and may be due to a lack or reduction 
of signals inhibitory for osteoclast generation. These results were partially 
recreated by the inhibition of β-glucocerebrosidase using CBE indicating deficient β-
glucocerebrosidase activity is directly related to osteoclast development and 
function. This conclusion was supported by findings that addition of GD-specific 
therapy reduced osteoclast generation in GD cultures and that glucosylceramide 
increased osteoclast generation in both control and GD cultures.  
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4  In vitro osteoclast cultures – clinical correlations 
4.1 Introduction 
The findings from chapter 3 that Gaucher patient PBMC’s generate greater 
numbers of osteoclasts compared to controls and that these cells are larger, have 
more nuclei and are more active suggests that osteoclasts may play an important 
role in the skeletal disease of GD. Additionally, the reduction of osteoclast 
generation in the presence of ERT or SRT suggests there is a direct effect by these 
therapies on osteoclast differentiation and activity as suggested in other recent 
publications (134,540). This may suggest the substrate, glucosylceramide, is a key 
factor as data shown in chapter 3 demonstrated addition of exogenous 
glucosylceramide increases osteoclast generation in vitro therefore reduction of 
this sphingolipid either by preventing its synthesis by SRT or degrading it by ERT 
would result in a reduction in osteoclast generation. 
However, these findings may be of limited value due to the fact that these are 
observations of osteoclast generation in isolation and therefore cannot take into 
account the effects of other cell types such as osteoblasts and osteocytes, present 
in the bone microenvironment and known to modulate osteoclastogenesis and 
activity (315). While these interactions can be explored with animal models such as 
knock out mice, of which there are several for GD (271,554,555) there may still be 
ambiguity as to how they translate to the human setting due to a number of 
differences in bone biology, for example in murine models bones have continuous 
growth versus growth plate closure in humans and different remodelling activities 
(556).  
As the osteoclasts characterised in chapter 3 are primary cells isolated from 
Gaucher patients this may allow us to test the validity of this data by comparison 
with human physiology and correlation with the Gaucher patients in this cohort for 
example in relation to bone disease and therapy. This data may also be useful in 
testing clinical correlations such as a recent finding that, in the Gaucher population, 
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anaemia is a risk factor for avascular necrosis (AVN) as anaemic patients were 60% 
more likely to develop AVN with an adjusted odds ratio of 1.56 (529). 
In Gaucher patients, bone disease is generally assessed by dual X-ray absorbiometry 
(DEXA) scans in conjunction with magnetic resonance imaging (MRI), the latter is 
also used to assess bone marrow burden (BMB) to assess the degree of Gaucher 
cell infiltration (557). Both DEXA and MRI are required to assess bone mineral 
density (BMD) as DEXA alone cannot compensate for local changes caused by AVN 
or sclerosis resulting in artificially low or high bone densities respectively (123). MRI 
is regarded as the most sensitive method for the detection of bone marrow 
infiltration of Gaucher cells in GD and is used to assess the severity of marrow 
involvement and response to GD specific treatment (558). 
Several studies have been conducted to investigate the usefulness of biochemical 
markers of bone formation including pro-collagen carboxyterminal propeptide 
(PICP), osteocalcin and bone resorption including cross-linked type I collagen C-
terminal telopeptide (CTX) and d-pyridinolines in assessing bone disease in GD. 
However, there appears to be substantial variability and little consensus in the 
findings from the different studies. While some studies found reduced bone 
formation markers and elevated resorption markers, suggesting bone loss due to 
increased osteoclast activity (512,513) another study found reduced bone 
formation markers but no change in resorption markers (515) suggesting reduced 
osteoblast activity. In addition, studies following response to ERT and SRT either 
found no significant changes in bone formation markers over 4.5 years on ERT (514) 
or conflicting data in which two studies found significantly increased osteocalcin 
(508,516) while a third study found a decrease in osteocalcin, although this did not 
reach statistical significance (509). 
As a consequence, bone markers are not generally used to assess bone disease in 
GD. Investigating the roles of cells such as osteoclasts in the bone 
microenvironment may shed some light on the reasons for the observed variability 
in biochemical bone markers and clinical correlation of the osteoclast data may lead 
to a means of following skeletal response to therapy in conjunction with MRI and 
DEXA.  
150 
 
4.2 Aims and Hypotheses 
Aim: To understand the relationship between in vitro findings and clinical features 
of bone disease in GD patients. 
Objectives: 
(1) To validate in vitro osteoclast data by correlation with MRI findings of active 
bone disease in GD patients. 
(2) To investigate whether in vitro osteoclast generation correlates with anaemia in 
GD patients providing a potential link to anaemia being a risk factor for AVN. 
(3) To determine whether in vivo treatment of GD patients with Gaucher-specific 
therapies affects osteoclast generation in vitro.   
 
Hypothesis 1: GD patients with active bone disease generate more osteoclasts in 
vitro. 
Rationale: A number of bone diseases such as osteoporosis can be caused by 
increased osteoclast generation leading to increased bone resorption. The number 
of nuclei per osteoclast has also been shown to correlate to osteoclast activity. 
Methods: Correlation of MRI based evidence of active bone disease with 
contemporaneous in vitro osteoclast generation and size.  
 
Hypothesis 2: GD patients with anaemia generate more osteoclasts in vitro.  
Rationale: A recent publication by Khan et al in 2012 has shown anaemia to be a 
risk factor for avascular necrosis in GD patients with anaemic patients 60% more 
likely to develop AVN with an adjusted odds ratio of 1.56. 
Methods: Correlation of patients with levels of haemoglobin indicative of anaemia 
with in vitro osteoclast generation.  
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Hypothesis 3: Treatment of GD patients with GD-specific therapies will reduce in 
vitro osteoclast generation. 
Rationale: Previous data in this thesis has shown increased osteoclast generation is 
directly related to a decrease in β-glucocerebrosidase activity and that addition of 
GD-specific therapy to GD in vitro cultures reduced osteoclast generation. 
Therefore, GD-specific treatments such as ERT and SRT designed to replace the 
enzyme or reduce the impact of its decreased activity will probably ameliorate the 
effect on osteoclastogenesis in vivo. 
Methods: Compare osteoclast generation of naïve patients with patients receiving 
therapy. Longitudinal study of individual patients by taking blood samples for 
osteoclast culture at each patient visit. Osteoclasts will be identified either by being 
histochemically positive for TRAP or high surface expression of vitronectin receptor 
in conjunction with actin ring formation labelled with fluorochromes. 
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4.3 Results 
4.3.1 In vitro osteoclast generation, nucleation and activity correlate 
with active bone disease and osseous manifestation in Gaucher 
subjects. 
To investigate the clinical relevance of our findings that Gaucher subjects in vitro 
osteoclast cultures generated greater numbers of osteoclasts which were larger, 
had more nuclei and higher resorptive activity compared to control subject cultures 
we correlated several clinical parameters with osteoclast generation in our Gaucher 
cohort. Firstly, we compared Gaucher subjects classified as having active vs inactive 
bone disease based on annual MRI assessment performed as part of routine 
assessment for Gaucher patients. Gaucher subjects with active bone disease had 
significantly higher osteoclast generation compared to control (p < 0.0001) or 
Gaucher subjects with inactive bone disease (p = 0.0019), figure 4.1a. The number 
of nuclei per osteoclast were also significantly greater in cultures from subjects with 
active bone disease compared to control (p = 0.015) or Gaucher subjects with 
inactive bone disease (p = 0.0093), figure 4.1b. In addition, Gaucher subjects with 
inactive bone disease did not generate significantly more osteoclasts than control 
subjects nor did the osteoclasts contain a significantly greater number of nuclei 
compared to the control cohort. 
Correlation of osteoclast generation and activity with osseous manifestations of 
individual Gaucher subjects showed that, in general, subjects with relatively high 
osteoclast generation or activity correlated with a higher number and severity of 
osseous manifestations as shown in figure 4.2. The correlations observed of 
osteoclast number and activity with active bone disease and osseous 
manifestations suggest high osteoclast generation and activity in vitro indicate 
more severe bone disease in vivo.  
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Figure 4.1 Correlation of active bone disease with osteoclast generation and size. 
(a) Number of osteoclasts generated from control and Gaucher subject adherent 
mononuclear cells after 21 days of culture on glass. Active and inactive bone 
disease in Gaucher subjects determined by annual MRI assessment. (b) Averaged 
nuclei per osteoclast of TRAP stained osteoclast cultures, mean ± SEM shown by 
horizontal lines. (c, d, e) Representative TRAP staining of Gaucher and control 
subject derived osteoclasts cultured for 21 days on glass. *p ≤ 0.05, **p ≤ 0.01, 
***p ≤ 0.001, unpaired t-tests.    
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Figure 4.2 Correlation of osseous manifestations with osteoclast generation and 
activity. (a) Number of osteoclasts generated from adherent mononuclear cells of 
individual Gaucher subjects after 21 days of culture on glass correlated with clinical 
markers of bone disease. (b) Bone pits resorbed by osteoclasts of individual 
Gaucher subjects after 21 days of culture on bone correlated with clinical markers 
of bone disease. Clinical parameters are coded DEXA scanning (white: normal bone 
density, grey: osteopenia, black: osteoporosis); skeletal MRI (white: no evidence of 
bone inﬁltration, grey: mild patchy inﬁltration, black: severe, diffuse inﬁltration); 
joint replacement (white: no joints replaced, grey: 1 joint replaced, black: joint 
revision or multiple replacements) and pain (white: no pain, grey: mild intermittent 
pain, black: severe or chronic pain). 
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4.3.2 In vitro osteoclast generation correlates with bone pain and 
anaemia in Gaucher subjects. 
In addition to quantification of bone disease, data obtained from the ICGG Gaucher 
registry was also used to assess which Gaucher subjects were experiencing bone 
pain and whether this also correlated with increased osteoclast generation. This 
was shown to be the case in this cohort as subjects reporting bone pain had 
significantly higher osteoclast numbers (p = 0.014, figure 4.3a) compared to those 
without bone pain. 
Anaemia was recently reported as being associated with an increased risk for 
avascular necrosis in type 1 Gaucher patients (531). To evaluate this in the Gaucher 
cohort, subjects were categorised as being anaemic if a male had haemoglobin of 
less than 130g/l or a female had haemoglobin of less than 115g/l and osteoclast 
generation was compared between the anaemic vs non-anaemic groups. Osteoclast 
generation in the anaemic cohort was significantly higher (p = 0.0051, figure 4.3b) 
in comparison to the non-anaemic cohort. Clinical data for bone pain and anaemia 
collected by Yehudit Bauerfreund and Niamh Cunningham.  
Chitotriosidase activity is commonly used as a surrogate marker to follow overall 
disease progression in Gaucher subjects. To determine whether chitotriosidase 
activity measured as part of routine assessment for Gaucher patients in the Royal 
Free LSDU correlated with osteoclast generation, data for both parameters 
obtained from the same patient visit were plotted. Linear regression analysis 
showed no correlation between chitotriosidase activity and osteoclast number (r = 
0.15, figure 4.3c).  
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Figure 4.3 Correlation of osteoclast generation with clinical parameters and a 
surrogate marker of disease. (a, b, c) Number of osteoclasts generated from 
adherent mononuclear cells after 21 days of culture on glass. (a) Correlation of 
osteoclast generation with bone pain. No bone pain n = 92, with bone pain n = 62, 
mean ± SEM plotted. (b) Correlation of osteoclast generation with anaemia, defined 
as haemoglobin < 13g/dl for males and < 11.5g/dl for females. Non-anaemic             
n = 135, anaemic n = 20, mean ± SEM plotted. (c) Correlation of osteoclast 
generation with chitotriosidase activity determined at the same patient visit, n = 
155, correlation not significant. *p ≤ 0.05, **p ≤ 0.01, unpaired t-tests. Clinical data 
for bone pain and anaemia collected by Yehudit Bauerfreund and Niamh 
Cunningham. 
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4.3.3 In vivo Gaucher specific therapies appear to reduce the number 
of osteoclasts generated from Gaucher subjects in vitro. 
An alternative method of osteoclast identification to TRAP staining was used. This 
involved immunofluorescent labelling of vitronectin receptor (CD51/61), highly 
expressed on the osteoclast surface, with fluorescent co-labelling of internal f-actin 
ring structures unique to osteoclasts with phalloidin. An example of this method is 
shown in figure 4.4a in which vitronectin was labelled green and f-actin was 
labelled red. The osteoclast number is assessed by counting the number of double 
positive cells in the observable field at x400 magnification with a minimum of 10 
fields chosen at random. To determine whether Gaucher specific therapies 
correlated with lower osteoclast numbers in vivo as well as in vitro, subjects were 
divided into three groups, control, Gaucher subjects who did not receive Gaucher 
specific therapies and Gaucher subjects who did receive Gaucher specific therapies. 
The number of osteoclasts generated from in vitro osteoclast cultures of these 
subjects mononuclear cells were enumerated by fluorescent labelling and 
correlated with these groups. Both treated and untreated Gaucher subject groups 
had significantly higher osteoclast numbers when compared to control subjects 
(treated p = 0.044, untreated p = 0.0005, figure 4.4b). The untreated Gaucher group 
also had higher osteoclast numbers than the treated group however this did not 
reach statistical significance (p = 0.054).  
To further assess the effect of in vivo therapy on osteoclast generation in vitro, 
osteoclast cultures were performed for 5 Gaucher subjects on three sequential 
visits for each subject. Plotting osteoclast numbers for the sequential visits showed 
that for subjects with relatively high osteoclast numbers at the first visit, labelled Pt 
1, Pt 4, Pt 5 in figure 4.4c, treatment with Gaucher specific therapies led to a 
marked reduction in osteoclast numbers and that those with relatively low 
osteoclast at the first visit labelled pt 2, pt 3, remained low.  
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Figure 4.4 In vivo treatment effect on in vitro osteoclast generation. (a) 
Representative image of immunofluorescent staining of vitronectin receptor 
(green) highly expressed in osteoclasts and actin rings (red), structures primarily 
found in osteoclasts, marked with white arrows. (b, c) Number of osteoclasts 
generated from adherent mononuclear cells after 21 days of culture on glass, 
identified by immunofluorescent staining. (b) Correlation of osteoclast generation 
with in vivo therapy, control n = 16, treated Gaucher subjects n = 20, untreated 
Gaucher subjects n = 4. Mean ± SEM plotted. (c) Number of osteoclasts generated 
from adherent mononuclear cells of 5 individual Gaucher patients over 3 time 
points each cultured on glass coverslips for 21 days and identiﬁed by 
immunofluorescent staining. *p ≤ 0.05, *** p ≤ 0.001, unpaired t-tests.   
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4.4 Discussion. 
Bone disease in GD patients is generally assessed by review of BMD by DEXA in 
conjunction with analysis of bone marrow infiltration and secondary bone events by 
MRI (123) however these techniques only provide a snapshot of disease 
progression and cannot provide information on when bone dysregulation begins or 
whether a patient is undergoing a period of bone loss. To address this issue several 
studies have been carried out to assess the efficacy of markers of bone turnover 
(508,512–519). However, due to conflicting data between studies and the fact that 
few studies have measured the same analytes in their respective patient cohorts or 
were consistent in how samples were taken and stored, markers of bone turnover 
are not routinely used to assess bone disease in GD. To investigate whether our in 
vitro osteoclast assay could be used as an early indicator of active bone disease and 
whether it reflects in vivo response to treatment data from in vitro osteoclast 
cultures have been correlated with clinical features of bone disease and time 
courses of in vitro osteoclast generation from patients receiving GD-specific 
therapy. 
The results discussed below demonstrate for the first time that GD patient derived 
osteoclasts correlate with several clinical features including evidence of active bone 
disease and may indicate a direct causative link between increased osteoclast 
generation and bone disease in GD patients and provide a possible method for 
tracking bone disease in GD patients.  
 
GD patients with active bone disease generate more osteoclasts in vitro. 
GD patients with active bone disease assessed by MRI generated significantly more 
osteoclasts than the GD cohort with inactive disease and control cohort. This 
finding suggests the degree of osteoclast generation is indicative of active bone 
disease in GD patients. However, there is overlap in osteoclast number between the 
groups. This overlap could occur for several possible reasons (a) the sample could 
have been taken after the recorded bone event as it is very difficult to know 
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precisely when the event began and therefore the sample would potentially have 
lower osteoclast numbers as osteoclast numbers may only have been elevated 
during the event. (b) Those in the inactive group with higher osteoclast numbers 
may be entering a bone event or may have ongoing but sub-clinical osteopenia 
which may not be as yet detectable by MRI. These limitations highlight the need for 
time courses for individual patients as in regards to these patients we do not have a 
base line to indicate whether the osteoclast number is abnormally high or low.  
Similar results were obtained for the average number of nuclei per osteoclast with 
the average numbers higher for GD patients with active bone disease than patients 
with inactive bone disease and the control cohort, suggesting osteoclasts are more 
active in patients with active bone disease. If this translates to the bone marrow 
having a higher number of more active osteoclasts this may account for a significant 
proportion of the bone events observed in GD and provide a direct causative link.  
GD patients without active bone disease were not significantly different to the 
control cohort in either number of osteoclasts generated or number of nuclei per 
osteoclast. Taken together this data suggests there may be a subset of GD patients 
which have uncoupling of osteoclasts and osteoblasts while still receiving ERT 
supporting clinical observations in certain studies which found some GD patients 
continue to suffer bone events after receiving ERT and in some cases after 
increasing doses of ERT.  
Comparison of individual patient clinical features with in vitro osteoclast generation 
and activity showed that in the majority of cases higher osteoclast numbers and 
activity correlated with higher number and severity of osseous manifestations, 
supporting the hypothesis that higher osteoclast numbers and activity may be a 
major factor in contributing to the bone disease in GD patients. This finding may 
also demonstrate that this assay can be patient specific and possibly be used to 
follow the progress of a patient and indicate if a bone event is ongoing. However, it 
also suggests that both osteoclast number and activity need to be assessed as in the 
case of patient 247 assays generated conflicting data with relatively low osteoclast 
numbers but relatively high resorption. This may be due to assay conditions being 
less favourable in the enumeration assay as they are cultured in different sized 
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wells and on a different material i.e. glass rather than bone. As glass is not the 
natural surface for osteoclast generation it may affect generation. However, as this 
is not seen for other patients this may be an anomalous result suggesting the assay 
for this patient for both number and activity needs to be repeated to determine 
which result if any is anomalous. 
Correlation of bone pain recorded in the International Collaborative Gaucher Group 
(ICGG) Gaucher Registry with osteoclast generation further supports the theory 
that in vitro osteoclast generation is indicative of bone disease in GD patients. As 
patients are routinely assessed by MRI if the patient reports bone pain a concurrent 
osteoclast assay may be useful to support the need for anti-resorptive agents as 
MRI may not be able to distinguish new bone degradation if the degradation is at 
an early stage and developing at a site with previous disease. Also, this approach 
may provide additional data to validate the use of the osteoclast assays for 
indicating active bone disease and its possible use as an early indicator/marker of a 
bone event. However, limitations of this approach should be noted during data 
analysis as the data provided is subjective and may not be sufficiently time specific 
i.e. patients may not accurately report when the pain was experienced and 
therefore may not provide a robust correlation with osteoclast number and activity. 
 
GD patients with anaemia generate more osteoclasts in vitro. 
Correlation of osteoclast generation with anaemia was also found. This may be 
relevant as a recent finding that, in the Gaucher population, anaemia is a risk factor 
for avascular necrosis (AVN) as anaemic patients were 60% more likely to develop 
AVN with an adjusted odds ratio of 1.56 (529). As this study found similar clinical 
and surrogate markers of disease severity between the groups of patients with and 
without AVN it is unlikely that this correlation is a reflection of patient severity.  
AVN is caused by reduction in blood flow to the bone leading to cellular necrosis 
and localised bone loss however the atraumatic causes are poorly understood 
(559). Anaemia may also be a consequence of reduced blood supply to the bone as 
this would have a negative impact on the bone marrow which may affect HSC 
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number and differentiation. A recent publication using iPSC’s as a model of GD 
showed abnormal hematopoietic progenitor cell (HPC) differentiation in favour of 
myeloid lineage cells over erythroid lineage cells (140) which may lead to a 
reduction in red cell production and an increase in monocyte/osteoclast precursor 
production which, between the two scenarios may in part provide a link between 
anaemia and AVN.   
No correlation was found between chitotriosidase activity and osteoclast number. 
Chitotriosidase is made by GD macrophages and so is an indirect biomarker and is 
used as an indicator of general disease burden. Chitotriosidase is used to follow GD 
patient response to therapy over time as it decreases over time when patients 
receive GD-specific therapy. While in the normal population its activity range is 
quite narrow in the GD population its range is very broad with reported ranges of 
4–76 nmol/ml/h in controls and 3122–65,349 nmol/ml/h in GD patients (560) 
therefore a single measurement of chitotriosidase activity is unlikely to correlate 
with osteoclast number as to assess if the chitotriosidase activity is high or low 
depends on the previous and naïve activities of the GD patient. This data suggests 
chitotriosidase cannot be used to indicate bone disease at a single time point and 
that osteoclast numbers do not reflect overall disease burden but are specific for 
bone disease at a single time point. To investigate a temporal correlation, it would 
be necessary to perform a time course of chitotriosidase activity with 
contemporaneous osteoclast number and activity to determine if osteoclast 
number also correlates with general disease burden over time.  
 
Treatment of GD patients with GD-specific therapies will reduce in vitro 
osteoclast generation. 
Untreated GD patients generate significantly more osteoclasts than treated 
patients suggesting in vivo therapy is effective for the majority of patients at 
reducing osteoclast generation and follows clinical observations of several studies 
which demonstrate that bone events are reduced in the majority of GD patients 
(506–510). This may be expected as although the plasma half-life of imiglucerase 
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reportedly ranges from 3.6 to 10.4 minutes its reported half-life in GD patient bone 
marrow is 14.1 hours (618). Bone marrow monocytes and osteoclast precursor 
migrate to and from the bone marrow and peripheral blood, in part mediated by 
S1P concentration gradient (584) and therefore may receive sufficient enzyme to 
ameliorate the inherent deficiency in β-glucocerebrosidase activity. However, this 
does not exclude the possibility of the existence of a non-responsive subgroup, to 
determine this a larger cohort would be required.  
Time courses of GD patients show either a decrease or maintenance of osteoclast 
generation when receiving therapy. This data demonstrates that osteoclast 
generation in this assay is responsive to changes of in vivo conditions i.e. active 
bone disease, response to therapy. This responsiveness suggests the osteoclast 
assay may be useful for following response to therapy and that therapy may be 
effective in these patients at treating bone disease. However, previous data 
suggests the existence of a non-responsive subgroup the possibility of which this 
data does not exclude. To confirm the existence of this subgroup it would be 
necessary to follow more patients over longer time periods of time. To fully explore 
the uses of this assay it would be necessary to assess patients who have been found 
to be refractory in regards to bone disease by clinical parameters to see if therapy is 
having no effect at the osteoclast level and to follow a relatively young but 
substantial cohort for several years to determine if a resistant subgroup emerges 
and whether this could be predicted by the osteoclast assay. 
 
Limitations. 
In addition to the limitations stated within the above discussion it should be noted 
that all of the above correlations were with retrospective clinical data which 
resulted in incomplete data sets for some patients, limiting the size of cohorts for 
some of the correlations. 
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Summary. 
In summary, osteoclast numbers generated from GD cultures and their resorptive 
activity correlated with active bone disease, as did the number of nuclei per 
osteoclast. In addition, osteoclast number correlated with bone pain reported by 
questionnaire and anaemia. Patients not receiving GD-specific therapy generated 
significantly more osteoclasts in vitro and those receiving therapy generated fewer 
osteoclasts when cultures were repeated over a period of up to 21 months.   
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5. In vitro osteoblast culture 
5.1 Introduction 
Osteoclasts have been shown to be regulated by an ever increasing number of local 
and systemic mechanisms ranging from local signalling by osteocytes (306) to 
signalling by the immune (561,562) and neuropathic systems (563,564). However, 
the main paradigm for bone homeostasis remains the interaction and signalling 
between osteoclasts and osteoblasts, commonly referred to as coupling (289,436). 
Such a close relationship would suggest that changes in osteoclast generation, size 
and activity may have a direct effect on osteoblast number and activity but it may 
be the case that osteoblasts are also abnormal in GD due to factors other than 
osteoclast abnormalities. Murine models of GD have suggested that the bone 
disease may be caused by reduced osteoblastic activity (271,541). Other 
publications have shown that mesenchymal stem cells (MSC’s) have a decreased 
capacity to differentiate into osteoblasts when isolated from type 1 Gaucher 
patients and impaired proliferation with altered secretion of soluble factors when 
normal MSC were inhibited with CBE (138,524). These findings suggest there may 
be an imbalance between osteoclasts and osteoblasts in GD both in terms of 
numbers and activity possibly caused by a reduced source of MSC leading to a 
reduction in overall osteoblast numbers and abnormal secretion profiles of mature 
osteoblasts causing increased osteoclast activity resulting in the uncoupling of the 
osteoclast-osteoblast homeostatic mechanism.  
Unlike for in vitro osteoclast culture, isolation of osteoblasts from peripheral blood 
has remained problematic due to the relative low percentage of osteoblast 
precursors in PBMC’s, estimated to be 1 to 2% (565). As a result, several techniques 
were developed to isolate MSC from peripheral blood however MSC are a similarly 
rare population in PBMC’s and so these techniques either required large quantities 
of blood or the subject required a course of GCSF injections to mobilise the MSC 
(566). Other sources of MSC include adipose tissue (567) and bone marrow (568) of 
which the latter was chosen for this project. However, due to the invasive nature of 
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obtaining bone marrow or adipose tissue the use of human osteoblast cell lines is 
common. 
In regards to osteoblast cell lines only two human cell lines capable of producing 
calcium deposits are described, namely MG-63 (regarded as an osteoblast pre-
cursor) and SaOs-2 (regarded as osteoblast-like cells) both originally isolated from 
osteosarcomas (569). As with most cell lines neither the MG-63 nor SaOs-2 fully 
recapitulate the characteristics of primary human osteoblasts. MG-63 show poor 
mineralisation, hence regarded as pre-osteoblastic, and heterogeneity, while SaOs-
2 appear to over express alkaline phosphatase over time (570). In addition, both 
cell lines have a much higher proliferative rate than primary human osteoblasts. 
However, SaOs-2 have been shown to have many of the expression markers of 
primary osteoblasts and to form mineral-matrix readily (569) making them a 
potentially useful model for investigating the possible effects of CBE, GD specific 
therapies and sphingolipids on the rate of mineralisation when assessed in parallel 
to primary MSC-derived osteoblast cultures. 
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5.2 Aims and Hypotheses 
Aim: To understand the role of osteoblasts in GD bone disease. 
Objectives: 
(1) To differentiate control, GD and MM MSC’s into functional osteoblasts.  
(2) To characterise GD osteoblast activity in comparison to control and MM 
osteoblasts. 
(3) To determine the effects of GD-specific therapies on osteoblast activity in both 
primary cells and a cell line. 
(4) To determine the effects of exogenous sphingolipids on osteoblast activity in 
both primary cells and a cell line. 
 
Hypothesis 1: There is dysregulation between osteoblasts and osteoclasts, 
commonly referred to as uncoupling, in GD patients. 
Rationale: Osteoblasts and osteoclasts are normally very tightly regulated primarily 
by each other. In GD increased osteoclast generation and activity may result in an 
imbalance between osteoclast and osteoblast number and function leading to bone 
loss.  
Methods: Flow cytometry using markers identifying osteoblast precursor 
percentage in peripheral blood samples is correlated with the number of 
osteoclasts generated by contemporaneous in vitro osteoclast cultures.  
 
Hypothesis 2: Osteoblast mineralisation is reduced when β-glucocerebrosidase 
activity is inhibited.  
Rationale: Studies of a GD murine model by Mistry et al (272) showed reduced 
proliferation of bone marrow stromal cells and reduced osteoblast differentiation 
and two Zebra fish GD models developed by Zancan et al (523) demonstrated loss 
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of Gba1 function was associated with impaired canonical Wnt signalling, osteoblast 
differentiation and reduced bone mineralisation.   
Methods: Primary and cell line osteoblasts cultured with CBE under mineralising 
condition. Mineralisation quantified by alizarin red staining and solubilisation.   
 
Hypothesis 3: Osteoblast mineralisation is reduced in the presence of exogenous 
glucosylceramide. 
Rationale: Previous data in this thesis has shown exogenous glucosylceramide 
directly affects osteoclast generation by significantly increasing osteoclast numbers 
in both control and Gaucher cultures indicating that this is a bioactive sphingolipid 
and therefore may also affect osteoblast function.   
Methods: Primary and cell line osteoblasts cultured with exogenous 
glucosylceramide under mineralising condition. Mineralisation quantified by alizarin 
red staining and solubilisation.   
 
Hypothesis 4: Osteoblast function is not directly impacted by GD-specific therapies. 
Rationale: Previous data in this thesis has shown GD-specific therapies reduce 
osteoclast generation in vitro both directly and when given to patients. However, a 
subset of patients have been reported to continue to suffer bone events while 
receiving GD-specific therapy suggesting a negative impact on osteoblast function is 
negating the reduction in osteoclast numbers. This may be via the indirect impact 
of reduced osteoclast activity having the overall effect of reducing bone matrix 
resorption which in turn means a reduction in osteoblast signalling factors released 
from the bone matrix.  
Methods: Primary and cell line osteoblasts cultured with GD-specific therapies in 
the absence or presence of CBE under mineralising conditions. Mineralisation 
quantified by alizarin red staining and solubilisation.   
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5.3 Results 
5.3.1 Uncoupling between Gaucher subject osteoblasts and 
osteoclasts.  
While bone remodelling is influenced by a number of factors both locally and 
systemically a major factor controlling the rate of bone resorption and formation 
are the interactions, commonly referred to as coupling, between osteoclasts and 
osteoblast (289,436). To investigate a possible imbalance between osteoblasts and 
osteoclasts the numbers of osteoclasts differentiated from peripheral blood 
mononuclear cells and the percentage of osteoblast precursors in the mononuclear 
cell fraction isolated from peripheral blood were evaluated. The overall percentage 
of peripheral blood osteoblast precursors, identified as CD15-ve, osteocalcin+ve, 
did not significantly differ between control and Gaucher cohorts (figure 5.1a). 
However, when osteoclast numbers were plotted against osteoblast precursor 
percentage for each subject the control cohort showed a strong correlation (r = 0.6, 
figure 5.1b, p = 0.022) whereas only a very weak correlation was observed in the 
Gaucher cohort (r = 0.06, figure 5.1c, p = not significant) suggesting Gaucher subject 
osteoblasts and osteoclasts may be uncoupled. 
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Figure 5.1 Evidence for uncoupling between osteoclasts and osteoblasts in Gaucher 
subjects. (a) Percentage of osteoblast precursors, CD15-ve osteocalcin+ve, in 
mononuclear cells isolated from the peripheral blood of control and Gaucher 
subjects. (b) Control osteoblast precursors, CD15-ve osteocalcin+ve, plotted against 
the number of osteoclasts generated by the same patient in vitro. (c) Gaucher 
osteoblast precursors, CD15-ve osteocalcin+ve, plotted against the number of 
osteoclasts generated by the same patient in vitro.   
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5.3.2 Confirmation of mesenchymal stem cell markers. 
BM-derived MSCs were isolated from freshly obtained healthy BM donor and MM 
patient samples as detailed in Chapter 2: Methods. To ensure the isolated cells met 
the criteria specified by the International society for cellular therapy (ISCT) for 
confirmation of the MSC’s phenotype, after expansion MSC’s underwent cellular 
characterization to confirm successful isolation and purity. All MSCs were shown to 
be adherent to tissue culture plastic under standard growth conditions. MSC 
samples were successfully differentiated into adipocytes (by Dr Brendan Beaton) 
and osteoblasts as shown in figure 5.2. All samples were phenotyped with a panel 
of markers specified by the ISCT using flow cytometry. An example of the 
histograms obtained are shown on the next page in figure 5.3. It should be noted 
that due to autofluorescence at the emission wavelengths of FITC and PERCP Cy5.5 
a relatively high amount of fluorescence for isotype control was obtained, 
confirmed as autofluorescence by comparing the fluorescence of unstained cells to 
isotype control. Flow cytometry staining and analysis was carried out by Dr Brendan 
Beaton. Image of adipocytes in figure 5.2 and histograms shown in figure 5.3. 
provided by Dr Brendan Beaton.  
 
 
Figure 5.2 MSC differentiation. Representative photographs demonstrating 
osteoblast and adipocyte differentiation of bone marrow MSC’s, sample 2186. (a) 
Calcium deposition by osteoblasts confirmed by alizarin red staining. (b) Lipid 
storage in adipocytes confirmed by Oil red O staining.  
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5.3.3 Differentiation of mesenchymal stem cells into functional 
osteoblasts.  
Several publications have shown that osteoblasts may play a direct role in 
contributing to bone disease in Gaucher patients (138,272,523,541). To assess 
osteoblast function in GD a primary osteoblast cell culture model was optimised. 
Mesenchymal stem cells isolated from subjects bone marrows were cultured for 35 
days in alpha minimal essential medium supplemented with 10% FBS, 2mM L-
glutamine, 10mM HEPES, 100 units/ml penicillin, 0.1mg/ml streptomycin and a 
range of concentrations of dexamethasone, β-glycerophosphate and ascorbate-2-
phosphate to induce differentiation of the mesenchymal stem cells into functional 
osteoblasts. Mature osteoblasts were defined by their ability to deposit calcium. 
Alizarin red, a chemical which binds monomerically to calcium, was used to visualise 
the calcium deposition, staining it red (figures 5.4a, b). This stain was subsequently 
solubilised and quantified by absorbance spectrometry. In order to permit the 
detection of increased or decreased calcium deposition due to modifications in 
culture conditions an intermediate degree of calcium deposition was selected, as 
indicated by a black arrow in figure 5.4c and a representative image, figure 5.4b 
(optimised medium referred to as A10-OB). To assess optimal culture duration 
control subject mesenchymal stem cells were cultured in optimal calcium 
deposition conditions for a total of 49 days. At 7-day time points 3 wells of a 24 well 
plate were fixed in 4% paraformaldehyde and stained for calcium with alizarin red, 
solubilised and quantified by absorbance spectrometry. Under these conditions 
little calcium deposition was observed for the first 28 days. However, the rate of 
calcium deposition markedly increased between days 28 and 49. An optimal degree 
of calcium deposition was determined to be at day 35.  
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Figure 5.4 Optimisation of conditions required to differentiate control MSC into 
osteoblasts and to induce calcium deposition. (a, b) Representative images of 
control MSC cultured (a) without and (b) with optimised osteogenic conditions for 
35 days. (c) Control MSC cultured with a range of conditions for 35 days in 
triplicate, mean ± SEM plotted. Selected conditions for subsequent cultures 
indicated by red arrow. (d) Time course of calcium deposition by control MSC 
cultured with optimised osteogenic conditions. Quantification of calcium deposition 
by absorbance spectrometry of alizarin red solubilised post staining of calcium 
deposits on cell monolayer surface. Separate plates of MSC monolayers were 
cultured for each time point, 3 wells per time point. Black arrow indicates selected 
osteogenic conditions for subsequent osteoblast cultures. Mean ± SEM plotted. 
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5.3.4 MSC’s as a model for Gaucher disease.  
To determine whether the MSC-osteoblast cultures could be used as a model for 
Gaucher disease, control MSC were cultured in optimised osteogenic medium A10-
OB in the presence of β-glucocerebrosidase inhibitors CBE (100µM) or isofagomine 
(100µM) for 35 days, assessed for degree of β-glucocerebrosidase inhibition after 4 
days (figure 5.5a) and for viability at weekly time points for the duration of the 
culture (figure 5.5b). In addition, the effect of Gaucher specific therapies 
imiglucerase (1 unit/ml) and miglustat (50µM) on viability was also assessed at 
weekly time points for the duration of the culture (figure 5.5c).                                   
β-glucocerebrosidase activity was reduced to 8.3% of standard in the presence of 
CBE (p = 0.005) and 9.9% of standard in the presence of isofagomine (p = 0.0006). 
No statistically significant change to viability was observed in the presence of either 
inhibitor over the 3 week period.  
 
Figure 5.5 Assessment of control MSC, sample DM001, differentiated into 
osteoblasts in A10-OB as a model of Gaucher disease. (a) Inhibition of β-
glucocerebrosidase activity by addition of an irreversible inhibitor CBE (100µM) or 
reversible inhibitor isofagomine (100µM) cultured for 4 days in triplicate per 
condition. Activity in cell lysates measured by fluorometric assay. (b) Viability of 
control MSC when cultured for 35 days in optimised osteogenic conditions with CBE 
(100 µM) or isofagomine (100 µM) in triplicate per condition. Viability measured by 
MTS assay, 100% calculated from the averaged absorbance values obtained from 
the standard condition. Mean ± SEM plotted. Unpaired t-tests. ** p ≤ 0.01, *** p ≤ 
0.001.  
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5.3.5 MSC viability was reduced by Gaucher specific therapies. 
To assess the potential impact of inhibitors, therapy and sphingolipids on MSC 
viability when added exogenously to osteoblast cultures MTS assays were 
performed after 7 days of culture, the time point at which medium is normally 
replaced. In general, the addition of inhibitors CBE and isofagomine did not affect 
MSC viability. Statistically significant decreases were observed for control subject 
DM001 for both CBE (p = 0.02) and isofagomine (p = 0.009) and for control subject 
2186 with isofagomine (p = 0.04). The addition of GD specific therapies to cultures 
led to a statistically significant decrease in viability for control and MM subject 
MSC’s with the exception of MM subject 2167 for imiglucerase and miglustat, (table 
5.1).  
In comparison, the addition of exogenous sphingolipids to osteoblast cultures did 
not reduce MSC viability with the exception of glucosylsphingosine which 
significantly reduced viability in control subject DM001 (p = 0.006) and MM subjects 
2036 (p = 0.0001), 2314 (p = 0.023). Culture with lactosylceramide or 
glucosylceramide resulted in a generally higher viability for all subjects and was 
statistically significantly higher for MM subject 2167 MSC’s (lactosylceramide p = 
0.024, glucosylceramide p = 0.007) as shown in table 5.2.  
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Table 5.1 Viability of MSC’s when cultured in A10-OB with β-glucocerebrosidase 
inhibitors CBE (100µM), isofagomine tartrate (100µM) or GD specific therapies 
imiglucerase (1 unit/ml), miglustat (50µM), ambroxol hydrochloride (20µM) for 7 
days. Viability determined by MTS assay, percentage viability calculated as 
percentage of standard condition i.e. MSC’s in osteoblast differentiation medium 
alone. 9 replicates per condition. Control samples highlighted in blue, MM samples 
in red. Unpaired t-tests. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. NS = No statistically 
significant difference. All p values are in comparison to standard condition i.e. A10-
OB only.  
 
 
Table 5.2 Viability of MSCs when cultured in A10-OB with sphingolipids (1µM) for 7 
days. Viability determined by MTS assay, percentage viability calculated as 
percentage of carrier i.e. MSCs in osteoblast differentiation medium with methanol 
(1:10,000 dilution). 9 replicates per condition. Control samples highlighted in blue, 
MM samples in red. Unpaired t-tests. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. NS = No 
statistically significant difference. All p values are in comparison to carrier condition 
i.e. A10-OB + methanol. 
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5.3.6 Calcium deposition by osteoblasts differentiated from a control 
subjects MSC’s was reduced when cultured with imiglucerase, 
lactosylceramide or glucosylceramide.  
MSC’s isolated from the bone marrow of a control subject (2186) were cultured in 
optimised osteoblast medium A10-OB for 35 days in the presence of β-
glucocerebrosidase inhibitors, Gaucher specific therapies or sphingolipids involved 
in the synthesis pathway of glucosylceramide for the duration of the culture, 
medium replaced once per week. Addition of irreversible inhibitor CBE (100µM) or 
reversible inhibitor isofagomine (100µM) to MSC osteoblast cultures did not 
significantly affect the amount of calcium deposition (CBE p = 0.29, isofagomine p = 
0.54, figure 5.6a). Addition of enzyme replacement therapy (ERT) imiglucerase 
resulted in a 61.5% decrease (p = 0.03) while addition of another ERT velaglucerase 
did not significantly alter the degree of calcium deposition (p = 0.98). Addition of 
substrate reduction therapy (SRT) miglustat or potential chaperone therapy 
ambroxol hydrochloride also did not significantly affect calcium deposition (p = 0.32 
and p = 0.54 respectively, figure 5.6b). In regards to MSC-osteoblast culture with 
exogenous sphingolipids, no significant changes in calcium deposition were 
observed between standard and carrier (methanol), p = 0.12, or between carrier 
and sphingosine based lipids (sphingosine p = 0.23, glucosylsphingosine p = 0.46, 
sphingosine-1-phosphate p = 0.15). However, a significant reduction in calcium 
deposition was observed for lactosylceramide (55.4% decrease, p = 0.016) and 
glucosylceramide (48.9% decrease, p = 0.025) when compared to carrier, figure 
5.6c.  
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Figure 5.6 Exogenous effects on calcium deposition of control osteoblasts, subject 
2186. (a, b, c) Control MSC’s cultured for 35 days in optimised osteogenic medium 
A10-OB with (a) irreversible inhibitor CBE (100µM) or reversible inhibitor 
isofagomine (100µM), (b) Gaucher disease specific therapies imiglucerase (1 
unit/ml), velaglucerase (1 unit/ml), miglustat (50µM) or ambroxol hydrochloride 
(20µM), (c) sphingolipids (1µM) or carrier (methanol, 1:10,000 dilution). 
Quantification of calcium deposition by absorbance spectrometry of alizarin red 
solubilised post staining of calcium deposits on cell monolayer surface. Minimum of 
6 replicates per condition. Mean ± SEM plotted. *p ≤ 0.05, unpaired t-tests. 
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5.3.7 Calcium deposition by osteoblasts differentiated from a multiple 
myeloma patients MSC’s was reduced when cultured with 
imiglucerase, miglustat, lactosylceramide or glucosylceramide. 
The same experimental approach was used for MSC’s isolated from the bone 
marrow of a multiple myeloma subject, sample 2036. MSC’s were cultured in 
optimised osteoblast medium for 35 days in the presence of β-glucocerebrosidase 
inhibitors, Gaucher specific therapies or sphingolipids for the duration of the 
culture, medium replaced once per week. As for the control sample, addition of 
inhibitors CBE (100µM) or isofagomine (100µM) to MSC osteoblast cultures did not 
significantly affect the amount of calcium deposition (CBE p = 0.84, isofagomine p = 
0.25, figure 5.7a). While addition of ERT imiglucerase significantly reduced the 
amount of calcium deposition as seen for the control. In this case deposition was 
reduced by 56.1% (p = 0.002). However, for this MM subject, the SRT miglustat 
decreased calcium deposition by 49% (p = 0.021), a decrease not observed in the 
control MSC cultures. There were no significant changes in calcium deposition for 
another ERT velaglucerase (p = 0.51) or for the potential chaperone therapy 
ambroxol hydrochloride (p = 0.23), figure 5.7b. A similar pattern of calcium 
deposition to the control MSC was observed for the MM MSC osteoblast culture 
when sphingolipids were added exogenously. There were no significant changes in 
calcium deposition between standard and carrier (methanol) or between carrier 
and sphingosine (p = 0.68), glucosylsphingosine (p = 0.55), sphingosine-1-phosphate 
(p = 0.41) or ceramide (p = 0.37). However, as in control cultures, calcium 
deposition was significantly reduced in the presence of exogenous lactosylceramide 
(32.7% decrease, p = 0.03) or glucosylceramide (32.7% decrease, p = 0.016), figure 
5.7c.  
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Figure 5.7 Exogenous effects on calcium deposition of a multiple myeloma subjects 
osteoblasts, subject 2036. (a, b, c) MSC’s cultured for 35 days in optimised 
osteogenic medium A10-OB with (a) irreversible inhibitor CBE (100µM) or reversible 
inhibitor isofagomine (100µM), (b) Gaucher disease specific therapies imiglucerase 
(1 unit/ml), velaglucerase (1 unit/ml), miglustat (50µM) or ambroxol hydrochloride 
(20µM), (c) sphingolipids (1µM) or carrier (methanol, 1:10,000 dilution). 
Quantification of calcium deposition by absorbance spectrometry of alizarin red 
solubilised post staining of calcium deposits on cell monolayer surface. 6 replicates 
per condition. Mean ± SEM plotted. *p ≤ 0.05, **p ≤ 0.01, unpaired t-tests. 
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5.3.8 Calcium deposition by osteoblasts differentiated from a second 
multiple myeloma patients MSC’s was reduced when cultured with 
imiglucerase, velaglucerase or miglustat. 
MSC’s isolated from the bone marrow of a second multiple myeloma subject (2167) 
were cultured in optimised osteoblast medium for 35 days in the presence of β-
glucocerebrosidase inhibitors, Gaucher specific therapies or sphingolipids for the 
duration of the culture, medium replaced once per week. Addition of inhibitors CBE 
(100µM) or isofagomine (100µM) to MSC osteoblast cultures did not significantly 
affect the amount of calcium deposition (CBE p = 0.59, isofagomine p = 0.27, figure 
5.8a). However, addition of current Gaucher specific therapies significantly reduced 
the amount of calcium deposition over 35 days of culture for this subject. Both 
enzyme replacement therapies led to the greatest reductions, addition of 
imiglucerase resulted in a 69% decrease (p < 0.0001) and velaglucerase in a 53.7% 
decrease (p =0.001). While addition of substrate reduction therapy miglustat 
reduced calcium deposition to a lesser extent (19.5% decrease, p = 0.049) addition 
of a potential chaperone therapy, ambroxol hydrochloride, did not significantly 
alter the degree of calcium deposition (p = 0.843, all therapy conditions shown in 
figure 5.8b). In contrast, addition of a range of sphingolipids (all at 1µM) including 
glucosylsphingosine and glucosylceramide did not significantly affect the amount of 
calcium deposition when compared to carrier only (methanol, 1:10,000 dilution 
ratio) as shown in figure 5.8c.  
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Figure 5.8 Exogenous effects on calcium deposition of a multiple myeloma subjects 
osteoblasts, subject 2167. (a, b, c) MSC’s cultured for 35 days in optimised 
osteogenic medium A10-OB with (a) irreversible inhibitor CBE (100µM) or reversible 
inhibitor isofagomine (100µM), (b) Gaucher disease specific therapies imiglucerase 
(1 unit/ml), velaglucerase (1 unit/ml), miglustat (50µM) or ambroxol hydrochloride 
(20µM), (c) sphingolipids (1µM) or carrier (methanol, 1:10,000 dilution). 
Quantification of calcium deposition by absorbance spectrometry of alizarin red 
solubilised post staining of calcium deposits on cell monolayer surface. 6 replicates 
per condition. Mean ± SEM plotted. *p ≤ 0.05, ***p ≤ 0.001, unpaired t-tests. 
184 
 
5.3.9 Calcium deposition by osteoblasts differentiated from a third 
multiple myeloma subjects MSC’s was unaffected by addition of 
Gaucher specific therapies or sphingolipids. 
MSC’s isolated from the bone marrow of a third multiple myeloma subject (2314) 
were cultured in optimised osteoblast medium for 35 days in the presence of β-
glucocerebrosidase inhibitors, Gaucher specific therapies or sphingolipids for the 
duration of the culture, medium replaced once per week. Unlike the previous 
control or MM subjects no statistically significant changes in calcium deposition 
were observed for any condition when compared to either standard (CBE p = 0.27, 
isofagomine p = 0.91, imiglucerase p = 0.93, velaglucerase p = 0.85, miglustat p = 
0.91, ambroxol hydrochloride p = 0.91, carrier p = 0.41) or carrier (sphingosine p = 
0.73, glucosylsphingosine p = 0.85, sphingosine-1-phosphate p = 0.91, 
lactosylceramide p = 0.38, glucosylceramide p = 0.32), figures 5.9a, b and c.  
 
5.3.10 Calcium deposition by osteoblasts differentiated from GD 
subjects MSC’s was suboptimal. 
MSC’s isolated from the bone marrow of two GD subjects (2158 and 2371) were 
cultured in optimised osteoblast medium for 35 days in the presence of β-
glucocerebrosidase inhibitors, Gaucher specific therapies or sphingolipids for the 
duration of the culture, medium replaced once per week. However, due to limited 
expansion of the 2158 sample MSC’s too few experiments could be carried out to 
obtain statistical analysis. In addition, osteoblast cultures of samples 2158 and 2371 
produced suboptimal amounts of calcium preventing assessment of the effects of 
exogenous factors. The amount of calcium deposited in GD osteoblast cultures in 
the presence of GD-specific therapies are shown in figures 5.10a and 5.10b.  
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Figure 5.9 Exogenous effects on calcium deposition of a multiple myeloma subjects 
osteoblasts, subject 2314. (a, b, c) MSC’s cultured for 35 days in optimised 
osteogenic medium A10-OB with (a) irreversible inhibitor CBE (100µM) or reversible 
inhibitor isofagomine (100µM), (b) Gaucher disease specific therapies imiglucerase 
(1 unit/ml), velaglucerase (1 unit/ml), miglustat (50µM) or ambroxol hydrochloride 
(20µM), (c) sphingolipids (1µM) or carrier (methanol, 1:10,000 dilution). 
Quantification of calcium deposition by absorbance spectrometry of alizarin red 
solubilised post staining of calcium deposits on cell monolayer surface. 6 replicates 
per condition. Mean ± SEM plotted. ***p ≤ 0.001, unpaired t-tests. 
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Figure 5.10 Exogenous effects of GD specific therapies on calcium deposition of GD 
subjects’ osteoblasts. (a, b) MSC’s cultured for 35 days in optimised osteogenic 
medium A10-OB with imiglucerase (1 unit/ml), miglustat (50µM) or ambroxol 
hydrochloride (20µM). Quantification of calcium deposition by absorbance 
spectrometry of alizarin red solubilised post staining of calcium deposits on cell 
monolayer surface. (a) Minimum of 2 replicates per condition. (b) 6 replicates per 
condition. Mean ± SEM plotted. Unpaired t-tests, no significance. 
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5.3.11 Optimisation of culture conditions for the human osteoblast 
cell line SaOs-2. 
To further assess osteoblast function in Gaucher disease an osteoblast cell culture 
model was optimised. The human osteoblast cell line SaOs-2 was cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS, 2mM L-
glutamine, 10mM HEPES, 100 units/ml penicillin, 0.1mg/ml streptomycin, 10nM 
dexamethasone and a range of concentrations of β-glycerophosphate and 
ascorbate-2-phosphate for up to 4 weeks to induce calcium deposition on the 
monolayer surface, medium replaced twice per week. In order to permit the 
detection of increased or decreased calcium deposition due to modifications in 
culture conditions an intermediate degree of calcium deposition was selected, as 
indicated by a red arrow in figure 5.11d and a representative image, figure 5.11b. 
SaOs-2 cells were cultured in these conditions i.e. supplemented DMEM + 10nM 
dexamethasone, 4mM β-glycerophosphate, 100µM ascorbate-2-phosphate, for 21 
days for all subsequent calcium deposition experiments for this cell line, referred to 
as D10-OB for subsequent experiments. 
 
 
188 
 
 
Figure 5.11 Optimisation of conditions required for calcium deposition by 
osteoblast cell line SaOs-2. (a, b) Representative images of SaOs-2 cells cultured (a) 
without and (b) with optimised osteogenic conditions for 21 days, stained with 
alizarin red. (c, d, e) SaOs-2 cells cultured with 10nM dexamethasone and a range 
of concentrations of β-glycerophosphate and ascorbate-2-phosphate for (c) 14 
days, (d) 21 days, (e) 28 days. Duplicates per condition, mean ± SEM plotted. 
Selected osteogenic conditions for subsequent cultures indicated by red arrow. 
Quantification of calcium deposition by absorbance spectrometry of alizarin red 
solubilised post staining of calcium deposits on cell monolayer surface. Mean ± SEM 
plotted. 
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5.3.12 SaOs-2 as a model for Gaucher disease subject osteoblasts. 
To determine if the SaOs-2 cell line could be used as a model of Gaucher disease 
these cells were cultured in a range of CBE concentrations in optimised calcium 
deposition medium for 4 days. β-glucocerebrosidase activity was reduced by 92.8% 
when cultured with 100µM CBE. Maximal inhibition was achieved with 250µM CBE 
(95.9%). No significant reduction in viability, measured using MTS assay, was 
observed for any of the CBE concentrations however to minimise the potential of 
off-target effects SaOs-2 cells were cultured with 100µM CBE in subsequent 
experiments, figure 5.12a. To determine whether addition of therapies or 
sphingolipids in the absence or presence of CBE would affect viability and therefore 
potentially affect the amount of calcium deposition through cell death rather than 
osteoblast activity MTS assays were performed for all conditions after 4 days of 
culture in the presence of the condition in optimised osteoblast medium with a 
minimum of six cultures per condition. Cultures with GD specific therapies did not 
lead to significant changes in viability either in the absence or presence of CBE. 
However, SaOs-2 cells cultured with glucosylsphingosine resulted in highly 
significant decreases in viability in the absence or presence of CBE (no CBE p < 
0.0001, with CBE p < 0.0001). Significant decreases in viability were also observed 
for glucosylceramide (no CBE p < 0.008, with CBE p = 0.001). To a lesser degree 
viability was also decreased in the presence of CBE for sphingosine-1-phosophate  
(p = 0.025), ceramide (p = 0.033) and lactosylceramide (p = 0.006), figures 5.12b, c 
and d.  
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Figure 5.12 Assessment of SaOs-2 osteoblast cell line as a model of Gaucher 
disease. (a) Viability of cell line (blue line) measured by MTS assay, inhibition of β-
glucocerebrosidase activity (red line), by addition of an irreversible inhibitor CBE at 
a range of concentrations when cultured in D10-OB for 4 days in triplicate. Activity 
measured by fluorometric assay. (b, c, d) Viability of cell line when cultured in D10-
OB for 4 days with (b) Gaucher disease therapies or (c, d) sphingolipids in the 
absence (white bars) or presence (black bars) of 100µM CBE, minimum of 6 cultures 
per condition. Viability measured by MTS assay, 100% calculated from the averaged 
absorbance values obtained from the standard condition. Mean ± SEM plotted. 
Unpaired t-tests. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
 
5.3.13 Calcium deposition was reduced in the presence of current 
Gaucher specific therapies in the absence or presence of CBE. 
To further assess the potential effects of GD specific therapies on osteoblast activity 
a human osteoblast cell line, SaOs-2, was cultured in optimised osteogenic medium 
D10-OB for 3 weeks in the presence of ERT’s imiglucerase or velaglucerase, SRT 
miglustat or potential pharmacological chaperone therapy ambroxol hydrochloride 
in the absence or presence of 100µM CBE for 3 weeks, medium changed twice per 
week. As seen in figures 5.6, 5.7 and 5.8 for primary MSC derived osteoblast 
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cultures, SaOs-2 cells cultured in the presence of imiglucerase resulted in the most 
substantial decrease in calcium deposition (27.3% decrease, p < 0.0001). However, 
unlike in the majority of the MSC osteoblast cultures, addition of the other GD 
specific therapies also resulted in statistically significant reduction in calcium 
deposition (velaglucerase: 14% decrease, miglustat: 7.7% decrease, ambroxol 
hydrochloride: 19.3% decrease, p < 0.0001 for each condition), figure 5.13a. 
Addition of GD specific therapies in the presence of CBE generated a very similar 
pattern in regards to calcium deposition as seen in cultures without CBE inhibition 
with the exception of ambroxol hydrochloride. Again, addition of imiglucerase 
resulted in the greatest reduction (26.8% decrease, p < 0.0001) while addition of 
velaglucerase or miglustat led to more modest reductions in calcium deposition 
(8.6%, 4.4% decrease, p < 0.0001, p = 0.0002 respectively). Conversely, addition of 
ambroxol hydrochloride in the presence of CBE led to an increase in calcium 
deposition (11%, p < 0.0001), figure 5.13b.  
In addition, SaOs-2 cultured in the presence of CBE led to statistically significant 
decreases in calcium deposition for all equivalent conditions e.g. comparing 
imiglucerase to imiglucerase+CBE, again with the exception of ambroxol 
hydrochloride cultures which deposited significantly more calcium in the presence 
of CBE than those without CBE, percentage changes and statistical significances 
shown in table 5.3 below and figure 5.13c. 
 
Table 5.3 Percentage changes in calcium deposition by SaOs-2 cell line when 
cultured for 3 weeks in optimised osteogenic medium D10-OB in the presence of 
GD specific therapies in the presence of CBE relative to conditions in the absence of 
CBE. p values refer to statistical significance of percentage changes in calcium 
deposition. Unparied t-tests.   
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Figure 5.13 Culture with therapy and CBE reduce calcium deposition by osteoblast 
cell line SaOs-2. (a, b, c) SaOs-2 cultured for 3 weeks in optimised osteogenic 
conditions in D10-OB in the absence (white bars) or presence (black bars) of CBE 
with either carrier (PBS) labelled as standard, imiglucerase (1 unit/ml), 
velaglucerase (1 unit/ml) or miglustat (50µM), ambroxol hydrochloride (20µM). 
Quantification of calcium deposition by human osteoblast cell line SaOs-2 by 
absorbance spectrometry of alizarin red solubilised post staining of calcium on cell 
monolayer surface. Mean ± SEM plotted. 9 repeat experiments per condition.         
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Unpaired t-tests.  
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5.3.14 Calcium deposition by SaOs-2 is increased when cultured with 
sphingosine-1-phosphate or glucosylsphingosine in the presence of 
CBE. 
To assess the effect of exogenous sphingolipids on calcium deposition by the GD 
osteoblast model, SaOs-2 cells were cultured in D10-OB medium for 3 weeks in the 
presence of carrier (methanol) or sphingolipid in the absence or presence of CBE for 
the duration of the culture, medium changed twice per week. No statistically 
significant differences in calcium deposition were observed when comparing carrier 
with any sphingolipid in the absence of CBE or when comparing carrier with CBE 
with any sphingolipid in the presence of CBE, figure 5.14a. 
In contrast to the previous figure (figure 5.13), addition of CBE to SaOs-2 cultures in 
osteogenic medium D10-OB did not result in any statistically significant changes in 
calcium deposition with the exception of SaOs-2 cultured in the presence of 
exogenous sphingosine-1-phosphate or glucosylceramide in which addition of CBE 
resulted in statistically significant increases in calcium deposition (31% and 25.6%, p 
= 0.0016 and 0.005 respectively), figures 5.14b and c.   
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Figure 5.14 Exogenous effects of sphingolipids on calcium deposition of human 
osteoblast cell line SaOs-2. (a, b, c) SaOs-2 cultured for 21 days in optimised 
osteogenic medium D10-OB with sphingolipids (1µM) or carrier (methanol, 
1:10,000 dilution) in the absence or presence of irreversible β-glucocerebrosidase 
inhibitor CBE (100µM). (b, c) selected data from (a). Quantification of calcium 
deposition by absorbance spectrometry of alizarin red solubilised post staining of 
calcium deposits on cell monolayer surface. 6 repeat experiments per condition. 
Mean ± SEM plotted. **p ≤ 0.01. Unpaired t-tests.        
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5.4 Discussion 
The main paradigm for bone homeostasis is the interaction and signalling between 
osteoclasts and osteoblasts, commonly referred to as coupling (289,436). Such a 
close relationship would suggest that changes in osteoclast generation, size and 
activity may have a direct effect on osteoblast number and activity but it may also 
be the case that osteoblasts are abnormal in GD due to factors other than 
osteoclast abnormalities. Murine models of GD have suggested that the bone 
disease may be caused by reduced osteoblastic activity (272,541). Other 
publications have shown that type 1 GD patient MSC’s have a decreased capacity to 
differentiate into osteoblasts and normal MSC’s have impaired proliferation with 
altered secretion of soluble factors when inhibited with CBE (138,524). These 
findings suggest there may be an imbalance between osteoclasts and osteoblasts in 
GD both in terms of numbers and activity. To investigate the potential imbalance 
and dysfunction of GD patient osteoblasts MSC’s were isolated from the bone 
marrow of control, Gaucher and multiple myeloma subjects and differentiated into 
functional osteoblasts to allow for characterisation and comparison of GD MSC’s 
and osteoblasts with control and myeloma patient MSC’s and osteoblasts. A model 
of GD osteoblasts was also created using the SaOs-2 human osteoblast cell line and 
the β-glucocerebrosidase inhibitor CBE. 
The results discussed below indicate possible uncoupling between osteoclasts and 
osteoblast precursors in GD patients and investigate for the first time the effects of 
GD-specific therapies and sphingolipids on the function of a human osteoblast cell 
line and human primary osteoblasts. 
 
Evidence of uncoupling between GD osteoclasts and osteoblasts. 
No difference was found in the number of circulating osteoblast precursors 
between control and GD cohorts. This may indicate that initial commitment of MSC 
to osteoblast precursors is not impaired in GD patients. If the initial stages of 
differentiation in regards to either rate or proportion of MSC’s was reduced fewer 
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would be in the peripheral blood assuming the migration rate is the same for 
control and GD subjects. However, this does not mean the anabolic aspect of bone 
metabolism is normal in GD as osteoblast precursor migration to the bone marrow 
niche from the peripheral blood could be impaired and maturation of precursors in 
the bone marrow could also be impaired as a number of publications have reported 
altered differentiation capacity of GD patient MSC’s (138,141). In addition, 
migration and maturation could be affected by extracellular factors in the bone 
marrow and peripheral blood which may prevent precursors from either reaching a 
state in which they respond to the migration factors or reduce their ability to 
differentiate into functional osteoblasts once they reach the bone marrow.  
Analysis of osteoclast generation and osteoblast precursors present in peripheral 
blood showed there may be uncoupling between GD osteoclasts and osteoblast 
precursors. While there was a correlation between the control cohort osteoclast 
generation and osteoclast numbers there was no correlation between these cells 
for GD patients which in combination with previous data showing increased 
osteoclast generation in vitro, correlating with clinical bone features, provides a 
strong case for bone microenvironment dysregulation in GD favouring an imbalance 
towards high resorption and low deposition leading to overall bone loss. Evidence 
of an osteoblast role is supported by findings of defects in osteoblast formation in a 
GD murine model which exhibited bone disease similar to that observed in GD 
patients including osteopenia and avascular necrosis (272). However, the lack of 
correlation of GD osteoclast generation with osteoblast precursors only 
demonstrates uncoupling between immature cells and may not lead to uncoupling 
between the mature forms of the osteoblasts and osteoclasts. 
 
CBE inhibition reduces control MSC viability. 
A reduction in viability of control MSC’s in the presence of CBE and isofagomine was 
detected. However, the reduction in percentage viability was small and although 
statistically significant may not have a significant effect on the cell culture outcome. 
In addition, it should be noted that the assay used, MTS, can also be used to 
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measure proliferation and may indicate reduced proliferation instead of reduced 
viability as MSC’s actively divide. In either case it indicates a lower number of 
mitochondria which, assuming the number of mitochondria per MSC is equal in all 
conditions, equates to a lower total cell number. This result may also indicate 
deficiency in GBA activity may reduce either proliferation or viability or both of 
MSC’s resulting in a decreased pool of MSC’s to differentiate into osteoblasts 
further skewing the balance between osteoblasts and osteoclasts towards 
catabolism of bone. 
 
Effects of GD-specific therapies on in vitro cultures of MSC’s and primary 
osteoblasts. 
As mentioned in the chapter 3 discussion, treatment of GD patients with ERT has 
resulted in significant BMD increases in a number of long term studies however 
BMD can take several years to show improvement (84,507,571) with considerable 
residual skeletal disease after several years of ERT (84,571). To investigate the 
potential effects of GD-specific therapies on MSC’s and osteoblasts, MSC’s were 
differentiated into functional osteoblasts or a human osteoblast cell line, SaOs-2, 
were cultured with GD-specific therapies added to the medium for the duration of 
the culture. Viability of MSC’s and SaOs-2 cells was assessed and calcium deposition 
by osteoblasts was measured by alizarin red staining.  
GD-specific therapies imiglucerase, miglustat and ambroxol reduced the viability of 
non-GD MSC. The decreases in viability/proliferation in those samples affected 
were considerably greater than the reduction observed for the inhibitors. Again, 
whether these reductions are substantial enough to affect the outcome of the cell 
culture is unknown. While unexpected, the reduction in proliferation/viability of the 
MSC’s in the presence of therapies may in part explain the slow response of bone 
improvement in GD to therapy reported (180) as while these therapies have been 
shown to decrease osteoclast generation this may be offset by a concomitant 
reduction in osteoblast numbers leading to a smaller than expected overall gain. 
This finding may also provide some rationale as to why some GD patients do not 
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appear to improve with therapy as if the osteoclast generation in these patients is 
particularly high, as suggested by previous data, the reduction in generation may 
not be sufficient to outweigh the reduction in osteoblast numbers resulting in 
continued bone loss. However, these findings were generated from an in vitro 
culture with several limitations including being a mono-culture and planar and may 
not recreate the effects of therapy in vivo. The potential mechanisms behind the 
reduction in MSC viability/proliferation remains unclear but may involve GD-specific 
therapy mediated alteration in intracellular sphingolipid ratios including 
glucosylceramide and sphingosine-1-phosphate which have been found to 
stimulate proliferation of cells (276,278), though these publications do not look 
specifically at their effects on MSC’s. It should be noted that other lipids such as 
ceramide can have pro-apoptotic effects (285) and glucosylsphingosine has been 
reported to both enhance proliferation and to cause cell death depending on the 
cell type (272,572) therefore the ratios between these sphingolipids and their 
specific effects on MSC’s need to be elucidated.  
The activity of osteoblasts differentiated from subject MSC’s was assessed by the 
amount of calcium deposited in culture, determined by staining of the calcium with 
alizarin red followed by solubilisation and quantification of the stain. Substantially 
reduced calcium deposition was measured in one control and two of the three MM 
samples when cultured with imiglucerase of up to 69% measured for MM sample 
2167. Culture with miglustat also resulted in substantially reduced calcium 
deposition for two of the three MM samples, with the greatest reduction of 37% for 
MM sample 2036 and while the decrease in the control sample did not reach 
statistical significance for miglustat it was still a substantial decrease in calcium of 
26%. A statistically significant decrease was also observed for velaglucerase for MM 
sample 2167 of 54%. As the differentiation of the MSC’s into osteoblasts is not 
initiated until the MSC’s are confluent in every well to minimise variation between 
wells and cultures the decrease in calcium deposition is unlikely to be related to 
reduction in proliferation. It is therefore likely that these effects are either due to 
increased apoptosis as indicated by the MTS assay or due to a reduction in capacity 
for the MSC’s to differentiate into mature, functional osteoblasts or both. However, 
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the fact that for ERT this effect was observed to a greater degree for imiglucerase in 
comparison to velaglucerase raises questions as to the specificity and mechanism/s 
of this effect. It is possible that this effect is mediated by the carrier for 
imiglucerase rather than the enzyme itself, an effect not anticipated as the volume 
of enzyme added to culture equated to 1:400 of the total volume and that this 
carrier had been formulated by the manufacturer for administration to patients.  
To address this possibility cultures with carrier alone need to be carried out which 
would require the provision of the specific formula from the manufacturer. 
However, as miglustat also reduced calcium deposition and for one MM sample 
addition of velaglucerase to culture did lead to a substantial and statistically 
significant decrease in calcium deposition this effect may be therapy specific and 
therefore warrants further investigation. In addition, as none of these cultures were 
carried out with GD patient MSC’s it cannot be determined whether addition of GD-
specific therapies would affect calcium deposition. It should also be noted that in 
these cultures the cells were continuously cultured in the presence of the therapies 
for the 35-day duration of the culture which may not equate to physiological 
conditions for GD patients, especially for imiglucerase, as enzyme replacement 
therapy is most commonly administered as an infusion once every two weeks. With 
a half-life reportedly ranging from 3.6 to 10.4 minutes (573) in patient plasma 
MSC’s may not be exposed to imiglucerase continuously as the half-life of 
imiglucerase has been shown to be 14.1 hours (618). For control cells β-
glucocerebrosidase is continuously present and active however in this case the 
majority of the enzyme is intracellular whereas in our cultures the enzyme is added 
exogenously and internalised via the mannose receptor. 
 
Effects of sphingolipids on in vitro cultures of MSC’s and primary osteoblasts. 
Research into the potential roles of sphingolipids in relation to MSC’s and 
osteoblasts has shown S1P produced by osteoclasts to be a chemoattractant for 
MSC’s resulting in their migration to the bone marrow (431) and its receptor S1PR 
affects proliferation, migration and differentiation of MSC’s (574). In addition, 
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catabolism of sphingomyelin by neutral sphingomyelinase 2 (nSMase2) has been 
shown to be essential for mineralisation in a fro/fro mouse model (432). To 
investigate the potential effects of sphingolipids present in the synthesis and 
degradation pathway of glucosylceramide (including glucosylsphingosine), these 
sphingolipids were added to osteoblast medium for the duration of the cultures and 
their effects on viability of MSC’s and SaOS-2 and calcium deposition by primary 
osteoblasts and SaOS-2 was assessed. 
The majority of sphingolipids do not reduce cell viability with the exception of 
glucosylsphingosine which resulted in a reduction in conversion of MTS substrate 
for all 5 samples, three of which reaching a statistically significant reduction of up to 
21% in the case of MM sample 2036. However, this decrease could indicate 
decreased viability or proliferation, in either case the data suggests 
glucosylsphingosine reduced the number of MSC’s present. As this sphingolipid has 
been found to be elevated over 10 fold in GD plasma compared to an average of 3 
fold for glucosylceramide (155) with one study reporting <4pmol/ml for normal 
population plasma elevated up to 1860pmol/ml in GD plasma (173), its potential 
effect on circulating MSC’s/pre-osteoblasts and MSC’s/pre-osteoblasts resident in 
the bone marrow may be considerable. Treatment with ERT has been shown to 
reduce plasma glucosylsphingosine which may in part reverse the detrimental 
effects of glucosylsphingosine and thus aid in the gradual increase in bone mineral 
density observed in a number of therapy related GD patient studies (506–510). 
However, the potential effect of ERT reducing MSC viability may limit this effect. 
Addition of glucosylceramide and lactosylceramide consistently increased 
viability/proliferation however in the majority of samples the increase was not 
statistically significant only reaching significance for multiple myeloma sample 
2167. This data would suggest elevated concentrations of glucosylceramide may be 
beneficial for MSC’s in contrast to the effect of glucosylsphingosine. This at least in 
part may explain the detrimental effect of GD-specific therapies on MSC’s as none 
of the samples were from GD patients all would have a normal level of 
glucosylsphingosine and glucosylceramide. Therefore, the beneficial effect of GD-
specific therapies on lowering the concentration of glucosylsphingosine would not 
201 
 
be observed while the potentially detrimental effect of lowering glucosylceramide 
would be. To investigate this further, GD and control subject derived MSC’s could 
be cultured in the presence of ERT, glucosylsphingosine and glucosylceramide both 
individually and in combination.  
Interestingly, addition of lactosylceramide or glucosylceramide to the control and 
MM sample 2036 resulted in substantial and statistically significant decreases in 
calcium deposition. Previous data from the MTS assay suggested MSC proliferation 
may be enhanced in the presence of glucosylceramide. However, as previously 
stated the MSC’s in these cultures were already confluent and therefore this effect 
may have been limited. These results suggest lactosylceramide and 
glucosylceramide may inhibit MSC to osteoblast differentiation. While this effect 
was only observed in two of the four samples tested it may indicate that the high 
concentrations of glucosylceramide in bone marrow of GD patients may reduce 
osteoblast activity again to investigate this further it would be necessary to increase 
the size of the control cohort and to culture GD patient samples. However, if this is 
the case it would be expected that addition of GD-specific therapies designed to 
reduce the amount of glucosylceramide present would result in an increase in MSC 
differentiation into osteoblasts which suggests lactosylceramide concentration is 
also a factor. A histochemical study of GD bone marrow and spleen Gaucher cells 
found decreased concentrations of lactosylceramide compared to control 
macrophages (553) and a separate study found significantly lower concentrations in 
GD versus control plasma (154). Addition of GD-specific therapy to MSC cultures 
may result in an increase in lactosylceramide as the sphingolipid pathway may be 
closer to functioning normally. If this is the case the effect of reducing the amount 
of glucosylceramide may be negated by a concomitant increase in lactosylceramide. 
GD patient derived MSC’s did not produce sufficient calcium to allow assessment of 
exogenous factors such as inhibitors, therapies and sphingolipids. In the case of 
sample 2158 the MSC’s were very slow to expand which made it very difficult to set 
up sufficient culture replicates for statistical analysis. While MSC’s isolated from 
subject 2371 expanded normally they still did not produce sufficient calcium to 
assess. Whether this was due to experimental failure or due to a reduction in 
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differentiation capacity, reported by Lecourt et al (138) would require repeating 
this experiment in these samples and in a larger cohort of GD subject MSC’s.  
 
Effects of GD-specific therapies and sphingolipids on in vitro cultures of the SaOS-
2 cell line. 
In comparison to primary cells the SaOs-2 cell line responded differently to 
exogenous factors showing no reduction in viability to either inhibitors or GD 
specific therapies. This may be due to a number of factors. Firstly, the SaOs-2 cell 
line is not comparable to the primary MSC’s as they are described as osteoblast-like 
cells and therefore already committed to the osteoblast lineage which may alter 
their response to external factors. Secondly, the SaOs-2 cells proliferate much more 
quickly than primary MSC’s.  
In contrast, SaOS-2 cells did exhibit reduced viability/ proliferation in the presence 
of certain sphingolipids, namely glucosylsphingosine (both in the absence and 
presence of CBE), sphingosine-1-phosphate, ceramide, lactosylceramide and 
glucosylceramide but only in the presence of CBE. While the reduction in viability in 
the presence of glucosylsphingosine was present for both primary MSC’s and the 
SaOS-2 cell line the effect of sphingosine-1-phosphate and ceramide on the SaOS-2 
cell line was not observed in the MSC cultures. Moreover, the presence of 
lactosylceramide and glucosylceramide in cultures led to opposite results from 
appearing to increase proliferation in MSC cultures to reducing 
viability/proliferation in SaOs-2 cultures. These differences again could relate to the 
different rates of proliferation between the SaOs-2 and MSC’s but may also be due 
to the SaOs-2 being osteoblast-like. If the latter is the case it may suggest the 
viability effects of inhibitors, therapies and lipids affect MSC’s differently to 
osteoblasts and therefore may have stepwise effects in terms of MSC numbers 
differentiating into osteoblasts and the number of osteoblasts maturing into 
functional cells. However, glucosylsphingosine appears to have a more consistent 
effect of reducing viability/proliferation further supporting the hypothesis that high 
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concentrations of glucosylsphingosine in the bone marrow may lead to a reduction 
in MSC and osteoblast numbers resulting in reduced calcium deposition. 
Although different results were obtained in regards to viability between primary 
MSC’s and the SaOs-2 cell line the effects of GD-specific therapies on calcium 
deposition were similar. Calcium deposition by this cell line was reduced in the 
presence of each therapy with the exception of ambroxol hydrochloride which 
showed a slight but statistically significant increase in calcium deposition. As seen 
with the MSC’s the greatest decrease was seen when SaOs-2 cells were cultured 
with imiglucerase. In this case the decrease of 27.3% without CBE and 26.8% with 
CBE although substantial was not as marked as for some of the MSC’s with 
decreases of up to 69% for multiple myeloma sample 2167. This may indicate that 
imiglucerase is affecting differentiation with its effect being limited in regards to 
the SaOs-2 due to already being differentiated into the osteoblast lineage unlike the 
MSC’s. As previously mentioned, whether this effect is specific to the enzyme or 
due to the carrier is unknown and requires investigation. Again, as with MSC’s, 
cultures with velaglucerase and miglustat resulted in less substantial decreases in 
calcium and although these are statistically significant whether this is clinically 
relevant is unknown. The increase in calcium deposition in the presence of 
ambroxol hydrochloride was similar to that observed for several MSC cultures 
although in all cases the increase is very small and few reached statistical 
significance suggesting either at worst ambroxol has no detrimental effect and at 
best has a small beneficial effect on bone mineralisation. 
Inhibition by CBE resulted in consistently reduced calcium deposition in the cultures 
set up with GD specific therapies however this result is not replicated in a separate 
experiment in which sphingolipids were added to culture. In this experiment 
calcium levels were not affected by addition of CBE under standard or carrier 
conditions. These findings suggest results may vary between cultures. To determine 
if CBE does reduce calcium deposition several separate repeat experiments will be 
required to account for this apparent variation.  
In contrast to effects observed on calcium deposition for MSC samples 2186 
(control) and 2036 (MM) culture of SaOs-2 with lactosylceramide or 
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glucosylceramide did not reduce calcium deposition. In the presence of CBE, the 
SaOs-2 culture with sphingosine-1-phosphate or glucosylceramide conversely 
resulted in substantial increases in calcium deposition suggesting these 
sphingolipids, both found to be elevated in GD plasma and serum, may act as a 
counterbalance to the detrimental effects on cell number to glucosylsphingosine at 
least for the osteoblast-like cell line. MSC osteoblast cultures with CBE and 
sphingolipids will need to be carried out to determine if this effect is also present 
for primary cells. Again, the effect of glucosylsphingosine on cell 
viability/proliferation may have been negated by the necessity to only initiate 
differentiation and mineralisation once the cells had reached confluence. 
 
Limitations 
In addition to the limitations stated within the above discussion it should be noted 
that all of the above findings were generated from in vitro culture which has several 
limitations compared to in vivo studies. Firstly, MSC’s and osteoblasts were cultured 
and differentiated in isolation which does not take into account the potential 
effects of other cells in the bone marrow such as osteoclasts, osteocytes, plasma 
cells, and T-cells. Secondly, these cells were cultured as a monolayer which does 
not replicate the three-dimensional environment present in vivo. Thirdly, cell 
cultures were performed in static medium. This method can lead to a depletion of 
nutrients and osteogenic factors and a build-up of waste products between 
medium changes. 
 
Summary 
In summary, the results in this chapter based on data from the human osteoblast 
cell line SaOs-2 and the majority of MSC derived osteoblasts suggested that GD-
specific therapies reduced calcium deposition and MSC viability, as did 
glucosylsphingosine. In comparison, glucosylceramide increased MSC viability but 
decreased their degree of calcium deposition. However, the effects of GD-specific 
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therapies and sphingolipids on GD MSC’s was not investigated due to difficulties 
encountered in expanding and differentiating the MSC’s isolated from GD patient 
bone marrow. Inhibition of β-glucocerebrosidase using CBE did not appear to affect 
calcium deposition by osteoblasts differentiated from MSC’s and was inconclusive 
in regards to the human osteoblast cell line.  
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6. In vitro plasma cell culture 
6.1 Introduction 
Several studies have reported an increased risk of cancer in GD, in particular for 
multiple myeloma (MM) with reported risk ratios of 25 in an N370S/N370S GD 
cohort of 367 (242) up to a standardised rate ratio of 51.1 in a mixed GD population 
of 131 from western Europe (157). In addition a conditional knock out murine 
model of GD was found to have increased incidences of B-cell lymphoma and 
monoclonal gammopathy (575). Pre-treatment of this model with a substrate 
reduction therapy, eliglustat tartrate, appeared to reduce the incidence of B-cell 
lymphoma and myeloma (576) suggesting the cause of the lymphoma and myeloma 
was directly linked to GD in this murine model.  
A major feature of MM is extensive and recurrent bone disease with 70-80% of 
patients suffering osteolytic lesions at diagnosis (577). The development of cell 
culture techniques for the isolation and differentiation of cells present in the bone 
marrow microenvironment, especially osteoclasts and osteoblasts, has facilitated 
research into the interaction between plasma cells and other components of the 
bone marrow niche. A major component for survival and proliferation of the plasma 
cells has been found to be the monocyte/macrophages in the bone marrow shown 
to secrete factors such as IL-1b, IL-10, TNF-α and IL-6 (578). Studies have also shown 
that physical contact between macrophages and plasma cells protect the MM 
plasma cells from apoptosis by chemotherapy (579). Similarly, in vitro osteoclast-
plasma cell cultures were found to greatly increase the survival of plasma cells 
when in direct contact (580) while plasma cells were also found to increase 
osteoclast generation by physical contact (581). Secretion of osteoclastogenic 
chemokines such as macrophage inflammatory protein 1α (MIP1α) and MIP1β by 
MM plasma cells have also been shown to affect adhesion of the MM plasma cells 
to the bone marrow stroma leading to increased RANKL expression and thus 
osteoclastogenesis (388).  
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In addition, recent research has provided evidence that many sphingolipids are 
bioactive and are involved in migration, proliferation and survival of several cell 
types (582,583) including plasma cells (584) osteoclasts and osteoblasts (380,585). 
Several sphingolipids including sphingosine-1-phosphate and ceramide-1-
phosphate have been linked to cancers both solid tumour such as breast cancer for 
which Maczis et al demonstrate that S1P acts as an anti-apoptotic and growth-
promoting factor (586) and pancreatic cancers in which Rivera et al suggest an 
increase in ceramide-1-phosphate enhanced migration of pancreatic cancer cells 
(587) and haematological such as multiple myeloma for which S1P has been 
suggested to increase plasma cell migration and inhibit dexamethasone-induced 
apoptosis (584).    
The findings that GD macrophages differentiated either from monocytes isolated 
from peripheral blood (131) or from induced pluripotent stem cells (iPSC) (132) 
showed inflammasome activation with increased secretion of IL-1β and IL-6, in 
conjunction with evidence of elevated concentrations of several sphingolipids 
including sphingosine, sphingosine-1-phosphate and glucosylsphingosine in the 
serum and plasma of GD patients (152,153), with our findings of increased 
osteoclast generation in vitro suggests that the GD bone marrow may contain a 
combination of factors which provide both a pro-proliferation and pro-survival 
environment for plasma cells which may in part explain the increased incidence of 
multiple myeloma in GD.  
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6.2 Aims and Hypotheses 
Aim: To understand the relationship between plasma cells and in vitro GD 
osteoclastogenesis. 
Objectives: 
(1) To determine whether plasma cells affect GD patient osteoclastogenesis in vitro. 
(2) To determine whether sphingolipids found to be increased in GD plasma affect 
plasma cell survival and proliferation.  
  
Hypothesis 1: GD osteoclastogenesis is further enhanced when cultured with 
myeloma plasma cells e.g. the NCI-H929 myeloma plasma cell line. 
Rationale: Myeloma patient plasma cells and myeloma plasma cell lines have been 
reported to express cytokines such as IL-6, RANKL, TNF-α, MIP-1α known to 
stimulate osteoclastogenesis, contributing to the osteopenia and bone lesions 
found in over 80% of myeloma patients. 
Methods: Co-culture of control or GD patient osteoclast cultures with a myeloma 
plasma cell line. Osteoclasts will be identified by being histochemically positive for 
TRAP. 
 
Hypothesis 2: The altered sphingolipid profile in GD patients creates a pro-survival 
environment for plasma cells which in turn stimulate osteoclast generation, 
creating a positive effector loop between plasma cells and osteoclasts in GD.  
Rationale: Several sphingolipids including glucosylsphingosine and 
glucosylceramide have been suggested to have roles as bioactive molecules in 
cancer. Both sphingolipids have been linked with increasing cellular proliferation 
and reducing apoptosis and glucosylceramide has been suggested to be involved in 
drug resistance.  
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Methods: Culture of a myeloma plasma cell line with a range of exogenous 
sphingolipids. Cell number determined by haemocytometer. 
 
6.3 Results 
6.3.1 Myeloma plasma cell line NCI-H929 Gaucher disease model. 
Gaucher patients have been shown to have an increased relative risk of for 
developing multiple myeloma (157,241,260). 
To address the role of plasma cells in Gaucher disease and the bone 
microenvironment a human plasma cell line NCI-H929 was used to model reduced 
β-glucocerebrosidase activity in plasma cells. To validate this model 2x104 per ml 
NCI-H929 cells were cultured in RPMI-1640 supplemented with 10% FBS, 2mM L-
glutamine, 10mM HEPES, 100 units/ml penicillin, 0.1mg/ml streptomycin (R10) with 
a range of concentrations of irreversible inhibitor CBE. Substantial inhibition of β-
glucocerebrosidase was achieved with 100µM CBE (91.5% reduction in activity, 
figure 6.1a). While further reduction in activity was achieved with higher 
concentrations of CBE (250µM CBE resulted in a 95.7% decrease, figure 6.1a) 
100µM was chosen for future experiments to minimise possible off target affects 
associated with this inhibitor (593). However, no significant toxicity was observed 
either through MTS assay (figure 6.1b) or through annexin V/ PI assay (figure 6.1c).    
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Figure 6.1 Validation of NCI-H929 human plasma cell line as a model of Gaucher 
disease. (a) Inhibition of glucocerebrosidase activity by addition of an irreversible 
inhibitor CBE at a range of concentrations, cultured for 4 days in triplicate. Activity 
measured by fluorometric assay, mean ± SEM plotted. (b) Viability of cell line when 
cultured for 4 days with CBE at a range of concentrations in triplicate. Viability 
measured by MTS assay, 100% calculated from the averaged absorbance values 
obtained from the standard condition. Mean ± SEM plotted. (c) Viability of cell line 
when cultured for 4 days with CBE at a range of concentrations. Viability measured 
by annexin V/ PI flow cytometric assay, minimum of 50,000 gated events per 
condition. 
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6.3.2 NCI-H929 increased osteoclast generation when cultured with 
control subject mononuclear cells. 
To assess the effect of plasma cells on osteoclast generation mononuclear cells 
were isolated from control and Gaucher subjects and cultured for 14 days in 
osteoclastogenic medium at a density of 1.25x105/cm2 on glass coverslips in wells of 
a 24 well plate. At day 14 NCI-H929 plasma cells were added to the culture for the 
remaining 7 days of culture at a density of 2x104 cells/well either in direct contact 
or physically separated by being pipetted into transwells comprising a membrane 
with a pore size of 0.4µm which permitted exchange of chemicals and proteins 
while preventing migration of plasma cells and thus contact between osteoclasts 
and plasma cells. To investigate the Gaucher model in this system osteoclastogenic 
medium was supplemented with CBE (100µM), medium replaced twice per week 
for the 21 days of culture. NCI-H929 plasma cells were also pre-treated with 100µM 
CBE for 14 days in 25cm2 tissue culture flasks prior to addition to the osteoclast 
cultures. As previously observed control subject osteoclast generation was 
significantly increased when the mononuclear cells were cultured in the presence of 
CBE (p = 0.035, figure 6.2a). Similarly, control subject osteoclast generation was 
significantly increased in the presence of plasma cells (p = 0.006) when in direct 
contact. However, culture of control subject mononuclear cells with 
osteoclastogenic medium, CBE and plasma cells in direct contact, while significantly 
increasing osteoclast generation compared to standard conditions (p = 0.037), did 
not increase osteoclast numbers beyond those obtained for the individual 
conditions i.e. CBE only, plasma cells only. Similarly, cultures with pre-treated 
plasma cells either in the absence or presence of CBE during the 21 days of culture 
resulted in significant increases in osteoclast numbers (NCI pre-treated p = 0.018, 
NCI pre-treated + CBE p = 0.021) but not above those attained for individual 
conditions suggesting inhibition of β-glucocerebrosidase in this plasma cell line does 
not lead to further enhancement of osteoclast generation. Cultures in which the 
NCI-H929 plasma cells were physically separated from the osteoclasts by transwell 
showed no change in osteoclast generation either in the absence (p = 0.252) or 
presence (p = 0.362) of CBE suggesting direct contact is necessary for increased 
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osteoclastogenesis. Interestingly, while marked increases in osteoclast numbers 
were observed for control subjects no significant increases in osteoclast numbers 
were obtained in Gaucher subject cultures for any of the mentioned conditions 
(figure 6.2b).  
 
Figure 6.2 Increased generation of control subject derived osteoclasts when co-
cultured in contact with plasma cell line NCI H929. Number of osteoclasts 
generated from (a) control subjects, (b) Gaucher subjects, adherent mononuclear 
cells after 21 days of culture on glass with irreversible β-glucocerebrosidase 
inhibitor CBE (100µM), NCI H929 plasma cells, NCI H929 plasma cells pre-treated 
with CBE (100µM) for 14 days or a combination there of. Plasma cells were cultured 
either in contact or in transwells at a cell density of 2x104 cells/well for the final 7 
days of culture. For (a) n = 7 per condition except for transwell where n = 4 per 
condition, (b) n = minimum of 12 per condition except for transwell where n = 5 per 
condition. Mean ± SEM plotted, *p ≤ 0.05, **p ≤ 0.01, paired t-tests.    
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6.3.3 Exogenous sphingolipids affected NCI-H929 cell numbers over a 
14-day culture. 
To investigate the effects of exogenous sphingolipids on plasma cell proliferation 
and survival an initial experiment was carried out in which the NCI-H929 plasma cell 
line was cultured at a density of 4x104 cells/ml with carrier (methanol 1:10,000 
dilution) or sphingolipid (1µM) in the absence or presence of CBE (100 µM). 
Samples were collected for up to 14 days and cell density was determined by phase 
contrast microscopy using a haemocytometer. After 3 days, plasma cell density was 
significantly decreased when cultured in the presence of sphingosine (p = 0.0038) 
sphingosine-1-phosphate (p < 0.0001) or glucosylsphingosine (p < 0.0001) when 
compared to carrier alone (figure 6.3a). Cultures with CBE and sphingolipids 
resulted in similar reductions in cell density (sphingosine p = 0.0001, sphingosine-1-
phosphate p = 0.0041, glucosylsphingosine p < 0.0001), figure 6.3b. Conversely, 
plasma cells cultured for 3 days in the presence of ceramide showed a significant 
increase in cell density (p = 0.0006) when compared to carrier alone. Again, a 
similar effect was observed for plasma cells cultured with CBE and ceramide (p = 
0.0004). Plasma cell density was also higher in day 3 cultures with glucosylceramide 
however these did not reach significance (glucosylceramide p = 0.17, 
glucosylceramide + CBE p = 0.205), figures 6.3c and 6.3d. After 7 days of culture 
both glucosylceramide and ceramide cultures resulted in significantly increased cell 
density (glucosylceramide p = 0.001, ceramide p = 0.0008, figures 6.4a and 6.4b). 
Although these conditions in the presence of CBE also showed an increase in cell 
density the increases were not statistically significant (glucosylceramide + CBE p = 
0.064, ceramide + CBE p = 0.121). Cultures with glucosylsphingosine continued to 
show decreased cell density after 7 days both in the absence or presence of CBE (p 
< 0.0001 for both, figure 6.4c). However, in the presence of CBE the decrease of cell 
density was significantly larger from days 7 to 14 compared to plasma cell cultures 
with glucosylsphingosine alone (day 7 p = 0.00019, day 10 p = 0.015, day 14 p = 
0.003, figure 6.4d). Interestingly, the effects observed for sphingosine and 
sphingosine-1-phosphate were not present from days 7 to 14 (data not shown) 
suggesting their effects may be short lived.  
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Figure 6.3 Addition of exogenous sphingolipids in culture affect the total cell 
number of NCI-H929 plasma cells after 3 days. (a, c) Plasma cell line cultured with 
carrier (methanol 1:10,000 dilution) or sphingolipids (1µM) for 3 days. (b, d) Plasma 
cell line cultured with carrier (methanol 1:10,000 dilution) or sphingolipids (1µM), 
all with irreversible β-glucocerebrosidase inhibitor CBE (100µM) for 3 days. Total 
cell number determined by haemocytometer. Initial cell density 4x104 cells/ml. 6 
cultures per condition. 100% calculated as the averaged cell number of carrier or 
carrier + CBE. Mean ± SEM plotted. **p ≤ 0.01, ***p ≤ 0.001, unpaired t-tests.    
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Figure 6.4 Addition of exogenous sphingolipids in culture affect the total cell 
number of NCI-H929 plasma cells over time. (a, b, c) Plasma cell line cultured with 
carrier (methanol 1:10,000 dilution) or sphingolipids (1µM) in the absence (white 
bars) or presence (black bars) of irreversible β-glucocerebrosidase inhibitor CBE 
(100µM) for 7 days. (d) Plasma cell line cultured with glucosylsphingosine (1µM), 
cell number counted at days 3, 7, 10 and 14 of culture. Total cell number 
determined by haemocytometer. Initial cell density 4x104 cells/ml. 6 cultures per 
condition. 100% calculated as the averaged cell number of carrier or carrier + CBE. 
Mean ± SEM plotted. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, unpaired t-tests.     
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6.4 Discussion 
Several studies have reported an increased risk of cancer in GD, in particular for 
multiple myeloma (MM) up to a standardised rate ratio of 51.1 (157). In addition a 
conditional knock out murine model of GD was found to have increased incidences 
of B-cell lymphoma and monoclonal gammopathy (575). In vitro osteoclast-plasma 
cell cultures were found to greatly increase the survival of plasma cells when in 
direct contact (580) and plasma cells were found to increase osteoclast generation 
by physical contact (581). Recent research has provided evidence that many 
sphingolipids are bioactive and are involved in migration, proliferation and survival 
of several cell types (582,583,589) including plasma cells (584). Several 
sphingolipids including sphingosine-1-phosphate have been linked to 
haematological cancers such as multiple myeloma for which S1P has been 
suggested to increase plasma cell migration and inhibit dexamethasone-induced 
apoptosis (584). These findings in conjunction with our own finding of increased in 
vitro osteoclast generation in GD cultures suggest that GD patient bone marrow 
might provide an environment which supports plasma cell proliferation and 
survival. Therefore, to investigate this a human myeloma plasma cell line NCI-H929 
was cultured with control or GD osteoclasts or with sphingolipids added to plasma 
cell culture medium. 
The results discussed below demonstrate for the first time how osteoclast 
generation from GD patient samples is affected by the presence of a myeloma 
plasma cell line and how plasma cell number may be affected by sphingolipids 
found to be elevated in GD patient plasma, namely glucosylsphingosine and 
glucosylceramide.  
 
The NCI-H929 plasma cell line increase osteoclastogenesis when cultured in 
contact.  
As published by previous groups co-culture of plasma cells with control monocytes 
leads to an increase in osteoclast generation when in contact (590,591). While a 
217 
 
similar increase of osteoclast generation was seen with addition of CBE to 
osteoclast cultures there appeared to be no additive effect as cultures with both 
CBE and plasma cells added to the osteoclast culture did not result in a further 
increase in osteoclast number. Similarly, no significant increase in osteoclast 
number was observed for GD subject monocytes co-cultured with plasma cells 
suggesting the effect of reduced β-glucocerebrosidase activity and plasma cell co-
culture stimulate osteoclastogenesis through the same signalling pathway. The lack 
of further increase when combined suggests that individually these factors 
maximally stimulate through this pathway, at least over the duration of the three 
weeks of culture, and therefore cannot further enhance the stimulation when 
combined. Pre-treatment of the plasma cell line with CBE prior to addition to 
osteoclast cultures again did not further enhance the osteoclast generation 
suggesting either that maximal stimulation had already been achieved by the 
plasma cell line alone or that reducing β-glucocerebrosidase activity in plasma cells 
does not affect their capability for stimulating osteoclast generation.  
 
Sphingolipids affect NCI-H929 plasma cell number. 
Certain sphingolipids such as ceramide (285,592), ceramide-1-phosphate (593), 
sphingosine-1-phosphate (278), glucosylsphingosine (272) and glucosylceramide 
(277,594), can affect cell proliferation, differentiation and apoptosis. In regards to 
the NCI-H929 myeloma plasma cell line a time course revealed that culture with 
exogenous sphingosine based lipids including sphingosine, sphingosine 1-phosphate 
and glucosylsphingosine resulted in lower total cell numbers after 3 days suggesting 
these sphingolipids either inhibited cell proliferation, induced apoptosis or a 
combination thereof. However, this effect was no longer present after 7 days of 
culture for sphingosine and sphingoine-1-phosphate suggesting this effect is short 
lived. In addition, no significant difference was observed between cell densities for 
any sphingolipids in the absence or presence of CBE over the 14-day time course 
with the exception of glucosylsphingosine. Previous MTS assays of MSC and SaOs-2 
cultures with glucosylsphingosine suggested it may reduce proliferation or cell 
viability. This finding is further supported with this plasma cell line as the plasma 
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cell density was consistently lower across the 14-day time course in the absence of 
CBE (~65% of standard conditions). In the presence of CBE this effect appears to 
have been exacerbated as cell density continued to decrease over time decreasing 
from 70% of standard condition at day 3 to 20% by day 14. Whether this is a direct 
consequence of reduced β-glucocerebrosidase activity or related to altered 
sphingolipid processing is unclear.  
Conversely, addition of ceramide resulted in a consistent increase in cell density 
over time of roughly 20% while culture with exogenous glucosylceramide induced a 
gradual increase of cell density, reaching statistical significance after 7 days of 
around 29% above standard conditions both in the absence or presence of CBE.  
Assessment of viability using annexin V/Pi staining showed no significant difference 
in the percentage of viable cells for any sphingolipids suggesting their effects are 
related to proliferation rather than viability. The contrasting effects of 
glucosylsphingosine, ceramide and glucosylceramide suggests the relative 
concentrations of these sphingolipids in the bone marrow would dictate whether 
their overall effect would be to inhibit or stimulate proliferation of plasma cells and 
possibly MSC’s.   
 
Limitations. 
The above findings have several limitations, firstly all of the data is generated using 
a cell line which may not be representative of the interaction of primary plasma 
cells with monocytes and osteoclasts or with sphingolipids. Secondly, these cells 
were cultured in vitro either in isolation or with osteoclasts which does not take 
into account the potential effects of other cells in the bone marrow such as 
mesenchymal stem cells, osteoblasts, osteocytes and T-cells. Thirdly, an assay to 
measure proliferation was not used therefore increased proliferation can only be 
implied, not confirmed. Fourthly, this culture system, as for all the monocultures 
performed in this project, is planar (2D) i.e. all the cells are cultured on a flat 
surface. In vivo, these cells would exist in a three-dimensional (3D) lattice. Fifthly, 
cell cultures were performed in static medium. This method can lead to a depletion 
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of nutrients and osteogenic factors and a build-up of waste products between 
medium changes. Finally, the plasma cells were cultured in the continuous presence 
of sphingolipids which may not be the case within the bone marrow. In addition, 
several sphingolipids would be present at varying concentrations within the bone 
marrow and not in isolation. 
 
Summary 
In summary, osteoclast cultures with the human plasma cell line NCI-H929 
increased osteoclast numbers in control cultures but not GD cultures. Culture of the 
plasma cell line with glucosylsphingosine reduced plasma cell number consistently 
over a 14-day period, further reduced when also cultured with CBE. Conversely, 
culture with glucosylceramide increased plasma cell numbers. These findings 
demonstrate firstly that sphingolipids may play a significant role in the survival and 
proliferation of plasma cells and the development of multiple myeloma in GD 
patients. Secondly, that quantitation of the sphingolipid composition of GD patient 
bone marrow may provide insight as to whether the microenvironment is 
stimulating plasma cell proliferation potentially increasing the likelihood of 
developing multiple myeloma as different sphingolipids have been shown both in 
this chapter and other publications to affect proliferation and apoptosis. 
 
 
 
 
 
 
 
 
 
220 
 
7. In vitro co-culture of osteoblasts, osteoclasts and 
plasma cells 
7.1 Introduction 
In the previous chapters, some of the cells present in the bone marrow, namely 
osteoclasts, osteoblasts and plasma cells have been investigated in relation to 
reduced β-glucocerebrosidase activity, GD specific therapies and exogenous 
sphingolipids. In order to characterise these cells, it was necessary to culture these 
cells in isolation for the majority of experiments. Historically, this has also been the 
case for the majority of research into the differentiation and function of human 
cells in the bone microenvironment primarily due to the fact that establishment of 
techniques enabling isolation and culture of these cell types, in particular osteoclast 
precursors from peripheral blood, are relatively recent. This in turn has required 
substantial research focusing on determining what defines a cell as being for 
example an osteoclast or osteoblast and from which cell lineage these cells 
differentiated. As a result, there is now a wealth of data in relation to what 
constitutes for example an osteoclast, that they originate from the 
monocyte/macrophage lineage and their pre-cursors are present in the peripheral 
blood prior to homing to the bone marrow where they mature to become active, 
resorbing osteoclasts (595). 
However, in the bone microenvironment these cells along with several other cell 
types co-exist in close proximity affecting each-others differentiation and function 
through both direct contact and secretion of several signalling molecules. One of 
the most common methods of research into these interactions is through use of 
murine models. Creation of murine gene knock-in or knock-out models both global 
and conditional have identified several genes and their respective proteins such as 
OPG (596) and MCSF (597) as being critical in the development and function of 
osteoblasts and osteoclasts. Murine models are also being used to investigate 
several cancers including breast (598) and prostate (599) in relation to bone 
metastasis and osteolytic disease in multiple myeloma (600). Similarly, several 
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murine models have been created to investigate cancers, Parkinson’s disease and 
bone disease in GD (272,575,601,602). However, due to the fact that many of these 
murine models including GBA null (603), N370S homozygous (555), RecNcil 
homozygous and L444P homozygous (604) die shortly after birth or in the case of 
models homozygous for V394L, D409H, D409V (555) do not mimic the human 
phenotype, the creation of conditional knock-out models in specific cell types has 
been required to recapitulate the phenotypes seen in Gaucher patients, especially 
in regards to bone disease. The conditional knock-out model which most closely 
mimics the bone disease observed in GD is the Mistry murine model in which exons 
8 to 11 are conditionally deleted, 2 days postnatal, in the cells of the hematopoietic 
and mesenchymal stem cell lineages (272). While this model provides essential data 
in regards to possible causes of bone disease in GD the fact that the exon deletions 
do not mimic mutations of Gaucher patients and that GBA1 activity is not reduced 
in all cell types means that the observed causes of bone disease in the murine 
model may not reflect the causes in the Gaucher patient. Therefore, it is necessary 
to develop in vitro models of the bone microenvironment using both human cells 
isolated from Gaucher patients and human cell lines to assess the data acquired 
from GD murine models. As a first step towards developing this model system 
osteoblasts, either the SaOs-2 cell line or MSC-derived, will be cultured with 
osteoclasts differentiated from a control subject and the human myeloma plasma 
cell line NCI-H929 in this chapter.   
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7.2 Aims and Hypotheses 
Aims: To understand the effects of interaction between osteoblasts, osteoclasts 
and plasma cells in Gaucher disease.  
Objectives: (1) To create an in vitro culture model which allows for the assessment 
of the interactions between osteoclasts, osteoblasts and plasma cells. 
 
Hypothesis 1: GD osteoblast-osteoclast interaction with plasma cells enhances 
overall bone loss.  
Rationale: Plasma cells have been shown to increase osteoclastogenesis and to 
secrete cytokines which induce osteoclast generation and function and to decrease 
differentiation of MSC’s into osteoblasts. In addition, MGUS patients have been 
reported to have lower BMD. 
Methods: Co-culture of primary and cell line osteoblasts with primary osteoclasts 
and myeloma plasma cell line. Mineralisation quantified by alizarin red staining and 
solubilisation.    
 
Hypothesis 2: GD osteoclasts can protect plasma cells from apoptosis. 
Rationale: Osteoclasts have been shown to secrete cytokines including IL-6 which 
stimulate plasma cell proliferation and survival. 
Methods: Co-culture of primary and cell line osteoblasts with primary osteoclasts 
and myeloma plasma cell line. Viability assessed by flow cytometry.  
 
 
 
223 
 
7.3 Results 
7.3.1  Co-culture of osteoblasts, osteoclasts and plasma cells. 
To partially recreate the bone microenvironment a model culture system was 
developed in which osteoblast, osteoclast and plasma cells were co-cultured in a 
number of combinations and conditions to assess their interactions and the 
possible effects of having reduced β-glucocerebrosidase activity on these 
interactions.  
In the first model culture system, the human osteoblast cell line SaOs-2 was 
cultured in previously optimised osteoblast medium D10-OB for 21 days to induce 
calcium deposition. Subsequently, for cultures which included osteoclasts, control 
subject mononuclear cells were isolated from peripheral blood and seeded at a 
density of 2.5x105 cells per well either on their own or on top of the SaOs-2 
monolayer in direct contact or physically separated by being seeded into transwells. 
All cells were cultured in osteoblast medium with osteoclastogenic cytokines MCSF 
and RANKL for the remainder of the culture. After a further 14 days, for cultures 
which included plasma cells, NCI-H929 cells were added at a density of 2x104 cells 
per well either on their own, on top of SaOs-2 only, osteoclasts only or SaOs-2 with 
osteoclasts. Again these were seeded either in direct contact or physically 
separated using transwells which were either devoid of other cell types or already 
contained maturing osteoclasts. All conditions were cultured in the absence or 
presence of 100µM CBE. All cultures were continued for a further 7 days (42 days in 
total) prior to assessment.  
All the above-mentioned combinations of cells involving the SaOs-2 cell line are 
shown in figure 7.1 showing the degree of calcium deposition as determined by 
alizarin red staining, solubilisation and quantitation. In order to aid visualisation of 
significant effects on calcium deposition the data in figure 7.1 has been sub-divided 
into graphs highlighting differences observed between certain conditions.  
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Figure 7.1 An in vitro model of some of the cellular interactions of the bone 
microenvironment. A human osteoblast cell line SaOs-2 was cultured in osteogenic 
medium for 21 days in the absence or presence of irreversible β-glucocerebrosidase 
inhibitor CBE (100µM) prior to addition of control subject adherent mononuclear 
cells at a density of 2.5x105 cells/well either in direct contact or physically separated 
by being seeded into transwells. Both cell types were cultured for a further 14 days 
in the presence of osteogenic medium comprised of both osteoblast and osteoclast 
differentiation and maturation factors (MCSF 25ng/ml, RANKL 30ng/ml). After these 
14 days NCI H929 plasma cells were added for the final 7 days of culture at a cell 
density of 2x104 cells/well. Total cell culture time for each combination was 42 
days. 9 cultures per condition. Quantification of calcium deposition by human 
osteoblast cell line SaOs-2 by absorbance spectrometry of alizarin red solubilised 
post staining of calcium on cell monolayer surface. Mean ± SEM plotted. Unpaired 
t-tests, significant differences shown in subsequent figures.  
 
7.3.2 Inhibition with CBE resulted in reduced calcium deposition. 
Comparison of conditions in the absence or presence of CBE showed that 
osteoblast cultures which included osteoclasts with or without plasma cells had 
significantly reduced calcium deposition in the presence of CBE when in direct 
contact with the osteoblasts (osteoblasts + osteoclasts vs osteoblasts + osteoclasts 
+ CBE p = 0.016, osteoblasts + osteoclasts + plasma cells vs osteoblasts + osteoclasts 
+ plasma cells + CBE p = 0.0136, figures 7.2a and 7.2b). Interestingly, the presence 
of osteoclasts when physically separated from the osteoblasts led to a statistically 
significant increase in calcium deposition (osteoblasts + osteoclasts in transwell + 
plasma cells vs osteoblasts + osteoclasts in transwell + plasma cells + CBE p = 
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0.0289, figure 7.2c) however when cultured with CBE this effect was abrogated 
suggesting CBE may affect calcium deposition in addition to increasing osteoclast 
resorption in the presence of plasma cells.  
 
7.3.3 Osteoclasts in contact with osteoblasts resulted in lower calcium 
deposition.  
When assessing the effect of osteoclasts on calcium deposition, cultures in which 
osteoclasts were in direct contact with the osteoblast monolayer and thus the 
calcium matrix had significantly reduced amounts of calcium compared to cultures 
with osteoclasts physically separated by transwell (osteoblasts + osteoclasts vs 
osteoblasts + osteoclasts in transwell p = 0.0498, osteoblasts + osteoclasts + plasma 
cells vs osteoblasts + osteoclasts in transwell + plasma cells p = 0.0214, figure 7.3). 
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Figure 7.2 Addition of CBE to osteoblast cultures reduced calcium deposition. 
Human osteoblast cell line SaOs-2 was cultured in osteogenic medium for 21 days in 
the absence or presence of irreversible β-glucocerebrosidase inhibitor CBE (100µM) 
prior to addition of (a) control subject adherent mononuclear cells at a density of 
2.5x105 cells/well. Both cell types were cultured for a further 21 days in the 
presence of osteogenic medium comprising of both osteoblast and osteoclast 
differentiation and maturation factors in the absence (white bars) or presence 
(black bars) of irreversible β-glucocerebrosidase inhibitor CBE (100µM). (b) Cultured 
as in (a) but with NCI-H929 plasma cells (2x104 cells/well) added after 14 days of 
culture with the adherent mononuclear cells, 35 days into the overall culture. All 
three cell types were co-cultured for a further 7 days in the same medium in the 
absence or presence of CBE. (c) Cultured as in (b) except the control subject 
adherent mononuclear cells were physically separated from both osteoblasts and 
plasma cells by being seeded into transwells. 9 cultures per condition. 
Quantification of calcium deposition by human osteoblast cell line SaOs-2 by 
absorbance spectrometry of alizarin red solubilised post staining of calcium on cell 
monolayer surface. Mean ± SEM plotted. *p ≤ 0.05, unpaired t-tests.  
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Figure 7.3 Osteoclasts require contact to reduce calcium deposition. Human 
osteoblast cell line SaOs-2 was cultured in osteogenic medium for 21 days in the 
absence or presence of irreversible β-glucocerebrosidase inhibitor CBE (100µM) 
prior to addition of (a) control subject adherent mononuclear cells at a density of 
2.5x105 cells/well physically separated from osteoblasts by being seeded into 
transwells. Both cell types were cultured for a further 21 days in the presence of 
osteogenic medium comprising of both osteoblast and osteoclast differentiation 
and maturation factors. Osteoblasts cultured on their own, labelled OB, were 
cultured for a total of 42 days. (b) Cultured as in (a) except control subject adherent 
mononuclear cells were added either in direct contact or physically separated by 
transwell. (c) Cultured as in (b) but with NCI-H929 plasma cells (2x104 cells/well) 
added after 14 days of culture with the adherent mononuclear cells, 35 days into 
the overall culture. All three cell types were co-cultured for a further 7 days in the 
same medium. 9 cultures per condition. Quantification of calcium deposition by 
human osteoblast cell line SaOs-2 by absorbance spectrometry of alizarin red 
solubilised post staining of calcium on cell monolayer surface. Mean ± SEM plotted. 
*p ≤ 0.05, unpaired t-tests.  
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7.3.4 Myeloma plasma cells increase calcium deposition when in 
contact with osteoblast cells. 
Osteoblast-osteoclast co-cultures in which plasma cells were in direct contact with 
the osteoblast monolayer resulted in significantly higher calcium deposition 
compared to cultures in which the plasma cells were physically separated 
(osteoblasts + osteoclasts in transwell + plasma cells vs osteoblasts + osteoclasts + 
plasma cells both in transwell p = 0.04, osteoblasts + osteoclasts in transwell + 
plasma cells vs osteoblasts + osteoclasts + plasma cells in transwell p = 0.02, figures 
7.4a and 7.4b). However, the difference in deposition in figure 7.4b may also be due 
to direct contact between osteoblasts and osteoclasts. The presence of osteoclasts 
in the culture when separated from osteoblasts led to a significantly higher amount 
of calcium deposition compared to osteoblasts cultured in isolation, p = 0.0004, 
which was further increased in the presence of plasma cells, p = 0.0001 (figure 
7.4c). Suggesting there may be signalling factors from both plasma cells and 
osteoclasts which may increase calcium deposition.  
 
7.3.5 Addition of CBE increases the effect observed by different cell 
types on calcium deposition. 
Similar effects were observed in the presence of CBE. Osteoblast cultures in which 
osteoclasts were in direct contact again showed reduced calcium deposition 
however statistical significance was only achieved when plasma cells were also in 
direct contact (osteoblasts + CBE vs osteoblasts + osteoclasts + plasma cells + CBE p 
= 0.0398, figure 7.5a). Cultures in which osteoclasts were separated from 
osteoblasts by transwell led to significantly increased calcium deposition 
(osteoblasts + CBE vs osteoblasts + osteoclasts in transwell + CBE p = 0.0005, 
osteoblasts + osteoclasts + CBE vs osteoblasts + osteoclasts in transwell + CBE p = 
0.0005, figures 7.5b and 7.5c). When all three cell types were in direct contact 
calcium deposition was significantly lower than when either plasma cells or 
osteoclasts were physically separated from the osteoblast monolayer as shown in 
229 
 
figure 7.5d. As it has been previously shown that direct contact between plasma 
cells and mononuclear cells is required for increased osteoclast generation it would 
be logical to conclude that direct contact between these cells and the calcium 
matrix would result in lower amounts of calcium overall.  
 
 
Figure 7.4 Myeloma plasma cells increase calcium deposition when in contact with 
osteoblast cells. Human osteoblast cell line SaOs-2 was cultured in osteogenic 
medium for 21 days in the absence or presence of irreversible β-glucocerebrosidase 
inhibitor CBE (100µM) prior to addition of (a) control subject adherent 
mononuclear cells at a density of 2.5x105 cells/well physically separated from 
osteoblasts by being seeded into transwells. Both cell types were then cultured for 
a further 14 days in the presence of osteogenic medium comprising of both 
osteoblast and osteoclast differentiation and maturation factors. After these 14 
days NCI H929 plasma cells were added for the final 7 days of culture at a cell 
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density of 2x104 cells/well either in direct contact or physically separated by 
addition to transwells already containing the adherent mononuclear cells.              
(b) Cultured as in (a) except the transwells contained only plasma cells. (c) Cultured 
as in (a) except plasma cells were cultured in direct contact with osteoblasts.  9 
cultures per condition. Quantification of calcium deposition by human osteoblast 
cell line SaOs-2 by absorbance spectrometry of alizarin red solubilised post staining 
of calcium on cell monolayer surface. Mean ± SEM plotted. *p ≤ 0.05, ***p ≤ 0.001, 
unpaired t-tests.  
 
 
Figure 7.5 Addition of CBE increases the effect observed by different cell types on 
calcium deposition. Human osteoblast cell line SaOs-2 was cultured in osteogenic 
medium D10-OB for 21 days in the presence of irreversible β-glucocerebrosidase 
inhibitor CBE (100µM) prior to addition of (a) control subject adherent 
mononuclear cells at a density of 2.5x105cells/well. Both cell types were cultured 
for a further 14 days in the presence of osteogenic medium comprising of both 
osteoblast and osteoclast differentiation and maturation factors and irreversible β-
glucocerebrosidase inhibitor CBE (100µM). NCI-H929 plasma cells (2x104 cells/well) 
were added after a further 14 days of culture with the adherent mononuclear cells, 
35 days into the overall culture. All three cell types were co-cultured for a further 7 
days in the same medium. (b) Cultured as in (a) except control subject adherent 
mononuclear cells were physically separated by being seeded into transwells and 
without plasma cell addition. (c) Cultured as in (b) except adherent mononuclear 
cells were cultured either in direct contact or physically separated by being seeded 
into transwells. (d) Cultured as in (c) except control subject adherent mononuclear 
cells and plasma cells were either added directly or physically separated by culture 
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in transwell. 9 cultures per condition. Quantification of calcium deposition by 
human osteoblast cell line SaOs-2 by absorbance spectrometry of alizarin red 
solubilised post staining of calcium on cell monolayer surface. Mean ± SEM plotted. 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, unpaired t-tests.  
 
7.3.6 Plasma cell viability is greatly increased when cultured in contact 
with osteoclasts. 
At the end of the 42 day cultures the NCI-H929 plasma cells, added to the cultures 
for the final seven days, were harvested and assessed for viability by flow 
cytometry using annexin V/Pi staining with a minimum of 50,000 gated events per 
condition. Comparison of all conditions is shown in figure 7.6a in order of increasing 
percentage viability. Unexpectedly, direct contact between plasma cells and the 
osteoblast cell line SaOs-2 resulted in a substantial decrease in plasma cell viability 
decreasing from 64.3% when cultured in isolation to 5.1% when in contact with the 
osteoblasts. This effect was largely reversed when the plasma cells were physically 
separated by transwell, figure 7.6b. The presence of osteoclasts in the cultures also 
appeared to affect plasma cell viability, again mediated through direct contact. In 
cultures where osteoclasts were separated from osteoblasts and plasma cells by 
transwell viability was again markedly lower at 3.9% without CBE and 5.6% with 
CBE. Culture of plasma cells in contact with both osteoblasts and osteoclasts 
partially rescued plasma cell viability increasing to 23.5% without CBE and 26.9% 
with CBE. Separation of plasma cells from the osteoblasts and osteoclasts by 
transwell returned viability to a similar percentage observed for plasma cells 
cultured in isolation (64.6% without CBE, 62.3% with CBE) while the most 
favourable conditions appeared to be when plasma cells were cultured in direct 
contact with osteoclasts but separated from the osteoblasts, viability reaching 
85.5% without CBE and 85.9% with CBE, figure 7.6c. Suggesting osteoclasts may 
play a key role in plasma cell viability in the bone marrow microenvironment. 
Inclusion of the irreversible inhibitor CBE did not noticeably affect plasma cell 
viability in any of the co-culture combinations. 
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Figure 7.6 Plasma cell viability is greatly increased when cultured in contact with 
osteoclasts. (a, b, c) Human osteoblast cell line SaOs-2 was cultured in osteogenic 
medium D10-OB for 21 days in the absence or presence of irreversible β-
glucocerebrosidase inhibitor CBE (100µM) prior to addition of control subject 
adherent mononuclear cells at a density of 2.5x105cells/well either in direct contact 
or physically separated by being seeded into transwells. Both cell types were 
cultured for a further 14 days in the presence of osteogenic medium comprising of 
both osteoblast and osteoclast differentiation and maturation factors. After these 
14 days NCI H929 plasma cells were added for the final 7 days of culture at a cell 
density of 2x104 cells/well. Total cell culture time for each combination was 42 
days. Plasma cells were also cultured either in isolation or for the final 7 days of a 
21 day culture with control subject adherent mononuclear cells in osteogenic 
medium comprised of both osteoblast and osteoclast differentiation and 
maturation factors. Plasma cells were removed from culture at day 42 and 
percentage viability determined by annexin V/ Pi assay. (b, c) Selected data from 
(a). Minimum of 50,000 gated events per condition. All conditions in triplicate. 
Mean ± SEM plotted. 
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7.3.7 Plasma cells reduce calcium deposition by control subject 
osteoblasts. 
Further development of the culture system to partially recreate the bone 
microenvironment led to cultures with primary human mesenchymal stem cells 
(MSC’s) from a control subject differentiated into osteoblasts in place of the human 
osteoblast cell line SaOs-2. This system required culturing the MSC’s in optimised 
osteoblast medium A10-OB for 5 weeks prior to the addition of control subject 
mononuclear cells and plasma cell line NCI-H929. The remaining culture protocol 
remained the same as with the SaOs-2 cell line with an overall culture duration of 
56 days. The degree of calcium deposition, determined by alizarin red staining, 
solubilisation and quantitation for all combinations, again the same as those used 
for the SaOs-2 co-cultures, is shown in figure 7.7. In comparison to cultures with 
SaOs-2, physical contact between osteoblasts and osteoclasts led to a reduction in 
calcium deposition in the absence of CBE (20.7% decrease) however this decrease 
was not statistically significant. Cultures in which osteoclasts were in physical 
contact also had lower calcium deposition when compared to cultures with 
osteoclasts in transwell but again these differences were not statistically significant. 
Similarly, osteoblasts cultured with NCI-H929 plasma cells either in contact or 
transwell resulted in decreased calcium deposition in the absence of CBE (24.5% 
and 23.8% respectively, figure 7.7a) but again this decrease was not statistically 
significant in either case. However, this reduction in calcium deposition appears to 
be rescued in the presence of osteoclasts when the osteoclasts are physically 
separated by culture in transwell. Cultures in which plasma cells were in contact 
with osteoblasts with osteoclasts in transwell had significantly higher calcium 
deposition than cultures with osteoblast and plasma cells only both in the absence 
(48.7% increase, p = 0.02) or presence of CBE (40.4% increase, p = 0.01), figure 7.7b. 
Calcium deposition was also higher when plasma cells and osteoclasts were both 
physically separated from the osteoblasts by co-culture in transwell compared to 
osteoblasts cultured with plasma cells only either when the plasma cells were 
cultured in contact (44.9% increase, p = 0.007) or transwell (46.2%, p = 0.004) with 
osteoblasts, figure 7.7c.  
234 
 
 
Figure 7.7 Plasma cells reduce calcium deposition by control subject osteoblasts, 
rescued by osteoclasts in transwell. Control subject 2186 MSC were differentiated 
into active osteoblasts by culture in osteogenic medium A10-OB for 35 days in the 
absence (white columns) or presence (black columns) of irreversible β-
glucocerebrosidase inhibitor CBE (100µM) prior to addition of (a, b, c) control 
subject adherent mononuclear cells at a density of 2.5x105 cells/well either in direct 
contact or physically separated by being seeded into transwells. Both cell types 
were cultured for a further 14 days in the presence of osteogenic medium 
comprising of both osteoblast and osteoclast differentiation and maturation 
factors. After these 14 days NCI H929 plasma cells were added either in direct 
contact or physically separated by being seeded into transwells for the final 7 days 
of culture at a cell density of 2x104cells/well. Total cell culture time for each 
combination was 56 days. (b, c) selected data from (a). A minimum of 6 cultures per 
condition. Quantification of calcium deposition by MSC-derived osteoblasts 
determined by absorbance spectrometry of alizarin red solubilised post staining of 
calcium on cell monolayer surface. Mean ± SEM plotted.  
 
 
235 
 
7.3.8 Addition of CBE increases the effect of osteoclast related 
reduction of calcium deposition by osteoblasts. 
The same experimental approach was used for MSC’s isolated from the bone 
marrow of a multiple myeloma subject, sample 2167. While no significant 
differences were observed for any combination of cells without CBE, the addition of 
CBE to the culture system did result in some notable differences. Cultures in which 
osteoblasts and osteoclasts were in direct contact showed no significant differences 
in calcium deposition without CBE (p = 0.45) however in the presence of CBE 
calcium deposition was deceased by over 30% compared to osteoblasts cultured in 
isolation (p = 0.022). While significance was not obtained when comparing 
osteoblasts cultured in isolation with CBE and osteoblasts cultured in direct contact 
with osteoclasts with CBE (p = 0.12). Similarly, osteoblasts cultured in direct contact 
with osteoclasts in the presence of CBE resulted in significantly lower calcium 
deposition compared to osteoblast-osteoclast cultures without CBE (p = 0.044), 
figure 7.8b. The inclusion of plasma cell line NCI-H929, physically separated by 
transwell, in the osteoblast-osteoclast cultures also resulted in significantly lower 
calcium deposition (p = 0.035) compared to osteoblasts cultured in isolation, figure 
7.8c. For all conditions the degree of calcium deposition in the presence of CBE was 
lower than that obtained without CBE. Although statistical significance was not 
attained for many of these combinations it may be worth increasing the number of 
cultures with this subjects MSC’s and with other subjects to determine whether this 
general decrease is consistent and a potential consequence of reduced β-
glucocerebrosidase activity. 
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Figure 7.8 Addition of CBE increases the effect of osteoclast related reduction of 
calcium deposition by osteoblasts. Multiple myeloma subject 2167 MSC were 
differentiated into active osteoblasts by culture in osteogenic medium A10-OB for 
35 days in the absence or presence of irreversible β-glucocerebrosidase inhibitor 
CBE (100µM) prior to addition of (a, b, c) control subject adherent mononuclear 
cells at a density of 2.5x105cells/well either in direct contact or physically separated 
by being seeded into transwells. Both cell types were cultured for a further 14 days 
in the presence of osteogenic medium comprising of both osteoblast and osteoclast 
differentiation and maturation factors. After these 14 days NCI H929 plasma cells 
were added either in direct contact or physically separated by being seeded into 
transwells for the final 7 days of culture at a cell density of 2x104cells/well. Total 
cell culture time for each combination was 56 days. (b, c) selected data from (a).      
9 cultures per condition. Quantification of calcium deposition by MSC-derived 
osteoblasts determined by absorbance spectrometry of alizarin red solubilised post 
staining of calcium on cell monolayer surface. Mean ± SEM plotted. *p ≤ 0.05, 
unpaired t-tests.  
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7.3.9 NCI-H929 viability was not affected by culture with MSC derived 
osteoblasts, osteoclasts or combinations thereof.  
At the end of the 56 day cultures the NCI-H929 plasma cells, added to the cultures 
for the final seven days, were harvested and assessed for viability by flow 
cytometry using annexin V/Pi staining with a minimum of 50,000 gated events per 
condition. Comparison of all conditions is shown in figures 7.9a and b in order of 
increasing percentage viability for control subject 2186 and MM subject 2167 
respectively. No statistically significant differences in viability were observed 
between any co-culture cell combination either in the absence or presence of CBE 
or when comparing cultures with or without CBE with the same cell components 
and arrangements.  
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Figure 7.9 Plasma cell viability is unaffected when cultured in contact with primary 
osteoblasts. (a, b) Human MSC from (a) control subject 2186 and (b) MM subject 
2167 were cultured in osteogenic medium A10-OB for 35 days in the absence or 
presence of irreversible β-glucocerebrosidase inhibitor CBE (100µM) prior to 
addition of control subject adherent mononuclear cells at a density of 2.5x105 
cells/well either in direct contact or physically separated by being seeded into 
transwells. Both cell types were cultured for a further 14 days in the presence of 
osteogenic medium comprising of both osteoblast and osteoclast differentiation 
and maturation factors. After these 14 days NCI H929 plasma cells were added for 
the final 7 days of culture at a cell density of 2x104 cells/well. Total cell culture time 
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for each combination was 56 days. Plasma cells were also cultured either in 
isolation or for the final 7 days of a 21-day culture with control subject adherent 
mononuclear cells in osteogenic medium comprised of both osteoblast and 
osteoclast differentiation and maturation factors. Plasma cells were removed from 
culture at day 56 and percentage viability determined by annexin V/ Pi assay. 
Minimum of 50,000 gated events per condition. All conditions in triplicate. Mean ± 
SEM plotted. 
 
7.4 Discussion 
In the bone microenvironment osteoblasts, osteoclasts and plasma cells, along with 
several other cell types, co-exist in close proximity affecting each-others 
differentiation and function through both direct contact and secretion of several 
signalling molecules. One of the most common methods of research into these 
interactions is through use of murine models. The murine model which most closely 
mimics the bone disease observed in GD is the Mistry model in which exons 8 to 11 
are conditionally deleted, 2 days postnatal, in the cells of the hematopoietic and 
mesenchymal stem cell lineages (272). While this model provides essential data in 
regards to possible causes of bone disease in GD the fact that the exon deletions do 
not mimic mutations of Gaucher patients and that GBA1 activity is not reduced in 
all cell types means that the observed causes of bone disease in the murine model 
may not reflect the causes in the Gaucher patient. Therefore, it is necessary to 
develop in vitro models of the bone microenvironment using both human cells 
isolated from Gaucher patients and human cell lines to further assess the data 
acquired from GD murine models. As a first step towards developing this model 
system osteoblasts, either the SaOs-2 cell line or MSC-derived, were cultured with 
osteoclasts differentiated from a control subject and the human myeloma plasma 
cell line NCI-H929 in vitro.  
For the first time a human cell based model of the GD bone microenvironment has 
been developed to investigate the interactions between osteoclasts, osteoblasts 
and plasma cells in the GD bone marrow microenvironment.  
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SaOS-2 co-cultures.  
Culture with CBE led to a significantly lower amount of calcium deposition when 
SaOs-2 cells were co-cultured with osteoclasts with or without plasma cells. This 
supports previous findings that CBE increases osteoclast generation which in turn 
would result in increased bone matrix degradation and resorption resulting in 
overall lower calcium deposition. However, the same could be expected of cultures 
in which all three cell types were in contact in the absence of CBE as previous data 
showed that plasma cells in contact with monocytes also increase osteoclast 
generation. This was not the case as the triple culture with all cells in direct contact 
produced a small but not significant increase in calcium deposition in comparison to 
osteoblasts alone. However, this effect may have been negated as subsequent data 
showed that culture of the plasma cell line in contact with the SaOS-2 cells resulted 
in substantial plasma cell apoptosis of ~95%. 
A potentially interesting finding is that cultures in which osteoclasts were physically 
separated from the SaOs-2 resulted in higher amounts of calcium deposition in 
comparison to SaOs-2 on their own or co-cultured with osteoclasts in contact both 
in the absence or presence of plasma cells. This finding may suggest that 
osteoclasts and their precursors produce factors which stimulate osteoblast 
maturation and activity when not in physical contact, acting as coupling factors 
mediating bone metabolism.  
Plasma cells appear to increase calcium deposition when in physical contact with 
SaOs-2 cells though in most cases the presence of plasma cells increases calcium 
deposition relative to SaOs-2 alone whether they are in contact or not. These 
findings suggest that while plasma cells are known to stimulate osteoclastogenesis 
resulting in the severe bone disease suffered by the majority of multiple myeloma 
patients they may also increase the activity of osteoblast mediated mineralisation 
though probably to a much lesser extent as the observed increases are quite small 
reaching a maximum of a 10.5% increase for SaOs-2 cultured in contact with plasma 
cells with osteoclasts physically separated. Again, this result may have been 
affected by the apoptosis of the plasma cells when cultured in contact with the 
SaOs-2 cells.  
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It should also be noted that in the majority of conditions the increase or decrease in 
calcium deposition was relatively small. This may be due to the fact that these 
cultures are with the SaOs-2 cell line which may be less sensitive to external factors 
due to its high rates of proliferation and calcium deposition in comparison to MSC 
derived osteoblast cultures. 
 
Plasma cell viability is markedly reduced when in contact with SaOs-2 cells. 
Unexpectedly, co-culture of NCI-H929 myeloma plasma cells with the SaOs-2 
osteoblast-like cell line induced substantial apoptosis in the plasma cells of around 
95%. An effect not observed in MSC derived osteoblast co-cultures. This effect 
appears to be contact dependent with the percentage of viable plasma cells 
equivalent to monocultures when separated from the SaOs-2 by transwell. The 
cause of this apoptosis was not investigated but it demonstrates potentially 
important differences between this cell line and primary cells suggesting that while 
cell lines are useful in regards to availability, ease of generating large cell numbers 
for culture and eliminates sample variation they may not faithfully replicate the 
function of primary cells. Therefore, if possible primary cells should be used to 
confirm any findings based on cell lines especially when they are involved in 
systems which require such interdependent interaction between several cell types.  
Although this outcome appears to be an anomaly of this cell line it did provide an 
opportunity to investigate the interaction between osteoclasts and plasma cells in 
regards to plasma cell survival. Co-cultures in which osteoclasts were present 
increased the percentage of viable plasma cells with partial rescue of viability when 
all three cell types were in contact but a much more substantial effect when 
osteoclasts were in contact with the plasma cells in a transwell. As there was little 
difference in viability between cultures in the presence or absence of osteoclasts in 
contact with the SaOs-2 when plasma cells were cultured in transwell it would 
suggest this pro-survival effect is also contact dependent as the plasma cell cultures 
with the highest viability were those in which osteoclasts were in direct contact 
with plasma cells but not cultured with or not in contact with the SaOs-2 cells. This 
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finding suggests there may be a positive feedback loop between osteoclast 
generation and plasma cell survival in which plasma cells increase osteoclast 
numbers which in turn increase plasma cell survival. Increased plasma cell survival 
increases plasma cell numbers which in turn increases the pro-osteoclastogenic 
stimuli leading to a further increase in osteoclast generation etc.  
Addition of CBE to cultures did not lead to any significant differences suggesting 
deficiency in β-glucocerebrosidase activity does not affect the SaOs-2 pro-apoptotic 
or osteoclast pro-survival effect on the plasma cell line or affect plasma cell viability 
directly.  
 
MSC-derived osteoblast co-cultures.  
Similarities were observed in MSC derived osteoblast co-cultures to SaOs-2 co-
cultures. Osteoclasts in contact with osteoblasts again resulted in a decrease in 
calcium deposition though this did not reach significance for control or MM derived 
osteoblast co-cultures despite the decreases in many cases being greater than in 
SaOs-2 co-culture, a decrease of up to 20.7% in the control culture without 
inhibitor. Addition of CBE enhanced this osteoclast effect in MM co-culture 
resulting in a statistically significant difference but not in control culture.  
In contrast to SaOs-2 co-cultures control MSC-derived osteoblasts cultured with 
plasma cells resulted in lower calcium deposition instead of higher calcium 
deposition, suggesting osteoblast activity may be inhibited by plasma cells. 
However, as seen in the SaOs-2 co-cultures, inclusion of osteoclasts when physically 
separated in MSC-osteoblast cultures reversed the effect of the plasma cells. This 
finding may add further support to the suggestion that osteoclasts and their 
precursors produce factors which stimulate osteoblast maturation and activity 
when not in physical contact, acting as coupling factors mediating bone 
metabolism.  
However, while culture with primary cells appears preferable to cell lines certain 
limitations have been noted. Firstly, there was greater variation encountered with 
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primary cell MSC-osteoblast cultures compared to SaOs-2 cultures for both control 
and MM samples in regards to calcium deposition. Consequently, to confirm these 
results these cultures would need to be repeated with several subject samples with 
a number of replicates per sample. Generation of sufficient cells and the duration of 
these cultures may make such requirements very time consuming and possibly 
impractical suggesting alternative systems may need to be developed including 
immortalisation of primary MSC’s, ensuring cellular characteristics are not altered 
in the process. The clear differences in cellular interactions of SaOs-2 and MSC with 
other cell types would suggest that use of the SaOs-2 cell line in co-cultures may 
not provide relevant data for modelling the bone microenvironment.  
Unlike in SaOs-2 cultures, plasma cell viability was not affected by co-culture with 
MSC derived osteoblasts. In this system, the very high percentage of viable plasma 
cells may mask the pro-survival effects of osteoclasts in the bone 
microenvironment, preventing assessment of the potential pro-survival aspect of 
culture with osteoclasts. A potential solution may be to use primary plasma cells 
instead of a cell line as they are likely to be more susceptible to apoptosis than a 
cell line. 
 
Limitations. 
This model culture system has several limitations. Firstly, mature osteoblasts and 
osteoclasts do not co-exist in direct contact with each other in the bone 
microenvironment (294). Secondly, this culture system, as for all the monocultures 
performed in this project, is planar (2D) i.e. all the cells are cultured on a flat 
surface. In vivo, these cells would exist in a three-dimensional (3D) lattice. Thirdly, 
cell cultures were performed in static medium. This method can lead to a depletion 
of nutrients and osteogenic factors and a build-up of waste products between 
medium changes. In addition, all findings from primary co-cultures were based on 
only one control sample and one myeloma sample.  
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Summary. 
In summary, data from cultures involving the human osteoblast cell line SaOs-2 
indicated osteoclasts and plasma cells may act as coupling factors as calcium 
deposition by the SaOS-2 cells was increased when in the presence of the myeloma 
plasma cell line and when cultured with osteoclasts when not in physical contact. In 
addition, culture of the plasma cell line NCI-H929 in contact with the SaOs-2 cells 
resulted in substantial apoptosis of the plasma cells. This effect was partially 
rescued in the presence of osteoclasts with maximal effect attained when 
osteoclasts were in contact with plasma cells but separated from the SaOs-2 cells. 
When combined with data from the previous chapter which showed plasma cells 
can increase osteoclast generation it may indicate a positive feedback loop of 
plasma cell survival and osteoclast generation. While osteoclast generation was not 
further enhanced by plasma cells in GD osteoclast cultures the high number of 
osteoclasts present may still have a significant effect on plasma cell numbers. 
However, MSC osteoblast cultures did not induce a measurable increase in 
apoptosis in the human plasma cell line demonstrating that the use of the SaOs-2 
cell line may not be representative of in vivo primary cell interactions. Due to the 
lack of availability of alternative mature human osteoblast cell lines co-culture 
systems with human primary MSC’s or immortalised MSC’s appears to be the most 
accurate model of the in vivo environment. 
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8. Main discussion 
GD is an inherited disorder in which mutations in the GBA1 gene lead to deficient β-
glucocerebrosidase activity and the consequent accumulation of its substrate 
glucosylceramide (46). GD is typically divided into three types distinguished by the 
presence of neurological features in types 2 and 3 and an absence of such features 
in type 1 (91), the most common form of GD comprising ~94% of the GD patient 
population (63). Common features for type 1 GD include hepatosplenomegaly, 
cytopenias and bone disease (120). Present in around 84% of GD patients (84,85) 
bone disease can manifest in a number of forms ranging from bone loss including 
osteopenia and osteonecrosis to abnormal bone remodelling in the form of 
Erlenmeyer flask formation of the femoral head (101). Historically the cause of 
bone disease in GD has been attributed to bone marrow infiltration of foamy 
macrophages, known as ‘Gaucher cells’ (605). In GD macrophages are the primary 
storage cell due to their function as phagocytic cells, degrading effete red blood 
cells, cell debris and microbes, providing an additional source of substrate (47). GD 
bone disease can be partially explained by bone marrow infiltration of Gaucher 
cells, hypothesised to cause displacement of marrow cells to the periphery (123) 
which may lead to marrow infarcts including osteonecrosis of joints (122) and to 
elicit an inflammatory response which may affect bone metabolism (122). However, 
the range of severity and the variety of types of bone disease found in GD patients 
indicate the involvement of several mechanisms which cannot be explained by 
Gaucher cell infiltration alone.  
In this project we set out to investigate the unanswered question of the role of 
osteoclasts in GD and the interaction of osteoclasts with other cells in the bone 
marrow given the recent publications of GD animal models which have stated that 
osteoblasts may be the affected cells in the GD bone marrow. 
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Osteoclasts in GD. 
Current knowledge of the cellular contributions to bone disease in GD were very 
limited. Since this projects instigation research by Mucci et al published in 2012 
(525) demonstrated that soluble factors produced by CBE-treated PBMC’s induced 
differentiation of osteoclasts precursors into mature and active osteoclasts. In 
support of this, results produced in this research project have shown that 
monocytes isolated from the peripheral blood of Gaucher patients generate more 
osteoclasts which are larger, have more nuclei and are more active in comparison 
to control subject osteoclasts. These finding being subsequently confirmed in a 
publication by Mucci et al in 2015 (134), following our publication in 2013 (526), 
which also reported that PBMC’s isolated from type 1 GD patients generated more 
osteoclasts than controls. In addition, this effect was partially replicated by 
inhibiting control monocyte β-glucocerebrosidase with CBE which again led to 
increased osteoclast generation, size and activity indicating the enhanced 
osteoclastogenesis and activity is directly related to a deficiency in β-
glucocerebrosidase activity.  
Cultures which included exogenous glucosylceramide further enhanced 
osteoclastogenesis and indicate that elevated levels of this sphingolipid both intra 
and extra-cellularly due to this enzyme deficiency may contribute to the enhanced 
osteoclast generation in vitro. This conclusion is further supported by evidence in 
this thesis that GD-specific therapies intended to reduce substrate burden either by 
substrate degradation or synthesis inhibition reduced osteoclast generation in GD 
osteoclast cultures demonstrating that not only can the increased 
osteoclastogenesis observed in GD cultures be induced but also reversed.  
 
In vitro effects of GD-specific therapy on osteoclastogenesis. 
The finding that osteoclast generation in our in vitro culture system is responsive to 
GD-specific therapies suggests that this assay may be useful for initial studies of 
potential therapies for GD and to determine their possible effectiveness in treating 
bone disease. Indeed, our cultures which included ambroxol hydrochloride 
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demonstrated that it may reduce osteoclast generation in vivo but also 
demonstrated that unlike the majority of the GD-specific therapies ambroxol 
affected control osteoclast generation to a very similar degree suggesting its affect 
may be via a different pathway to the GD-specific therapies.  
Further investigation into the function of ambroxol and other chaperone therapies 
on osteoclastogenesis via this system may prove useful to define their mode of 
action and whether this is of particular benefit in regards to GD bone disease. Such 
investigations may include western blot of lysed osteoclast cultures targeting 
pathways known to stimulate osteoclast precursor fusion and osteoclast 
maturation e.g. OC-STAMP (332,606), DC-STAMP (331), RANKL/RANK/OPG (342), c-
fms (334,337) pathways and mass spectrometry of the sphingolipid content of 
osteoclasts pre and post exposure to GD-specific therapies to assess which 
sphingolipids are predominantly affected and whether these correlate with our 
findings of the potential effects of sphingolipids on osteoclast generation.   
The potential utility of the osteoclast culture system is further supported by 
correlations made in chapter 4 which found that the increased osteoclast number 
and average number of nuclei per osteoclast correlated with GD patients with 
active bone disease and that osteoclast number and activity correlated with 
individual patient osseous manifestations in the majority of cases. In addition, 
higher osteoclast generation also correlated with bone pain and anaemia, identified 
as a risk factor for avascular necrosis in Gaucher patients (529). These findings 
suggest accumulation of glucosylceramide is relevant to the pathology of GD, that 
osteoclasts may play a major role in the pathology of bone disease in GD and that 
therefore in vitro culture of patient osteoclasts may be a useful tool for identifying 
patients with high osteoclast numbers and activity in vitro which may indicate a 
greater likelihood of developing bone complications later in life.  
However, these findings, especially in regards to individual patient correlation, are 
based on a relatively small cohort. To confirm these findings a much larger cohort 
would be required which would include both patients with and without active bone 
disease to determine a potential cut off for osteoclast number and activity. A 
second study would also be required which would include younger patients yet to 
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develop bone complications which would be firstly grouped according to the 
previously defined osteoclast number cut off and then followed over a period of 
time to determine if this assay is predictive for patients developing bone 
complications. 
 
Correlation of GD patient in vitro osteoclastogenesis with in vivo response to GD-
specific therapies. 
Treatment of Gaucher patients with GD-specific therapies such as enzyme 
replacement and substrate reduction have proven successful in reducing disease 
burden especially in regards to hepatosplenomegaly (202,205,209,216,221). 
However, response of bone disease in Gaucher patients has been found to take 
much longer although in the majority of patients has been regarded as successful 
due to a gradual increase of bone mineral density and a reduction in fracture events 
(506–510). Our findings in chapter 3 in regards to in vitro effects of GD-specific 
therapy on osteoclast generation support the effectiveness of these therapies for 
GD bone disease as all the therapies tested significantly reduced osteoclast 
generation in vitro and therefore would be expected to do so in vivo. This 
assumption is further supported by correlations made in chapter 4 between 
osteoclast generation and in vivo therapy. Firstly, patients receiving GD-specific 
therapy generated significantly fewer osteoclasts in vitro than untreated patients 
and secondly the majority of time courses of GD patients show either a decrease or 
maintenance of osteoclast generation while receiving therapy with one patient, 
followed over several years, achieving a substantial decrease over time when 
treated with miglustat. In addition to providing supportive evidence of the 
effectiveness of GD-specific therapies in treating bone disease in Gaucher patients, 
at least in regards to osteoclasts, these findings also demonstrate that the in vitro 
osteoclast system is responsive to the in vivo changes achieved by therapy. This 
system may therefore be useful for monitoring patient response to therapy in 
relation to bone resorption and could be used in conjunction with established 
methods such as MRI to follow patient progress.  
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Several publications have reported patients developing new bone events after 
initiation of GD-specific therapy (84,85) or with bone complications which do not 
improve after a number of years of therapy even though dosages were increased 
(511) and a publication by Baris et al in 2015 found small bone crises increased after 
the initiation of ERT (505). From these studies it could be concluded that there may 
be a sub-group of patients which have bone disease that does not respond to 
current GD-specific therapies. However, evidence for this although compelling is 
limited as the patient cohorts in these studies are relatively small. In support of this 
a small number of patient in vitro osteoclast cultures did not decrease over time. 
These findings and the stated publications have led to the initiation of a project by a 
colleague in our group investigating this potential sub-group. 
To confirm the existence of this sub-group and their frequency in the GD population 
it would be necessary to assess and follow a much larger cohort of patients and 
divide them according to which therapy they are receiving. Inclusion of the in vitro 
osteoclast system may be informative in a prospective version of this study as we 
have shown that GD patients with active bone disease correlate with higher 
osteoclast generation in vitro. Therefore, if the bone disease of a Gaucher patient 
does not respond and remains active the assay may confirm this. In addition, if 
osteoclast generation strongly correlates with active bone disease in the potential 
non-responders in the prospective study it may prove to be a useful tool in 
identifying a potential non-responder indicating closer monitoring of the patient’s 
bone health may be required. It may also be used to add further support to 
radiological and MRI evidence that a patient’s bone manifestations are not 
responding to GD-specific therapies and may require adjunctive bone specific 
therapies such as bisphosphonates (607), parathyroid hormone (608) or therapies 
under development such as PTHrP analogues (609) and sclerostin antibodies (610). 
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Osteoblasts in GD. 
Evidence from chapters 3 and 4 clearly indicate that osteoclasts may contribute to 
the various bone complications suffered by Gaucher patients. However, as 
described in the introduction, the maintenance of bone requires the co-ordination 
of a number of cell types but in particular between osteoclasts and osteoblasts. It is 
therefore likely that if osteoclast generation and activity is altered in GD osteoblast 
function either in regards to migration, differentiation or activity is also affected. 
Previous publications investigating Gaucher patient MSC’s have provided some 
conflicting data with one showing no alteration in differentiation capacity (139) 
while two other studies reported a decrease in the capacity of GD-MSC’s to 
differentiate into osteoblasts (138,141).  
Animal studies have suggested osteoblast dysfunction may be a cause of bone 
disease in GD. A murine model of GD which exhibited bone involvement showed 
reduced proliferation of bone marrow stromal cells and reduced osteoblast 
differentiation (272) while a Zebra fish model exhibited impaired osteoblast 
differentiation and reduced bone mineralisation (523). However, in the murine 
model no alteration in osteoclast number or activity were found with the authors 
concluding that osteoclasts were unlikely to be involved in the pathogenesis of 
bone disease in GD.  
Given the data generated in vitro and the clinical correlations attained in chapters 3 
and 4 of this thesis the conclusion that osteoclasts are not involved in the 
pathogenesis of bone disease in GD from data generated by the murine model 
suggests the data in regards to osteoclast number and activity may be spurious in 
this murine model and highlights the necessity for human based cellular studies in 
addition to murine models (272). However, this is not to say that animal models are 
not of value as the findings in both the murine and zebra fish models of impaired 
MSC proliferation and osteoblast differentiation may provide vital mechanistic 
information with further investigation.  
In regards to our investigations, correlation of osteoblast precursors in peripheral 
blood with osteoclasts generated from peripheral blood showed a strong 
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correlation for controls but a very poor correlation for Gaucher patients indicating 
uncoupling between osteoclasts and osteoblasts in Gaucher patients. In addition, 
the difficulties encountered in expansion and differentiation of the two GD MSC 
samples may support the reports of impaired MSC proliferation and differentiation 
capacity from both GD patient and animal model studies however this finding is 
based on only two Gaucher patient samples and requires further investigation. The 
fact that difficulty in expanding MSC’s was only encountered for one of the two GD 
samples, not encountered for any of the control or multiple myeloma samples, 
suggests that the degree of proliferation impairment may vary from patient to 
patient. However, to assess this a much larger cohort of GD patient MSC’s will be 
required.  
The inability to obtain sufficient calcium deposition for accurate measurement with 
both GD MSC samples over the 5 weeks of osteoblast culture supports the theory 
that osteoblast differentiation may be impaired in GD leading to the reduction in 
bone mineralisation noted in the zebra fish model. However, to confirm this 
observation, additional repeats of the osteoblast culture with these MSC samples 
and osteoblast cultures of a much larger cohort of GD MSC samples will be 
required.  
If the capacity of GD-MSC’s to differentiate into osteoblasts is impaired, it may 
explain why GD patient bone disease is slow to respond to therapy as there may be 
fewer mature osteoblasts available to replace the resorbed bone and therefore a 
slower increase in bone mineral density than expected. In addition, if osteoblast 
differentiation is impaired it may have an impact on the effectiveness of both anti-
catabolic therapies such as bisphosphonates and anabolic therapies such as the 
sclerostin antibody currently under development.  
In regards to bisphosphonates, their mode of action of binding to calcium crystals, 
causing toxic effects on osteoclasts or affecting their signalling pathways (607) has 
the overall effect of reducing bone matrix resorption which in turn means a 
reduction in osteoblast signalling factors released from the bone matrix (289,436). 
Therefore, due to the coupling effect a reduction in osteoclast activity may lead to a 
reduction in osteoblast recruitment and activity. In this case, bisphosphonates 
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would be beneficial in terms of reducing osteoclast numbers, although our in vitro 
evidence suggests GD-specific therapies may be sufficient to reduce osteoclast 
numbers for GD patients in vivo, but the negative effect on osteoblast recruitment 
and activity may exacerbate the potentially already reduced number of osteoblasts 
due to the impaired differentiation capacity of the GD-MSC’s and therefore may not 
have an overall beneficial effect.  
The action of sclerostin antibody is to bind sclerostin, preventing it from binding to 
the low-density lipoprotein receptor-related proteins 5 and 6 thus preventing it 
from inhibiting osteoblast function (611). However, while it may increase the 
overall activity of osteoblasts in GD patients the fact that there may be fewer 
functional osteoblasts would limit its effectiveness and so the expected increase in 
bone mineral density may take considerably longer for GD patients than for non-GD 
patients.   
 
In vitro effects of GD-specific therapies on MSC’s. 
Our novel research into the potential effects of GD-specific therapies on MSC 
viability and differentiation and osteoblast activity indicates some of these 
therapies may be detrimental, at least in the in vitro system. Inclusion of 
imiglucerase, miglustat or ambroxol in the MSC-osteoblast cultures led to a 
reduction in viability for all control and multiple myeloma samples for all therapies 
but did not reach statistical significance in some cases. Calcium deposition was also 
substantially reduced in the presence of imiglucerase for one control, two of the 
three multiple myeloma MSC samples and in the SaOs-2 cell line cultures. With 
reductions also observed for miglustat and velaglucerase in some cases.  
However, as none of these samples are from GD patients it is possible that these 
effects are due to these cells having normal β-glucocerebrosidase expression and 
activity, thus addition of imiglucerase would lead to excessive amounts and activity 
of functional β-glucocerebrosidase altering the balance and potential signalling 
effects of a number of sphingolipids. An effect which would not be present in GD 
patient MSC’s and osteoblasts due to their deficiency in β-glucocerebrosidase. As 
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glucosylceramide has been linked with cell proliferation a substantial decrease due 
to excessive β-glucocerebrosidase may lead to reduced viability. This may be 
particularly relevant for MSC’s as they have been shown to have very high β-
glucocerebrosidase activity, similar to monocytes (138). Culture with miglustat may 
have a similar effect as by inhibiting glucosylceramide synthase it would reduce the 
amount of glucosylceramide to below normal levels within the cell and therefore 
alter the balance of sphingolipids within the cell.  
In contrast, calcium deposition in the presence of ambroxol was not significantly 
reduced for any of the samples.  As ambroxol is a pharmacological chaperone it 
may not affect cells with normal lysosomal β-glucocerebrosidase activity as 
trafficking to the lysosome is already optimal and therefore further enhancement 
by ambroxol may be minimal. As these experiments were not carried out on GD 
patient MSC’s due to difficulties faced in expansion and inducing measurable 
calcium deposition no data is available to determine if these therapies would have 
the same effect on viability or calcium deposition. To assess these effects, it may be 
necessary to further optimise culture conditions for GD MSC’s to firstly enhance 
expansion and secondly to enhance differentiation and calcium deposition. Once 
achieved, additional repeats of the osteoblast culture with these MSC samples and 
osteoblast cultures of a much larger cohort of GD MSC samples will be required. 
 
Potential effects of sphingolipids on osteoblasts, osteoclasts and plasma cells. 
Research into the potential of sphingolipids as bioactive molecules has revealed 
several important roles in regards to the bone microenvironment, many of which 
have been found to be elevated in GD patient plasma and serum. Sphingosine-1-
phosphate, found to be elevated in GD patient serum (153), has been shown to be 
an important regulator for migration of both osteoclast precursors and MSC’s from 
the peripheral blood to the bone marrow, to increase proliferation and reduce 
apoptosis. Ceramides, of which certain species have been found to be elevated in 
GD plasma but which decrease in response to ERT (150), have several actions 
depending on the chain length of the species including decreasing osteoclast 
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activity (375), pro-apoptotic and anti-inflammatory effects (285). Glucosylceramide, 
the main cellular storage sphingolipid in GD, has been linked with cell proliferation 
and suggested to be involved in drug resistance (276,612). Glucosylsphingosine, 
found to be highly elevated in GD plasma and serum (151,152) has been suggested 
to mediate cellular dysfunction and lead to increased levels of sphingosine-1-
phosphate (272).  
To investigate the potential roles of sphingolipids in the bone microenvironment 
MSC’s, osteoblasts, osteoclasts and plasma cells were cultured in isolation with a 
number of exogenous sphingolipids. Addition of glucosylsphingosine appears to 
have a consistent effect of reduced viability/proliferation as this effect was 
observed for MSC’s, SaOs-2 and the plasma cell line NCI-H929. An effect found to 
be further enhanced in the case of the plasma cell line in the presence of CBE. 
Sphingosine, shown to decrease the viability of a mouse pre-osteoblast cell line 
MC3T3.E1 by Mistry et al (153), had no significant effect on viability/proliferation of 
any of the MSC samples or the SaOs-2 cell line nor on osteoblast activity which may 
suggest sphingosine has different roles in mouse and human bone 
microenvironments.  
In contrast, addition of glucosylceramide led to a number of effects including 
increasing osteoclast generation in both control and GD cultures, increasing MSC 
differentiation/proliferation but decreasing MSC-derived osteoblast calcium 
deposition in 3 of the 5 samples cultured. Seemingly contradictory results in regards 
to the MSC’s was obtained for SaOs-2 culture with glucosylceramide decreasing 
viability/proliferation but increasing calcium deposition. While again, culture of the 
plasma cell line with glucosylceramide led to an increase in total cell number.  
The apparent contradiction of results between MSC’s and SaOS-2 cell line may be 
explained by lineage commitment as glucosylceramide may have different effects 
depending on how committed the cells are to becoming osteoblasts. In the case of 
the MSC’s they are at a very early stage of commitment therefore exposure to 
glucosylceramide may either reduce their differentiation capacity to forming 
osteoblasts or retard the differentiation process possibly redirecting cellular 
processes towards increasing proliferation of MSC’s and away from differentiation. 
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As the SaOs-2 cells are further committed to becoming osteoblasts, described as 
osteoblast-like cells in literature (569), this effect on differentiation may be very 
limited for these cells. The increase in calcium deposition in the SaOS-2 cultures 
may indicate that glucosylceramide has an additional effect on mature osteoblasts, 
post-differentiation, increasing their activity. These findings suggest 
glucosylceramide has a dual role of inhibiting MSC differentiation to osteoblasts 
while stimulating mature osteoblast activity.  
Together these findings suggest high concentrations of exogenous glucosylceramide 
in the GD patient bone marrow may create an environment in which osteoclast and 
plasma cell numbers are increased and osteoblast numbers are decreased which 
would create the uncoupling effect observed in figure 5.1 and may in part explain 
the bone complications present in up to 96% of GD patients, in particular the 
osteopenia present in 75% of GD patients (101).   
 
Potential roles of plasma cells in the GD bone microenvironment. 
Evidence that there may be a positive feedback loop between osteoclasts and 
plasma cells in which osteoclasts increase plasma cell survival, as shown both in the 
literature (475) and the findings from the SaOs-2 triple co-culture in figure 7.6, 
which in turn increase osteoclast generation, shown in figure 6.2, may be further 
enhanced by a high concentration of exogenous glucosylceramide in the bone 
marrow as our findings show that glucosylceramide increases osteoclast generation 
and total plasma cell number. In addition, myeloma plasma cells have also been 
found to decrease osteoblast differentiation and inhibit their maturation and 
activity by secretion of several factors including DKK-1, sFRP-2 and sclerostin (489–
492). Our finding that GD monocytes generate more osteoclasts in vitro than 
control subjects suggests GD bone marrow may be a supportive environment for 
plasma cell proliferation which in turn may lead to a reduction in osteoblast 
differentiation, maturation and activity. However, the interaction between normal 
plasma cells and osteoblast differentiation and activity is currently unclear 
therefore the consequence of an increase in normal plasma cell numbers on 
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osteoblast number and activity is unknown at present. The potential of an 
environment supportive of plasma cell proliferation in GD bone marrow with the 
combination of high osteoclast number and high concentrations of 
glucosylceramide may also lead to the generation of clonal populations leading to 
MGUS which in time may lead to multiple myeloma, in part explaining the increased 
incidence of multiple myeloma in the GD population.  
 
Development of a co-culture system. 
While many of the findings discussed may expand our understanding of the GD 
bone microenvironment and provide some explanation for the bone complications 
present in the majority of GD patients, all the data was obtained from cells cultured 
in isolation, a state not found in the bone microenvironment and therefore does 
not account for the effects of the interactions between cells present in the bone 
microenvironment. To investigate these interactions novel co-culture models were 
created which included either MSC derived osteoblasts or SaOs-2 cells cultured with 
monocytes subsequently differentiated into osteoclasts and finally, once the 
osteoclasts had matured, the plasma cell line NCI-H929.  
Co-culture of osteoblasts in contact with osteoclasts resulted in lower total calcium 
deposition in both the SaOS-2 and MSC model systems. Culture with CBE further 
reducing the amount of calcium present in the SaOs-2 and the MM MSC cultures. 
These results are expected as osteoclasts should resorb some of the calcium matrix 
deposited by osteoblasts resulting in a reduction in total calcium and based on 
results obtained in chapter 3, CBE was found to increase osteoclast generation in 
control cultures therefore an increase in osteoclast number would lead to further 
reduction in overall calcium deposition.  
Osteoclasts cultured with but physically separated from osteoblasts resulted in an 
increase in calcium deposition both in the SaOS-2 system and in the MSC-derived 
system though this effect was inconsistent for the MM sample 2167 and in the 
presence of CBE for both MSC cultures. These findings support the concept of 
coupling between osteoclasts and osteoblasts suggested by publications which 
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have shown that osteoclasts secrete pro-osteoblast factors such as sphingosine-1-
phosphate, BMP 6 and Wnt 10b (379).   
The myeloma plasma cell line NCI-H929 appears to reduce the degree of calcium 
deposition when cultured with control MSC derived osteoblasts. Again, this 
outcome is in line with research by other groups which has found myeloma plasma 
cells decrease osteoblast differentiation and inhibit their maturation and activity 
(489–492). However, this data is from a single control sample and requires 
confirmation with additional control MSC-osteoblast cultures. In contrast, co-
culture of the plasma cell line with the SaOs-2 osteoblast cell line resulted in a small 
increase in calcium deposition. This may again be due to the SaOs-2 cell line being 
osteoblast-like cells and thus more committed to differentiating to osteoblasts than 
the MSC’s abrogating the effect of plasma cell secreted proteins such as IL-3 and IL-
7 (493,494). In addition, this effect may be erroneous as the SaOs-2 cell line induced 
substantial apoptosis of the plasma cells with nearly 95% dead or dying when 
cultured in contact thus abrogating any inhibitory effect on osteoblast function the 
plasma cells may have.  
The substantial apoptosis of the plasma cell line induced by the SaOS-2 cells was 
not observed in MSC derived osteoblast cultures and therefore may be a particular 
feature of this cell line. If this is the case this cell line may not be suitable for 
potential future co-culture experiments as cellular interactions comparable to those 
of primary cells is essential for the creation of an accurate model of the human 
bone microenvironment. However, this apoptotic effect did enable assessment of 
the reported pro-survival effect of osteoclasts on plasma cells 
(475,486,487,577,613). Using the SaOs-2 cell line we were able to demonstrate that 
osteoclasts promote plasma cell survival and that this effect is predominantly 
contact mediated as reported by Abe et al in 2004 (613).  
 
Limitations of this co-culture system. 
From these finding it can be concluded that this co-culture system has generated 
several results similar to those found by other groups and therefore may be 
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informative for further investigation into cellular interactions and the potential 
effects of GD-specific therapies on the bone microenvironment. To enable 
investigation of the GD osteoblast-osteoclast interaction it will be necessary to 
enhance the differentiation of GD MSC’s into osteoblasts and possibly to adjust 
culture conditions to increase calcium deposition to allow accurate measurement.  
However, this model culture system has several limitations. Firstly, mature 
osteoblasts and osteoclasts do not co-exist in direct contact with each other in the 
bone microenvironment (294). In this culture system, to create a mineralised matrix 
which incorporated the proteins secreted by osteoblasts during mineralisation to 
assess osteoclast interaction with this matrix and to investigate how this affects 
their activity, it was necessary to culture the MSC derived osteoblasts or SaOs-2 
cells in osteogenic medium until substantial calcium deposition could be observed 
followed by direct co-culture with osteoclasts. As this mineralised matrix is 
deposited on the exposed surface of the osteoblast cells it is not possible to remove 
the osteoblasts and retain the bone matrix therefore it is necessary to culture 
osteoblasts with osteoclasts. This limitation was partially mitigated by the use of 
transwells to physically separate the cells and demonstrated that factors may be 
produced by osteoclasts which enhance calcium deposition by osteoblasts but it 
prevents osteoclast interaction with the mineralised surface and still creates the 
artificial scenario of osteoblasts and osteoclasts existing simultaneously in the local 
environment.  
To address the potential interactions between osteoclasts and osteoblasts by in 
vitro culture one solution in regards to effects on osteoclast function may be to 
culture the monocytes on bone discs, as in chapter 3, with osteoblast conditioned 
medium with or without the pro-osteoclastogenic cytokines MCSF and RANKL. 
Similarly, MSC’s could be cultured with osteoclast conditioned medium with or 
without the pro-osteoblastic factors dexamethasone, ascorbate-2-phosphate and β-
glycerophosphate. However, this approach also has potential limitations as the 
conditioned medium may be at least partially depleted of nutrients and may 
contain cell debris and waste products from the initial culture. Additionally, the 
medium may still contain pro-osteoclastic or pro-osteoblastic factors depending on 
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the initial culture. While this can be partially mitigated by diluting the conditioned 
medium with unused medium specific for the culture and control conditions can be 
included these potential confounding factors cannot be completely accounted for. 
Secondly, this culture system, as for all the monocultures performed in this project, 
is planar (2D) i.e. all the cells are cultured on a flat surface. In vivo, these cells would 
exist in a three-dimensional (3D) lattice, adhering to the trabecular or intracortical 
surface. Several studies have demonstrated that cell morphology, differentiation 
and gene expression differs in a 3D environment compared to 2D and suggest the 
3D model system may be more physiologically relevant (614,615). Of particular 
interest is the study by Marino et al 2014 (616), which uses X-ray µCT images of 
trabecular bone to print 3D scaffolds to which are adhered and cultured SaOS-2 
cells. Through this approach this group demonstrates that SaOs-2 morphology, 
viability, differentiation and gene expression are altered in comparison to 2D 
cultures.  
Thirdly, cell cultures were performed in static medium, replaced every 3 to 7 days 
depending on the cell type and stage of culture. This method can lead to a 
depletion of nutrients and osteogenic factors and a build-up of waste products 
between medium changes.  
 
Future development of a 3D cell culture system. 
To address these limitations a different approach may be required. The creation of 
3D scaffolds similar to those used by Marino et al with cells cultured in bioreactors 
with continuous perfusion of culture medium, as shown in figure 8.1, images 
published by Bouet et al (617). In addition to providing a closer physiological 
approximation with the 3D scaffold and continuous perfusion providing a constant 
supply of nutrients and removal of waste products the use of a cubic scaffold may 
permit quantitation of resorption by osteoclasts.  
This protocol may involve seeding the scaffold with MSC’s, culture in osteogenic 
medium until calcium deposition has led to a measurable mass increase, with a 
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control scaffold with undifferentiated MSC’s to account for cell division, followed by 
seeding with monocytes, re-weighing post cell adhesion, culture in osteoclastogenic 
medium for 3 weeks followed by re-weighing. If resorption has occurred the final 
mass should be less than the post-cell adhesion mass. The mass differential would 
therefore quantify the amount of calcium resorption.  
While this approach does not solve the first limitation of having osteoblasts and 
osteoclasts present at the same time it may provide a more physiological 
measurement of the difference in activity between control and GD osteoclasts. 
However, several factors will need to be optimised including the chemistry and 
architecture of the scaffold, the density of both MSC’s and monocytes seeded, the 
duration of each phase of the culture and the method for accurately weighing the 
scaffold at each stage.  
 
 
Figure 8.1 Example of 3-dimensional scaffold based culture system with continuous 
perfusion. (a). Scaffold image, direction of medium perfusion indicated with red 
arrow. (b). Bioreactor system with culture chamber, medium reservoir and effluent 
collector. Adapted from Bouet et al, European cells and materials, 2015 (617).   
 
Future work. 
1. Given that GD osteoclast generation appears to be increased in vitro I would 
suggest investigating osteoclast signalling pathways in regards to differentiation 
and fusion such as c-fms, RANK/RANKL/OPG and DC-STAMP, measuring both RNA 
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and protein expression, comparing GD and controls to see firstly if there is a higher 
proportion of monocytes pre-disposed to forming osteoclasts and why this 
formation appears to be accelerated in GD.  
2. Data in this thesis showed a decrease in osteoclast numbers in the presence of 
GD-specific therapies in vitro. I suggest investigating the cellular mechanisms for 
the reduction in osteoclast generation in the presence of GD-specific therapies. 
Initially assessing the same pathways stated in point 1. 
3. Findings in this thesis suggest glucosylceramide may increase osteoclastogenesis 
and decrease osteoblast function while glucosylsphingosine may reduce cell 
viability. I would therefore suggest investigating the protein pathways involved in 
sphingolipid signalling in osteoclasts and osteoblasts and MSC’s especially in 
regards to glucosylsphingosine and glucosylceramide, focusing on 
differentiation/fusion signalling pathways in regards to glucosylceramide (e.g. DC-
STAMP, OC-STAMP, c-fms for osteoclasts and RunX-2, Dlx-5, Osx for osteoblasts) 
and apoptotic/proliferation pathways in regards to glucosylceramide (e.g. pro-
apoptotic proteins BIM, Bcl-2, pro-survival proteins Bcl-XL, survivin and proliferation 
proteins b-FGF, VEGF). 
4. Given the difficulty encountered in both expanding and differentiating GD MSCs’ 
into osteoblasts, I would suggest further assessment of the differentiation capacity 
of GD vs control MSC into osteoblasts in vitro by assessing the rate and proportion 
which differentiate into adipocytes, chondrocytes and osteoblasts using adipogenic, 
chondrogenic or osteogenic medium or a combination thereof.  
5. As an extension to the previous point, I would suggest the assessment of 
components of the mineralised matrix produced by control and GD MSC’s including 
collagenous and non-collagenous proteins such as TGF-β, BMP-2, PDGF, and IGF’s.  
6. Our findings in this thesis that GD-specific therapies reduced the viability of 
control and MM MSCs’. I would suggest investigating whether the effects of GD-
specific therapies on MSC viability and osteoblast calcium deposition observed in 
some of our samples are valid and the same effect is seen for GD MSCs’. If so it 
would be necessary to investigate the cellular mechanisms involved by increasing 
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cohorts and quantification of RNA and protein of apoptotic and proliferation 
pathways stated in point 3. 
7. Data in this thesis indicates that several sphingolipids including glucosylceramide 
and glucosylsphingosine can affect plasma cell viability and proliferation. Therefore, 
I would suggest investigating the effects of glucosylceramide and 
glucosylsphingosine on plasma cells in regards to proliferation and apoptotic 
pathways respectively by quantification of RNA and protein of apoptotic and 
proliferation pathways stated in point 3.  
8. Given the limitations discussed in regards to the culture system used I would 
suggest the development of 3D scaffolds and culture systems to enable further 
investigation of cellular interaction in the Gaucher bone microenvironment possibly 
as depicted in figure 8.1.  
 
Summary. 
These studies have demonstrated that in vitro osteoclast culture of Gaucher patient 
monocytes results in increased osteoclast generation, size and activity in 
comparison to control cultures and that this finding was partially replicated by 
inhibition of β-glucocerebrosidase with CBE in control cultures. Evidence from other 
research groups and this study indicate that Gaucher patient MSC’s may have a 
reduced potential for differentiating into osteoblasts and that these osteoblasts 
have reduced calcium deposition. In addition, plasma cells were found to increase 
osteoclastogenesis in control osteoclast cultures which have been shown by other 
researchers to support plasma cell survival and proliferation which may result in a 
positive feedback loop resulting in increasing osteoclast and plasma cell numbers. 
Our finding that exogenous glucosylceramide increases both osteoclast and plasma 
cell number may further exacerbate this feedback loop in the Gaucher bone 
marrow. This combination of excessive osteoclast number and activity and reduced 
osteoblast number and activity may have the overall effect of an uncoupling 
between osteoclasts and osteoblasts in the GD bone microenvironment leading to 
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excessive bone resorption resulting in the bone pathology observed in GD patients, 
a simplified representation of which is shown below in figure 8.2.  
The findings discussed in this thesis may provide further insight into potential 
therapies for bone disease in GD possibly tailored to reduce osteoclastogenesis and 
increase MSC differentiation into osteoblasts, redressing the balance between 
these cells. In addition, the findings in relation to sphingolipids, especially 
glucosylceramide and glucosylsphingosine, may increase our understanding not 
only of their roles in the GD bone microenvironment but also their roles in non-GD 
bone homeostasis. These findings may also help to further expand current 
understanding of the roles of these sphingolipids in multiple myeloma and possibly 
other cancers.  
 
 
Figure 8.2 Summary of potential cellular interaction in GD which may be the cause 
of the bone pathology found in the majority of GD patients. Own figure. 
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